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1 Summary 
Human Alzheimer’s disease (AD) is a chronic neurodegenerative disease 
with progressive neuronal loss, extracellular plaque deposition and intraneu-
ronal tangle formation. Another hallmark commonly observed in AD patients 
is loss of myelin as well as focal demyelination in the plaque core areas. 
Here, I set out to examine the glial cell reactivity in mouse models of AD in 
order to determine similarities and differences to invasive injuries. One impor-
tant rationale for this comparison is the recent discovery of glial cells with 
stem cell properties after invasive injury. Therefore, the aim of this work was 
to determine if these cells also appear in non-invasive injuries. I analyzed 
astrocytes as these cells are commonly involved in the brain’s reaction to-
ward injury. In addition, I analyzed cells of the oligodendrocyte lineage to de-
tect possible myelin repair mechanisms in response to AD pathology.   
Under certain lesion conditions such as stab wound lesion, a great number of 
astrocytes up-regulate different markers known to be present in astroglial 
stem cells, resume proliferation and regain stem cell properties in vitro, since 
they give rise to self-renewing, multipotent neurospheres. Investigation of the 
astrocytes in APPPS1 mice, which by the age of six weeks exhibit progres-
sive plaque deposition of human AD, revealed a strong reaction toward 
plaque deposition as detected by the expression of different markers charac-
teristic of reactive astrocytes. In addition, a subset of these cells increased in 
proliferation, however, in contrast to stab wound lesion only a small number 
of astrocytes proliferated. When testing the neurosphere forming capacity of 
reactive glial cells of the cortical grey matter, it was significantly decreased in 
APPPS1 mice compared to the acutely injured brain. To understand if the 
decreased neurosphere forming capacity was due to the lack of neuronal 
loss, another mouse line, the CK/p25 mice, with pronounced inducible neu-
ronal cell death, intraneuronal Aβ and tau pathology was used. Surprisingly, 
despite a strong astrogliosis neurosphere forming capacity was nearly absent 
in cells isolated from the cerebral cortex of this mouse line. Interestingly, re-
active astrocytes also hardly proliferated in vivo, in line with the lack of neu-
rosphere forming capacity.  
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To unravel the molecular mechanisms mediating the differences in astrocyte 
proliferation and stem cell generation observed in the different lesion para-
digms, intracellular signalling cascades involved in astrocyte proliferation 
such as phospho-cJun and Olig2 were analyzed. Phospho-cJun expression 
was observed in a small subset of astrocytes upon stab wound and most 
prominently in CK/p25 mice, whereas it was nearly absent in APPPS1 mice. 
In contrast to that Olig2 expression was most prominently elevated in stab 
wounded animals and APPPS1 mice, whereas it was only mildly increased in 
CK/p25 mice. This suggests that both, phospho-cJun expression as well as 
Olig2 expression must be present to mediate proliferation of astrocytes upon 
stab wound injury.  
To understand which signals allow up-regulation of both phospho-cJun and 
Olig2 in the invasive brain injury paradigm, I examined the blood brain barrier 
integrity. First, I investigated if blood-derived immune cells would enter the 
brain in APPPS1 and CK/p25 mice as it is known that after stab wound many 
of these cells invade. Also in APPPS1 as well as CK/p25 mice few immune 
cells entered the brain indicating that the blood brain barrier is permissive for 
some of these cells. However, analysis of the blood brain barrier integrity in 
APPPS1 and CK/p25 mice revealed that it is closed for molecules over a size 
of 3000 dalton. Therefore, signals from the blood may be present upon stab 
wound injury and absent in AD-related mouse models, as they can enter the 
brain in the former and may trigger astrocyte proliferation and stem cell dedif-
ferentiation.  
Another hallmark commonly observed in AD patients is loss of myelin. To 
understand if this pathology is also reflected in APPPS1 mice, I analyzed the 
amount and integrity of myelin in APPPS1 mice. Plaque deposition was suffi-
cient to induce focal demyelination in plaque core areas of cortical grey and 
white matter in these mice, similar the observations obtained from AD pa-
tients. Myelin protein amounts per axon were significantly decreased in 
APPPS1 mice at six months of age and reached control levels again at nine 
months of age. Additionally, an increase in myelin aberrations was detected 
in APPPS1 mice at six months of age, while thereafter the number of aberra-
tions remained stable until nine months of age. The increase in myelin aber-
rations was accompanied by a transient increase in the number of cells of the 
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oligodendrocyte lineage already six months of age. Furthermore, these cells 
displayed an increased proliferation, which persisted up to eleven months of 
age. In addition, an elevated differentiation into mature oligodendrocytes in 
the cortical grey and white matter was observed in APPPS1 mice. Therefore, 
myelin is a vulnerable target upon chronic amyloid plaque deposition in mice 
and it appears that myelin repair mechanisms such as e.g. remyelination are 
induced in response to this pathology.  
When human brain tissue of patients with AD was examined, a decreased 
number of cells belonging to the oligodendrocyte lineage was present in dif-
ferent brain regions compared to normal, aged patients. These results indi-
cate that in human AD pathology myelin repair mechanisms seem to be not 
as efficient as in mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Introduction 4
 
2 Introduction 
For a long time it was believed that after brain lesion the adult central nerv-
ous system (CNS) does not have any capacity for repair and neurons are 
only generated embryonically. However, in 1969 it was discovered that the 
adult brain retains the ability to generate new neurons from neural stem cells 
in at least two zones of neurogenesis, namely the subependymal zone of the 
lateral ventricle and the subgranular layer of the hippocampus1,2. About thirty 
years later, these adult neural stem cells were found to be, surprisingly, of 
glial cell origin3-6. Furthermore, other glial cells residing in non-neurogenic 
brain parenchyma were discovered to represent more than a sole supportive 
structure, rather being actively involved in multiple brain functions. In addi-
tion, different glial cell types such as astroglia and NG2+ glia have been fre-
quently implicated in the brain’s reaction toward injury. This reaction harbours 
beneficial as well as detrimental features, which influence the regenerative 
capacity of the injured brain. Until today, most of the common brain diseases 
accompanied with neuronal loss, like e.g. Alzheimer's disease, cannot be 
cured. However, the growing knowledge on glial cells and especially their 
reaction toward different types of injury will help us to develop new therapeu-
tic strategies.  
2.1 Structural Elements of the Central Nervous System  
 
It is only about 200 years ago that Schwann and Schleiden put forward the 
cell theory in 1838. In their theory they proposed that there exists a general 
principle of construction for all organisms, which is the composition of basic 
units, named cells7-9. Their theory was further refined by Rudolf Virchow, a 
German medical doctor and biologist in 1855, who added the idea that every 
cell arises from another cell10. Only one year later he also discovered the 
existence of a connective substance, which embeds the nervous elements. 
As this connective substance appeared different from other organs he named 
it “neuroglia” 11,12. However, Virchow was not the first to discover glial cells, 
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since Müller had described the “müllerglia” of the retina already in 185113. In 
the beginning of the 1860s Otto Deiter identified stellate cells in cortical grey 
and white matter. Shortly after, Michael von Lenhossek put forward the ex-
pression “astrocyte” for this cell type14,15 and Andrietzen finally distinguished 
protoplasmic grey matter astrocytes from fibrous white matter astrocytes in 
189316. The famous neurobiologist Ramón y Cajal also had great impact on 
the discovery of the other glial cell types, by reporting the existence of an 
additional 3rd class of neuroglia (reviewed by12). Around the 1920s this third 
class of glia was shown to contain both, “oligodendroglia” and “microglia” by 
Pío del Río Hortega, a spanish physician and anatomist17,18. Later, Penfield 
further confirmed the existence of oligodendrocytes19. Recent studies re-
vealed that oligodendrocytes comprise a cell lineage, which includes oli-
godendrocyte progenitors in the adult brain which were originally described 
as beta astrocytes by H. Reiners in 198220. William Stallcup could further 
identify these cells by using an antibody directed against the chondroitin sul-
fate proteoglycan (NG2) protein21,22. As these NG2+ cells exhibit features 
associated with progenitor cells abut also establish synaptic contacts to neu-
rons they are currently recognized as a separate class of glia23,24.    
The discovery of glial cells took place during a time of conflict between the 
“reticularists and the neuronists”, who had different theories on how the brain 
is organized. Camillo Golgi held the reticularistic view, believing that nerves 
are structured in a syncytium-like continuum. On the contrary, Ramón y Ca-
jal, stated the “neuron doctrine”, which was based on the cell theory. He 
could demonstrate that the nervous system consists of individual cells, which 
he called “neurons”. Soon after, neurons were assumed to be the only sub-
strate for brain function, while glia cells remained as a sole supportive ele-
ment (reviewed by25). Recently, this view has been challenged by the dis-
covery of important roles of glial cells in brain function and neurogenesis. 
2.2 Glial Cells as Stem Cells in the Central Nervous System 
Recent reseach discovered that glial cells display stem cell functions in the 
developing embryo and in the adult central nervous system (CNS).  
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2.2.1 Radial Glia- Neural Stem Cells in Development  
 
An important step in CNS development is the formation of the three germlay-
ers during gastrulation, which takes place in mice at around embryonic day 
(E) 6.5, the endoderm, mesoderm and ectoderm. After induction of the dor-
sally located ectodermal neural plate, neurulation starts at around E8-8.5. 
During that process a part of the neuroectoderm thickens, unfurls and results 
in the closure of the neural tube along the rostro-caudal axis. The tube is fully 
established at E9.5-E1026. It consist of a single layer of neuroepithelial cells, 
which already generate the first neurons27 (Figure 2- 1). Finally, at E9-10 
neurogenesis starts with the appearance of radial glia cells, which function 
both as neuronal progenitors28,29 as well as a scaffold used by migrating neu-
rons30,31. The transition of the neuroepithelial cells into radial glia cells is 
characterized by the progressive downregulation of most epithelial features32, 
and also by gaining astroglial properties33,34. Radial glia therefore contain 
many features of astroglial cells. Furthermore, they are polarized cells, with 
one primary cilium-bearing apical domain that contacts the fluid of the ventri-
cle, and a basal domain that contacts the meninges, basal lamina and blood 
vessels5. Asymmetric cell division of radial glia cells leads to the generation 
of neurons and intermediate progenitors35. The intermediate progenitors may 
further differentiate into neurons and macroglial cells (astrocytes and oli-
godendrocytes) even though it is still debated if these cell types arise from 
the same or different intermediate progenitors. At the end of neurogenesis, 
radial glia possibly differentiate into ependymal or astroglial cells36 (Figure 2- 
1). 
The previous view of a complete developmental switch from neurogenesis to 
gliogenesis37 was recently re-defined, since some precursor cells are re-
stricted to produce either neurons or glia as early as E9.529,34,38. Only a sub-
population of radial glia cells gives rise to more than one cell type29,34,39,40. 
The presence of neural stem cells in adulthood can be explained by the 
maintainance of these multipotent radial glia cells in specific niches5. 
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2.2.2 Adult Neural Stem Cells  
Adult neural stem cells which retain the expression of characteristic mole-
cules  reminiscent of radial glia cells, reside in the sugranular zone of the 
hippocampal dentate gyrus and along the lateral ventricle in the subependy-
mal zone (SEZ)6. In the mouse, neurogenesis occurs most prominently in the 
SEZ5. Here, slow-proliferating astroglia-like stem cells, also refered to as type 
B cells, generate neuroblasts (type A cells) and oligodendrocyte progenitors 
after passing through an intermediate state of fast proliferating precursors 
(transit-amplifying precursors, type C cells)6. The neuroblasts in the SEZ mi-
grate through the rostral migratory stream (RMS) to the olfactory bulb, where 
they integrate as mostly GABA ergic (GABA; gamma-aminobutyric acid) and 
dopaminergic but also glutamatergic interneurons6,41. Adult neural stem cells 
of the SEZ are intercalated into the ependymal layer with their apical side 
contacting the ventricle via a single cilium, while their basal side is associated 
with blood vessels in the brain parenchyma42,43 (Figure 2- 1).  
Adult neural stem cells are situated in a certain “niche”, whose microenvi-
ronment enables self-renewal and the generation of progeny42-45. Compo-
nents that specify this niche include e.g. the presence of membrane bound 
molecules and a special extracellular matrix (ECM). The proximity to the spe-
cial ECM structure present in the vicinity of blood vessels, capillaries and un-
derneath the meninges, may be important for type B cell maintainance46. 
However, also the cilium, through which stem cells contact the ventricle has 
great impact on their ability to function as stem cells42. One important ECM 
component present in the postnatal and adult neural stem cell niche is a 
chondroitin sulfate proteoglycan, the dermatan sulfate-dependent proteogly-
can-1 (DSD-1). Interestingly, growth factors have binding sites in defined 
chondroitin sulfate motifs. Growth factors also contribute to the stem cell 
niche and are involved in neuronal progenitor proliferation47,48. Another rele-
vant ECM molecule, tenascin C (TNC), is also highly expressed within the 
SEZ throughout postnatal and adult life, contributing to the niche by e.g. 
modulating growth factor signalling49,50. But what defines a neural stem cell? 
These cells have the ability to self-renew and the potential to give rise to 
cells of all lineages (multipotency). To identify stem cells the neurosphere 
assay has been developed as an in vitro readout. After isolation from the 
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SEZ, cells are kept as a single cell suspension in growth factor (epidermal 
growth factor (EGF) and fibroblast growth factor (FGF)) containing medium. 
After a few days in culture, certain cells start to proliferate and generate float-
ing clonal neurospheres. These neurospheres are passagable for a long pe-
riod of time, which underlines the capacity of the isolated cells to self-renew. 
Upon plating onto coated cover slips and withdrawal of growth factors, neu-
rospheres can be differentiated into neurons, astrocytes and oligodendro-
cytes thus proving multipotency51-53.  
In conclusion, the specialized microenvironment in the SEZ allows the gen-
eration of new neurons throughout adulthood. However, when adult SEZ tis-
sue is transplanted into the striatum only glial cell types are generated54. 
These data suggest that the environment outside the neurogenic niches is 
less supportive for neurogenesis. Interestingly, upon stroke injury, neuro-
blasts become re-rerouted toward the damaged lesion side, thereby over-
coming this anti-neurogenic environment55,56. Ablation of these neuroblasts 
results in an increased infarct volume and exacerbated post-ischemic sen-
sory-motor deficits57. Also in another lesion paradigm where cortico-spinal 
neurons degenerate neuroblasts are recruited to the neocortex. These pro-
gressively differentiate into mature pyramidal neurons, with some even pro-
jecting into the spinal cord58. These results indicate that the microenviron-
ment in some injury conditions apparently has the ability to support neuro-
genesis. 
 
Figure 2- 1. Neuro/Gliogenesis from the Embryo to the Adult.  
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The progression from the embryo to the adult is shown from left to right (A to C). Black and 
grey arrows indicate self-renewal and/or differentiation from one cell type to another. Mark-
ers of macroglia and their precursors are listed. (A) Self-renewing neuroepithelial cells line 
the ventricles throughout the neuraxis at the stages of neural tube closure. These cells may 
generate some neurons. Neuroepithelial cells are transformed into radial glial cells as neuro-
genesis begins. (B) Radial glia generate either neurons directly or via intermediate progeni-
tor cells and oligodendrocyte precursor cells, which in turn produce neurons and oligoden-
drocytes, respectively. Radial glia can also become astrocytes, as well as producing inter-
mediate progenitors that expand in number before producing astrocytes. Protoplasmic astro-
cytes and fibrous astrocytes might arise from common or independent progenitors. Radial 
glia also produce ependymal cells. (C) In adults, oligodendrocytes are produced by two in-
dependent pathways: type B cells in the cortical subventricular zone produce transit-
amplifying cells (known as type C cells), which in turn produce OPCs as well as neurons. 
The OPCs subsequently generate oligodendrocytes, and OPCs that are already resident in 
the grey matter also produce oligodendrocytes. Furthermore, type C cells generate neuro-
blasts. GFAP, glial fibrillary acidic protein; GSTpi, pi form of the Glutathione-S-Transferase; 
NG2, chondroitin sulfate proteoglycan; MBP, myelin basic protein; PDGFR-α, platelet-
derived growth-factor receptor-α. All green cells are intermediate progenitors, with type C 
cells being a subset of these, and all blue cells are neural stem cells (even though each blue 
cell is a different type)  modifed from36. 
 
2.3 Glial Cells in the Adult Brain 
Recent research of the adult human brain discovered that glia cells are ap-
proximately as abundant as neurons59. However, the ratio differs enormously 
between regions. For example in the neocortex there are about 27.9 billion 
glia compared to 21.4 billion neurons59,60. This results in a glia to neuron ratio 
of 1.3 glia to one neuron59,60. In the adult human brain about 75% of all glia 
are oligodendrocytes, 20% astrocytes and 5% microglia61.  
Most interestingly, the total number of glial cells (glia is greek and means 
“glue”) in the brain increases with evolution62,63. In accordance with that for 
example in the flat worm Caenorhabditis elegans the ratio of neurons to as-
trocytes is six to one. In higher developed animals such as rodents only three 
neurons per one astrocyte are present64,65.  
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2.3.1 Astroctyes  
 
Soon after birth, radial glia cells retract their processes and differentiate into 
astrocytes or ependymal cells36,66,67. Radial glia can either transform directly 
into astrocyte progenitors or generate them via a basal progenitor stage36,68. 
Some astrocytes in the grey matter of the ventro-lateral forebrain and spinal 
cord are also generated from embryonic NG2+ cells69,70. After astrocyte 
specification, astrocyte precursors migrate to their final destinations, such as 
e.g. the adult grey matter.  
Adult grey matter astrocytes of the cerebral cortex are referred to as proto-
plasmic astrocytes (Figure 2- 2A). They are characterized by many fine 
branching processes appearing in a globoid distribution, which envelop syn-
apses71. Astrocytes populate the grey matter in an essentially non-
overlapping manner, yet, they form gap junctions at the distal tips of their 
processes with neighbouring astrocytes72-74. In rodents, a single astrocyte 
contacts several hundred dendrites and envelopes up to 100`000 syn-
apses75. Most synapses therefore consist of three elements, namely the as-
troglial perisynaptic process, the presynaptic neuronal terminal and the post-
synaptic neuronal membrane, which led to the expression “tripartite syn-
apse”76. The astrocyte’s ensheathment of synapses guarantees proper syn-
aptic function by maintaining ion concentration, pH, water and transmitter 
homeostasis. As astrocytes express different ion channels74 and transporters 
they are “somewhat excitable”. Changes in intracellular Ca2+ concentrations74 
are of importance for astrocyte-neuron and astrocyte-astrocyte communica-
tion77. Long range signaling between astrocytes is achieved by Ca2+ waves, 
which propagate via gap junctions78,79. Synaptically active gliotransmitters 
released by astrocytes, such as e.g. glutamate, adenosine triphosphate 
(ATP), γ-aminobutyric acid (GABA), tumor necrosis factor α (TNFα), shown 
to influence neuronal and synaptic physiology76,77,80,81. Besides the role of 
astrocytes in synaptic transmission, they also participate in synapse matura-
tion and maintenance82-84. Another important function of astrocytes is re-
moval of glutamate from the synaptic cleft via the glutamate-glutamine cycle. 
Glutamate is the most important excitatory transmitter in the CNS, however, if 
present in excess, it triggers excitotoxic neuronal death85. Glutamate is taken 
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up from the synaptic cleft via astrocytic transporters such as the excitatory 
amino acid transporter 2 (also known as GLT1) and the astrocyte-specific 
glutamate transporter 1 (GLAST)74. Within the astrocytes, glutamate is cata-
lyzed by the glutamine synthetase (GS) into the non-toxic glutamine and re-
cycled back to neurons.  
As astrocytes contact the basement membrane at the blood vessels via a 
specialized process called astrocyte endfoot, they exert an additional function 
in regulating blood flow (Figure 2- 2B). They produce and release vasoactive 
substances, which alter the blood vessel’s diameter86 according to changes 
in neuronal activity87. 
Astrocytes furthermore participate in the formation of the blood brain barrier 
(BBB), which is a diffusion barrier that separates the brain extracellular lumen 
from the blood. It limits the influx to the brain parenchyma based on molecu-
lar size and polarity88,89.  At the cellular level, endothelial cells ensheath the 
capillaries forming tight junctions between them (Figure 2- 2C). These cells 
are then surrounded by a basal lamina, perivascular pericytes and astrocyte 
endfeet88-90.  
In addition to the above described functions, astrocytes are also metaboli-
cally coupled to neurons e.g. by the brain glycogen metabolism. Glycogen is 
stored in glycogen granules mostly in astrocytes71. The glycolysis transforms 
glycogen into lactate, which then serves as an energy substrate for neu-
rons91.  
In summary, astrocytes are important for balancing the brain’s extracellular 
homeostasis. In addition, they regulate the metabolic support for neurons by 
e.g. adjusting the blood flow. Therefore, astrocytes are a prerequisite for 
proper brain function under physiological conditions. Also after brain injury, it 
is of importance to re-establish brain homeostasis.  
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Figure 2- 2. Schematic Overview of Astrocytes and the Blood Brain Barrier.  
(A) is a representative picture of a protoplasmic astrocyte. GFP was a staining performed in 
the GLAST::CreERT2 x CAGGFP, which is almost exclusively expressed by astrocytes. (B) 
depicts a schematic overview of the astrocyte’s contact to a blood vessel. (C) is an overview 
on the composition of cells contributing to the blood brain barrier. Endothelial cells ensheath 
the blood vessel and form tight junctions between them. Also pericytes are located at blood 
vessels. Astrocyte endfeeth surround the endothelial cells, building an additional barrier. 
Scale bar: 10 µm. Modified from71,90. 
 
 
2.3.1.1 Subsets of Astrocytes  
 
 
The increasing knowledge of the diversity and complexity of astrocyte func-
tions argues for a heterogenic cell population. Astroglia can be distinguished 
by their morphology, localisation, and the expression molecules such as e.g. 
intermediate filaments. The latter constitute together with actin filaments and 
microtubules, the cytoskeleton, which e.g. mediates dynamic scaffold and 
structures the cytoplasm of a cell92.  
The already mentioned, protoplasmic astrocytes of the cortical grey matter 
express markers such as the calcium binding protein S100b, the glutamate 
transporters GLAST, GLT1 and GS. Furthermore, they are characterized by 
the presence of glycogen granules. Both features are commonly shared with 
other astroglial subtypes. The so called fibrous astrocytes reside in the corti-
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cal white matter. They display an elongated morphology with many long fiber-
like processes, which envelop the nodes of Ranvier71. Besides their localisa-
tion, they can be distinguished from protoplasmic astrocytes by the additional 
expression of the glial fibrillary acidic protein (GFAP). Furthermore, they have 
overlapping domains, contrary to protoplasmic astrocytes, and may exert 
mostly supportive functions71. Most interestingly, also the adult astroglia-
like stem cells are considered an astrocyte subtype, as they express com-
mon astroglial markers such as e.g. S100b, GLAST, GS and GLT142,93 (for 
details see table 2- 1) and also exhibit the presence of glycogen granules. 
However, they also retain the expression of immature glia markers (radial 
glia) such as e.g. vimentin, nestin, DSD-1 and TNC40,42. Both, the adult neu-
ral stem cells as well as parenchymal astrocytes contact the blood vessels 
trough their basal domain. However, the apical domain of SEZ stem cells 
contacts the lateral ventricle, while parenchymal astrocytes ensheath syn-
apses.  
In conclusion, adult protoplasmic and fibrous astrocytes share hallmarks with 
the astroglia-like neural stem cells. However, the most striking discrepancy 
between radial glia and adult neural stem cells compared to adult cortical 
astrocytes is the neurogenic and proliferative capacity, which is lacking in the 
latter94. Interestingly, this changes upon injury, where astrocytes become 
reactive and gain some aspects of radial glia and neural stem cells. In the 
adult brain parenchyma, however, also other glial cell types such as the cells 
of the oligodendrocyte lineage reside.  
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Table 2- 1. Marker Expression of  Astrocyte Subtypes. 
The table depicts the marker expression of different astroglial subtypes as well as neuroepi-
thelial cells. DSD1 - dermatan sulfate-dependent proteoglycan-1, GFAP- Glial fibrillary acidic 
protein, GLAST - astrocyte-specific glutamate transporter 1, GLT1 - excitatory amino acid 
transporter 2, GS - glutamine synthetase, s100b – calcium binding protein, TNC - tenascin 
C. Modified from29,95.  
 
2.3.2 Oligodendrocyte Lineage 
 
During development three waves of oligodendrocyte progenitor cells 
(OPC) are generated. First, OPCs appear in the ventral forebrain at E12.5, 
and then also migrate into the telencephalon, entering the cerebral cortex at 
E16. However, most of these cells are eliminated at postnatal stages. The 
second wave starts in the lateral and/or caudal parts of the ganglionic emi-
nences around E15. After birth, OPCs are generated in the cortex and in the 
neurogenic niches6,96.  
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OPCs are stellate cells and can be identified by both: the earliest expressed 
platelet-derived growth factor alpha receptor (PDGFRα), and the chondroitin 
sulfate proteoglycan NG2 (NG2), which is up-regulated once progenitors 
leave their germinal zone97-101. The mammalian NG2 protein (also termed 
CSPG-4) is a single transmembrane spanning protein and could be classified 
as a member of the neurexin protein family, which are cell adhesion mole-
cules that are involved in the mediation of neuronal contacts at the synapse. 
However, the NG2 protein could also exert functions of a proteoglycan, since 
its chondroitin sulfate gylcosaminoglycan (CAG) chains are linked to the ex-
tracellular domain102. Different interaction partners may be relevant for the 
function of NG2+ cells at synapses and early myelination of axons but they 
are not fully understood until today. Furthermore, the NG2 protein is possibly 
involved in cell polarization and migration102. Antibodies directed against the 
NG2 protein are commonly used to identify OPCs in the developing and adult 
CNS (Figure 2- 3). In the adult, an OPC subset retains the ability to differen-
tiate into mature oligodendrocytes, while down-regulating NG2 expression103-
105. Mature oligodendrocytes can be visualized by their expression of the pi 
form of the Glutathione-S-Transferase (GSTpi)106 (Figure 2- 3). Signals from 
electrically active axons regulate the up-regulation of myelin-associated pro-
teins such as e.g. the proteolipid protein (PLP), the myelin basic protein 
(MBP) or the myelin-associated glycoprotein (MAG) in mature oligodendro-
cytes, resulting in lineage progression into myelinating oligodendro-
cytes107. Signalling also occurs from the oligodendrocyte to the neurons, 
since oligodendrocytes e.g. produce growth factors and induce axonal or-
ganization108-112.  
The basic helix loop helix transcription factor Olig2, a transcriptional repres-
sor, is expressed throughout the oligodendrocyte lineage (Figure 2- 3). It ex-
erts important functions in the specification and differentiation of oligodendro-
cytes113-115. Interestingly, Olig2 is up-regulated in different injury para-
digms116.  
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Figure 2- 3. Oligodendrocyte Lineage and their Specific Expression of Markers.  
Shematic pictures of cells of the cells belonging to the oligodendrocyte lineage. In the boxes 
below relevant marker for the specific cell types are listed. The green plus shows the pres-
ence of the depicted marker and the red minus its absence. CNPase - 2`3`-cyclic nucleotide 
3`-phosphodiesterase, GSTpi - Glutathione-S-Transferase, MAG - myelin-associated glyco-
protein, MBP - myelin basic protein, NG2 - Chondroitin sulfate proteoglycan, PDGFRα - 
platelet-derived growth factor alpha receptor , PLP - proteolipid protein. Modified from117. 
 
2.3.2.1 Features of NG2-Glia 
 
After myelination during development has occurred, NG2-positive cells still 
ubiquitously populate the adult cerebral cortex comprising 5-8% of all 
cells118,119. They exhibit a complex stellate morphology extending many finely 
branched processes120. Almost all NG2 cells co-express PDGFRα and Olig2, 
as well as Sox 10, whereas only a small subset additionally expresses astro-
cytic markers such as the glutamine synthetase (GS)102,121.  
NG2+ cells have the capacity to divide, while maintaining their multiple-
branched processes122. Therefore, they constitute the majority of the prolifer-
ating cell population outside the neurogenic niches in the adult mouse 
brain103,105,122,123. Also in the adult human brain, NG2 as well as Olig2 is ex-
pressed by the vast majority of cycling cells, located throughout the cortex124. 
The biological significance of the quiescent non-proliferating NG2+ cell popu-
lation still remains to be determined.  
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In contrast, the mitotically active oligodendrocyte progenitor cells are known 
to contribute to the generation of new oligodendrocytes during adult-
hood103,105,123. In addition, fate mapping analysis of Olig2+ cells revealed that 
some of these cells retain the ability to differentiate from an oligondendrocyte 
progenitor into myelinating oligodendrocytes in the rodent cortical white mat-
ter. In contrast, only a small proportion of Olig2+ oligodendrocyte progenitor 
cells in the cortical grey matter differentiates into mature oligodendro-
cytes103,105,125.  
Apart from their differentiation along the oligodendrocyte lineage in the adult 
brain, there is also evidence indicating some degree of lineage plasticity of 
NG2+ cells. Upon transplantation of fetally-derived OPCs into the adult glial-
depleted brain or shiverer mice (hypomyelinated mice) they can generate 
astrocytes and myelinating oligodendrocytes. Notably, adult-derived trans-
planted OPCs give only rise to cells of the oligodendrocyte lineage126,127. In 
line with these data, fate mapping analysis of embryonic NG2+ cells revealed 
a production of astrocytes in the grey matter of the ventral forebrain and spi-
nal cord in addition to the generation of cells of the oligodendrocyte lineage. 
In contrast, adult fate mapped NG2+ cells generate only cells of the oli-
godendrocyte lineage69,70,128,129. This suggests that NG2+ cells are intrinsi-
cally potent to generate astrocytes, but this ability is lost at adult stages. At 
early postnatal stages, NG2-positive cells in vitro could still generate astro-
cytes and mature, action potential-propagating neurons, suggesting that they 
not yet lost their multipotency130. Along this line, production of few neurons 
from adult NG2+ or PDGFRα+ oligodendrocyte progenitors has been ob-
served also in vivo131,132, suggesting that indeed some extent of neurogene-
sis may be mediated by NG2-positive cells. However, these data are still a 
matter of debate, since fate mapping of other mouse lines such as NG2-
EYFP knockin (EYFP, enhanced yellow flourescent protein) or 
Olig2::CreERTM mice did not reveal neurogenesis originating from these 
Olig2+ or NG2+ cells105,121,133.  
Another exciting feature of NG2+ cells is that most NG2-positive progenitors 
establish intimate contact to neuronal synapses and the nodes of Ranvier134-
137. Upon glutamate release by neurons, NG2+ cells generate an inward cur-
rent mediated by a postsynaptic-like structure present on the glial membrane, 
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which contains α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors136,138,139. This led to the idea of a neuron-NG2 glia synapse 
and to the expression “synantocytes” for NG2+ glia136. In addition, NG2+ 
cells in the corpus callosum express functional N-Methyl-D-aspartate 
(NMDA) receptors140. Besides glutamate, additional evidence for an evoked 
GABA(A) receptor current in response to interneuronal GABA release exists 
for NG2+ cells (Lin and Bergles, 2004). Therefore, NG2-positive glia can be 
distinguished according to their expression of different voltage-depended ion 
channels in both, the cortical grey and white matter, which results in different 
physiological properties. Strikingly, the generation of depolarization-induced 
immature spikes of a subpopulation of white matter NG2+ cells in the adult 
rat has been reported141. Yet, the consequences of the neurotransmitter re-
lated excitability of NG2+ cells is not well known. It is suggested that e.g. ac-
tivation via AMPA receptors may be involved in inhibiting proliferation and 
lineage progression in development142, while NMDA receptor mediated glu-
tamate inputs on NG2+ cells may play a role in cell migration143.  Whether all 
the above described synaptic features of NG2+ glial cells are transient or if 
they are a heterogenic cell population, where specific subpopulations exert 
different functions is still under debate. For example it has been shown that 
during the process of remyelination of a demyelinated area, axon-
oligodendrocyte progenitor synapses are formed only transiently. When the 
progenitors differentiated into mature oligodendrocytes, these synapses 
where lost144,145. Given all these facts, NG2+ cells exhibit features of both, 
progenitor cells, but also cells with synaptic contacts to neurons23,24,117.  
 
2.3.2.2 Myelinating Oligodendrocytes 
 
 
One important function of myelinating oligodendrocytes is myelin formation, 
which occurs in the central nervous system. Myelin enables rapid electrical 
conductance in neurons by electrically insulating the axons146,147. Upon mye-
lination, axon potentials are restricted to spaced intervals spared from myelin, 
referred to as “nodes of Ranvier” 148,149. Within the nodes of Ranvier, voltage-
gated sodium channels cluster on the axonal membrane which allow fast sal-
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tatory generation and conductance of action potentials148,150,151. In addition to 
the myelin acting as an insulator, different myelin proteins were shown to tro-
phically support the axon, as upon loss of certain myelin proteins, axons can 
undergo degeneration152,153. Therefore, many cognitive and motor functions 
depend on myelin formation. 
One oligodendrocyte is able to myelinate up to 50 axon segments, the so 
called “internodes” 147. Myelin consists of numerous wrappings of the oli-
godendrocytic bilayered plasma membrane around the axon. Up to now, 342 
proteins have been associated with CNS myelin147. In general, it can be sub-
divided into compact and non-compact myelin, with axonal internodes 
mostly consisting of the compact form of myelin (Figure 2- 4A,B,C). Ultra-
structurally, compact myelin is characterized by alternating circular dark (ma-
jor dense-line (MDL)) and lighter lines around an axon (intraperiod line (IPL)) 
(Figure 2- 4B). In areas of compact myelin, cytoplasm is mostly excluded, 
allowing tight stacking of plasmamembranes around the axon154. The most 
abundant proteins in the compact myelin are the PLP together with its 
smaller splice form DM20 as well as the MBP, which comprise to about 30-45 
% and 22-35 % of the total myelin amounts, respectively147,155,156 (Figure 2- 
4B`). MBP is so far the only myelin protein necessary for myelin formation. 
Accordingly, the shiverer mouse mutant, which lacks most of the gene en-
coding for MBP, has only thin myelin (hypomyelination)157-159. MBP has been 
implicated in e.g. signalling and cytoskeletal interactions160-162. On the con-
trary, the presence of the very hydrophobic transmembrane protein PLP is 
dispensable for myelin formation, since knockout mice still form myelin. How-
ever in the knockout mice, myelin stability decreases with age and addition-
ally axons develop defects such as axonal spheroids163.Other functions of the 
PLP protein include a role in oligodendrocyte survival153,154,163.  
The second component of CNS myelin is the non-compact myelin, which is 
not as densely packed as the compacted form so that intracellular cytoplasm 
and cytoskeletal assemblies still occur. Regions where non-compacted mye-
lin can be found in the CNS include myelin wrappings next to the axons 
(abaxonal) and myelin wrappings away from the axon (adaxonal) (Figure 2- 
4A`,A``,B) and the segments near the nodes154. For example, the enzyme 
2`3`-cyclic nucleotide 3`-phosphodiesterase (CNPase) is located in the cyto-
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plasm of non-compacted myelin (Figure 2- 4C). It constitutes approximately 
4-15 % of the total myelin amount. The physiological function of the phos-
phodiester hydrolysis of 2',3'-cyclic nucleotides to 2'-nucleotides, which is 
catalyzed by the CNPase, is still not known154. Yet, this enzyme has an im-
portant function in mediating axonal survival, since loss of the CNPase1 gene 
results in neurodegeneration152. Also the myelin-associated glycoprotein 
(MAG) is expressed in the non-compacted myelin (Figure 2- 4B``). It is en-
riched in the innermost non-compacted myelin membrane, which is directly 
apposed to the axonal membrane164,165. MAG accounts for 0.1-1% of the to-
tal myelin amount and is a type I transmembrane glycoprotein. It has been 
implicated in axon-myelin stabilization166 and has been speculated to inhibit 
axonal regeneration after injury167,168.  
Importantly, the number of wrappings of the oligodendrocytes membranes 
depends on the diameter of the axon: the thicker the axon diameter, the 
thicker is the myelin169. This is usually determined by the so called g-ratio, 
which is the ratio between the diameter of the axon and the outer diameter of 
the myelinated fiber170. The age of the maximum of myelination, where the 
rate of myelin formation is greatest, is around postnatal day 20156,171.  
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Figure 2- 4. Myelin Structure.  
(A) shows a schematic overview of an axon myelinated by an oligodendrocyte. Cross-
sections in internodal (A`), and paranodal (A``) segments. In (B) an overview of the structure 
of compacted myelin is depicted. (B`) is a blow up of the internodal compact myelin and its 
protein components PLP – proteolipid protein and MBP – myelin basic protein. (B``) is a 
magnification of the inner most myelin sheath, which is directly apposed to the axon. (C) 
represents structural components of non-compact myelin such as CNPase - 2`3`-cyclic nuc-
leotide 3`-phosphodiesterase. Picture was modified from147. Representative Electron Photo-
graph of a Myelinated Axon. (D) is a representative picture of a myelinated axon. (E) is the 
magnification of the myelin sheaths of the myelinating oligodendrocyte. (F) shows a further 
enlargement, where one can distiguish between the major dense line (MDL) and the interpe-
riod line (IPL).  
 
2.3.3 Microglia 
 
In contrast to astrocytes and oligodendrocytes, microglial cells emerge from 
the mesoderm and populate the cerebral cortex at around E10–E19 in ro-
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dents172-174,175,176. In the adult rodent CNS, they comprise more than 10% of 
all cells. In the healthy condition they are considered to be „surveillant micro-
glia“. They are referred to as “ramified cells” that have small cell somata and 
extend radial, non-overlapping processes177, which are constantly moving 
while sensing the environment178,179. Furthemore, a small number of micro-
glial cells seems to actively divide, which may contribute to their main-
tainance in the CNS180. Upon injury also bone marrow-derived cells can infil-
trate from the blood into the brain and adopt a microglial identity. Therefore, it 
is still under debate if these cells may also contribute to the microglial main-
tainance in the healthy brain172,181. Invasion of such bone marrow-derived 
cells was already observed, however other studies could not corroborate 
these observations182,183,180. Thus, the precise mechanisms of microglial cells 
maintainance in the adult brain remain to be elucidated. One important func-
tion of microglia is their ability to rapidly respond to changes in the environ-
ment such as brain injury.  
2.4 Glial Cells and their Reaction towards Injury 
 
Glial cells of the CNS provide structural and functional support for neurons 
under physiological conditions. In addition, glial cells also react toward brain 
injury. As observed in the peripheral wound repair, scar formation also takes 
place in the either mechanically or pathologically injured brain. The process 
of scar formation is evolving from glial cells with time at the lesion side184,185. 
The glial scar mainly consists of astrocytes, however, after severe lesion with 
open meninges, it also includes other cell types such as myelin debris, infil-
trating blood-borne immune cells, fibroblasts, pericytes, endothelial cells, mi-
croglia and NG2+ cells184,186-188. Such a severe lesion paradigm, where glial 
scar formation take place, is represented by the acute stab wound injury, 
where the cortical grey matter is acutely cut with a knife as well as experi-
mental stroke, where the middle cerebral artery is occluded (MCAO). In the 
former, the cut leads to a transient edema with necrotic and apoptotic cells 
death. Furthermore, opening of the meningitis results in invasion of blood-
derived cells189. In the latter, the blood flow falls to less than 20 % at the ves-
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sel which is occluded190,191. As a result, glucose and oxygen delivery are dis-
rupted, also causing neuronal and glial cell death via multiple processes such 
as excitotoxicity, acidotoxicity, ionic imbalance, oxidative and nitrative stress, 
inflammation, peri-infarct depolarisation and apoptosis192. The penumbral 
tissue next to the core area is less affected, since it gains perfusion from ad-
jacent vessels with the blood flow being reduced to 20-40 % 191. Here, cell 
death occurs in a slower progressive manner via inflammation and apop-
tosis192.  
Glial scar formation is mostly considered to be beneficial in the initial phase 
after brain injury, as it seals the lesion side and restores the brain’s homeo-
stasis by, amongst other things, initiating angiogenesis187,193. However, the 
same tissue additionally is considered an obstacle for axonal growth in the 
long run and is therefore also implicated in disturbing recovery185.  
 
 
 
Figure 2- 5. Mouse Models of Acute Brain Injury. 
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(A) is a representative picture of a mouse brain. (B) demonstrates coronal DAPI stained sec-
tiones, where the lesion area of a stab wound lesion and an MCAO (middle cerebral artery 
occlusion) model for stroke are indicated with the red arrowheads. Modified from194,195. 
 
 
Immediately after injury, glial cells first undergo morphological and functional 
changes. This leads e.g. to an increase of the de novo synthesis of soluble 
factors such as growth factors, cytokines and proteases95. In accordance to 
these differences also the extracellular matrix (ECM) changes196,197, which 
may strengthen the tissue and promote wound contraction184,185,198. The se-
verity of the glial cell reaction is correlated to the severity of the injury and 
must not always include glial scar formation, which is most prominent in large 
invasive injuries such as e.g. stab wound lesion described above187. In gen-
eral upon injury, microglial cells are considered as one of the first cell type 
located at the CNS injury side. Interestingly NG2+ cells react similarly fast 
since proliferation of both cell types is increased as early as three days after 
injury at the lesion side103. In contrast, reactivity of astrocytes is delayed with 
e.g. their increased proliferation occuring at seven days post injury184.  
 
2.4.1 Reactive Astrocytes 
 
Given the potential of astroglial cells to act as stem cells in two neurogenic 
niches such as the SEZ and the sugranular layer of the dentate gyrus of the 
hippocampus, it is of special interest to determine their reaction towards in-
jury also in non-neurogenic zones such as the cortical grey matter. 
Reactive astrogliosis is a well known feature upon brain injury where astro-
cytes become reactive. Depending on the duration, severity and type of in-
jury, the features of this phenomenon vary. The most striking event where 
astroglia take part is glial scar formation, which seems to be restricted to 
large invasive injuries. The glial scar is not only comprised of astrocytes but 
may also include e.g. fibromeningeal cells188, other glia (e.g. NG2+ glia) and 
dense collagen extracellular matrix. The astrocytes present in the glial scar 
include astrocytes, which were present before injury as well as the astrocytes 
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generated by proliferation after the lesion. Interestingly, protoplasmic astro-
cytes present in the glial scar now display overlapping regions contrary to 
their physiological non-overlapping distribution199,200. It has to be considered 
that the astrocyte’s reaction toward injury exerts both detrimental and benefi-
cial effects. Along this line, glial scar formation inhibits axonal regeneration, 
due to the enrichment in chondroitin sulphate proteoglycans (CSPGs) in the 
ECM, which are also released by astrocytes186. Other detrimental effects in-
clude e.g. the possible release of neurotoxic levels of glutamate201, reactive 
oxygen species202 or cytokines from astrocytes upon injury. The latter may 
worsen the inflammatory response, since in vivo antagonization of a cytokine 
signalling pathway (the NFkB pathway) in astrocytes promotes neuronal re-
sistance to injury203,204. Pro-apoptotic molecules may diffuse via gap junc-
tions into surrounding brain areas, thereby triggering further brain damage201. 
Strikingly, deletion of reactive astrocytes (GFAP/vimentin double knockout or 
GFAP ablationed mice) results in improved synaptic and post-traumatic re-
generation205,206.  
This view has been challenged by the fact that reactive astrocytes also pro-
tect the brain tissue in many ways. Ablation of reactive astrocytes simultane-
ously increases the infarct volume as seen e.g. upon MCAO207. This indi-
cates that astrocyte reactivity may exert different effects switching from ini-
tially positive to negative ones95. The glial scar additionally prevents inflam-
matory cells and other cells from entering the intact parts of the 
brain199,205,208. Consequently, ablation of proliferating astrocytes after injury 
results in an increase in inflammation and lesion volume as well as insuffi-
cient BBB repair205,208. Astrocytes additionally protect e.g. against oxidative 
stress209,210 and take-up potentially excitotoxic glutamate211. Furthermore, 
they metabolically support neurons upon brain lesion212. Beyond that, astro-
cytes are capable of releasing pro- and anti-inflammatory molecules, thereby 
contributing to the brain’s immune response213,214. 
Other prominent characteristics of astrocyte reactivity after injury include as-
trocytic hyperthrophy, up-regulation of intermediary filaments (Figure 2- 6) 
and eventual proliferation187. Moreover, extracellular matrix molecules such 
as the glycoprotein tenascin C (TNC) and the DSD-1 chondroitin sulfate epi-
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tope (detected by the 473HD antibody) are released by reactive astrocytes 
upon acute brain lesion48,95,215,216.  
Most interestingly, upon acute brain injury a subset of reactive astrocytes re-
gains the ability to proliferate, the most striking feature of embryonic and 
adult neural stem cells103,216,217. On the contrary, in the healthy cortical grey 
matter astrocytes rarely divide217. In terms of a time course of the reaction it 
is known that e.g. after acute stab wound injury, protoplasmic astrocytes first 
become hyperthrophic and up-regulate GFAP and/or nestin expression. At 
this early time point, astrocytes also up-regulate and secrete extracellular 
matrix proteins such as TNC and DSD-1. At later time points (7 days after 
injury) about 55 % of the total astrocyte cell pool resumes proliferation95,103. 
Could all astrocytes proliferate in a sufficiently large injury condition or is it a 
specific subset of astrocytes exhibiting a greater potential? So far these 
questions still need to be elucidated. 
 
 
Figure 2- 6. Reactive Astrocyte. 
Representative picture of an astrocyte in the healthy brain in (A) and a hyperthrophic, reac-
tive astrocyte, that up-regulated expression of the intermediate filament GFAP in (B). GFP is 
a staining performed in the GLAST::CreERT2 x CAGGFP, which is almost exclusively ex-
pressed by astrocytes. Notably, GFAP expression only co-localizes to the main fibers of the 
whole astrocyte. Scale bar: 10µm. 
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Another striking feature of protoplasmic reactive astrocytes after acute injury 
is that they exhibit the potential to generate multipotent neurospheres in vitro, 
a hallmark of neural stem cells216-218. Furthermore, upon injury distinct sub-
sets of reactive astrocytes in the cortical grey matter re-express markers 
reminiscent of stem cells (see table 2- 1). A further prove for their potential 
after acute injury is the astrocyte’s ability to adopt a neuronal fate e.g. upon 
forced expression of a neurogenic transcription factor116.  
In summary, the astrocyte’s reaction can exert beneficial as well as detrimen-
tal effects. Furthemore, protoplasmic astrocytes de-differentiate upon acute 
brain injuries, acquiring features of neural stem cells. However, if astrocytes 
would have an equivalent stem cells potential also upon AD pathology has 
not been investigated so far.  
2.4.2 The Reaction of NG2+ Glia toward Injury  
 
Apart from their contribution to the glial scar, the NG2+ glia, also react toward 
injury. Upon e.g. acute stab wound injury or demyelinating injury, NG2+ glia 
become hypertrophic, up-regulate the expression of the NG2 protein and re-
sume proliferation103,116,219-221 (Figure 2- 7). Consequently, three to five days 
after e.g. acute brain injury NG2+ cells increase in number at the lesion side. 
Furthermore, the newly formed glial scar contains high levels of NG2+ cells, 
which also includes NG2-expressing macrophages and pericytes188. With 
time, NG2 protein expression then gradually declines222,223. Up-regulation of 
the NG2 protein putatively inhibits axonal regeneration222, since the NG2 
core protein induces growth cone collapse and inhibits axonal growth in vi-
tro224,225. Accordingly, axonal growth within the glial scar increases in mice 
treated with an anti-NG2 antibody226. However, after spinal cord injury, NG2 
null mutant mice show no difference in axonal regeneration compared to 
wildtype mice227. Along this line, in a co-culture of hippocampal neurons with 
NG2+ cells, neurite tips actively establish contacts to NG2+ glia. In addition, 
neurons co-cultured with NG2+ glia extend longer axons than in co-culture 
with fibroblasts228. Therefore, it is still under debate, if the NG2 protein exerts 
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beneficial or detrimental functions in terms of axonal regeneration within the 
glial scar.  
Another feature of the reaction of NG2+ cells toward injury is their capacity to 
transdifferentiate under certain conditions. After acute cryolesion or demyeli-
nation in aged animals, NG2+ cells generate astrocytes229,230. In contrast to 
these findings, in other lesion paradigms, such as stab wound lesion, NG2+ 
cells fail to generate astrocytes105,231. This suggests that NG2+ cells may re-
acquire their embryonic ability to generate astrocytes after specific types of 
brain injury. Interestingly, the ability to transdifferentiate upon demyelination 
is gained in aged animals, which would be of particular interest for sporadic 
Alzheimer’s disease230. 
In addition to their possible abilities to transdifferentiate, NG2+ cells are fre-
quently implicated in the process of remyelination upon e.g. demyelinating 
diseases where “myelin sheaths are lost from around axons“ 170. Demyelina-
tion leads to a redistribution of the axonal sodium channels from the node of 
Ranvier along the nude axon232 resulting in non-saltatory and therefore 
slower conduction of action potentials. At places of remyelination saltatory 
condution is functionally re-acquired233. Yet, the remyelinated myelin usually 
is thinner than the original one234,235. NG2+ OPCs likely are the major cell 
population responsible for remyelination, as only little evidence indicates an 
involvement of mature opligodendrocytes in this process170. Proliferating 
NG2+ cells are observed around the demyelinated area before they possibly 
differentiate further into myelinating oligodendrocytes236-238. For demyelina-
tion occurring in the white matter, stem cells of the adult SVZ239,145,240 or their 
progenitor cells in the RMS were discovered to represent additional sources 
for myelin repair241,242 241,242.     
In conclusion, NG2+ cells take part in the glial scar formation after large in-
vasive injury. Furthermore, they proliferate after lesion and are likely involved 
in myelin repair after demyelination. However, so far little is known about the 
reactivity of NG2+ cells in response to chronic lesion paradigms such as Alz-
heimer’s disease.  
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Figure 2- 7. NG2+ Cells in the Healthy and Lesioned Brain. 
(A) represents NG2-positive cells populating the healthy cortical grey matter. (B) is a repre-
sentative and magnified picture of NG2+ cells after lesion (here plaque deposition). 5-
Bromo-2′-Deoxy-Uridine (BrdU) was applied to the drinking water for two weeks and incoop-
erates into the DNA upon S-phase of the cell cycle. Therefore, B` and B`` indicate a previ-
ously proliferating NG2+ cell. Scale bar: 20μm. 
2.4.3 The Reaction of Microglia toward Brain Injury 
 
When a surveillant, ramified microglia senses stimuli such as damaged or 
apoptotic cells upon injury, it changes into a “reactive“ state. For example, 
upon traumatic brain injury, ATP is released from dying cells which triggers 
via the purinoceptor P2Y12 the extension of microglial processes. Microglia 
then rapidly migrate from toward the injury243,244. In addition to elevated ex-
pression of purinergic receptors also induced nitric oxide (NO)-synthase ac-
tivity is correlated with an increased microglial activity245-247. Activated micro-
glia produce numerous pro- and anti-inflammatory cytokines, growth factors 
and neurotrophins177. Upon mild injuries, the conversion from a ramified mor-
phology into a “hyper-ramified” morphology is induced, which indicates the 
beginning of hyperthrophy. If the brain injury is more severe, hyper-ramified 
microglia enlarge their soma while retracting and shortening their processes 
so that they overt an amoeboid-like shape (see Figure 2- 8). In this stage of 
microglial activation, an increase in number via proliferation and/or recruit-
ment from the blood is often observed245. In addition, the expression of sev-
eral antigenes such as myeloid cell markers becomes elevated177. However, 
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in this reactive stage only little phagocytosis takes place248. Upon strong acti-
vation such as axotomy, microglia acquire the ability to phagocytose debris 
such as degraded cells or myelin sheaths249. Furthermore, in such a condi-
tion they may also produce reactive oxygen and nitrogen species and may 
express molecules related to T-cell activation (Figure 2- 8)177,249.  
Microglia exert important functions in the early brain reaction toward injury as 
well as in the inflammatory response and it should be noted that the specific 
microglial reaction also depends on the specific injury paradigm.  
 
 
Figure 2- 8. Stages of Microglial Activation. 
In response to injury microglial cells become reactive, by passing through an immediate 
stage. Phagocytic activity is little in reactive microglia, while in severe injuries they addition-
ally gain phagocytic properties. Modified from250-252.  
2.5 Alzheimer’s Disease – a Chronic Lesion Paradigm 
 
Neurodegenerative diseases occur in an acute or chronic manner. In acute 
lesions such as stroke, different types of neurons and glial cells in a restricted 
brain area are injured and consequently lost in a short period of time. On the 
contrary, in a chronic injury, degeneration takes place over a time period of 
several years either selectively affecting a specific neuronal type as in Park-
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inson’s disease or acting more widespread as observed in Alzheimer’s dis-
ease (AD)253 .   
2.5.1 Epidemiology 
 
AD is a pathology responsible for 70-80 % of all dementia cases worldwide 
among people over 65 years of age254. Unfortunately, the incidence of AD 
doubles with every five years increase in age. Thus, the risk to get AD is 
around 0.6 % at the age of 65 to 69 and 8.4 % at the age of 85 years and 
older255,256. Especially, in highly developed countries where life expectancy is 
increased, this may lead to severe social and economic problems. For exam-
ple, in the USA 4.5 million residents suffered from AD in 2000 257 and it has 
been predicted that in 2050 the number of AD patients will be as high as 13.2 
million in the USA258.  
Two forms of AD can be distinguished: the familial form and the sporadic 
form. The onset of the disease in the familial cases takes place at an age of 
20-40 years as a consequence of mutations in certain genes (5-10 % of all 
AD cases; 259). The sporadic form of AD affects patients later in life, at the 
age of 60 to 70 years259. For this AD form, age is considered a major risk fac-
tor260. In addition, the inheritance of the ε4 allele of the apoE4 transporter is 
another established risk factor. About 40-80 % of the sporadic AD patients 
are carriers of at least one allele261,262. The APOE4 allele increases the risk 
by three times in heterozygous and 15 times in homozygous carriers263. 
2.5.2 Clinical Presentation 
AD is a disease that causes impairments in memory, thinking and behavior. 
The progression of AD is defined by different stages initially described by Dr. 
Barry Reisberg as the Global Deterorientation Scale (GDS), which character-
izes seven stages264,265. A modified stage system, the Functional Assess-
ment Staging of AD (FAST), measures more specifically the progression of 
mental decline266-268. In general, staging is based on the theory of retrogene-
sis, which claims that “degenerative mechanisms reverse the order of acqui-
sition in normal development” (see table 2- 2), meaning that patients pro-
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gressively loose the latest acquired memories first and afterwards the early 
childhood memories269. In general, the progression of AD occurs over many 
years and is difficult to predict. 
2.5.3 Pathology 
 
In 1907 the physician Alois Alzheimer270 discovered the presence of extracel-
lular amyloid plaques and the accumulation of intraneuronal neurofibrillary 
tangles in brain tissue of patients, who suffered from the disease that later 
was named after him. 
 
Stage GDS FAST Characteristics 
1 No cognitive decline No functional decrement manifests 
2 Very mild cognitive 
decline 
Complains of forgetting location of objects;  
Subjective work difficulties. 
3 Mild cognitive decline Decreased functioning in demanding em-
ployment setting evident to co-workers;  
Difficulty in travelling to new locations. 
4 Moderate cognitive 
decline 
Decreased ability to perform complex tasks 
such as planning dinner for guests, or han-
dling finances 
5 Moderately severe 
cognitive decline 
Requires assistance in choosing proper 
clothing; may require help to bath properly. 
6 Severe cognitive de-
cline 
(a) Difficulty putting on clothing properly 
(b) Requires assistance bathing 
(c) Inability to handle mechanics of toileting 
(d) Urinary incontinence 
(e) Fecal incontinence 
7 Very severe cognitive 
decline 
(a) Ability to speak limited to one to five   
     words 
(b) All intelligible vocabulary lost 
(c) All motoric abilities lost 
(d) Stupor 
(e) Coma 
Table 2- 2. Decline in Human Alzheimer’s Disease. Modified from268. 
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2.5.3.1 Amyloid Plaques 
 
Amyloid plaques are found in all AD cases. Per definition they are spherical 
extracellular deposits in the brain parenchyma, predominantly composed of 
the amyloid-β-peptide (Aβ). Initial patches of plaques are seen in the basal 
neocortex, while with time plaques spread into adjacent neocortical areas 
and the hippocampus271. How is the Aβ peptide produced? It turned out that 
Aβ is produced via a sequential proteolytic cleavage of an amyloid precursor 
protein (APP)272,273. The APP protein, which is encoded by a gene located on 
chromosome 21, is a type I transmembrane protein272. It is ubiquitously ex-
pressed272 and is localised at the plasma membrane, trans-Golgi network, 
endoplasmatic reticulum, endosomal, lysosomal as well as mitochondrial 
membranes. In neurons, its functions range from roles in synaptogenesis, 
neurite outgrowth and cell adhesion274-276. Interestingly, APP expression is 
elevated during neuronal differentiation277 as well as after brain injury278.  
Initially, the APP ectodomain (extracellular side) is shedded by a membrane-
anchored protease, called β-secretase279,280. The remaining APP-stub is then 
proteolyzed by the γ-secretase complex, an aspartyl-protease281. It regulates 
the intramembranous cleavage within the APP transmembrane domain to 
finally release the Aβ peptides of different length (Aβ39-Aβ43)282. The γ-
secretase is composed of 4 different proteins. Most important are the pro-
teins presenilin 1 (PS1) and/or presenilin 2 (PS2), which harbour the active 
side of the γ-secretase283. The amino acid sequence of the Aβ peptide may 
differ due to the variability of the intramembranous cleavage. Aβ40 is the 
peptide predominantly present in the healthy condition, while Aβ42 is gener-
ated to a lesser extent. Upon AD, the Aβ40/Aβ42 ratio is shifted in favour of 
Aβ42, which is more hydrophobic, prone to form oligomers or aggregate into 
fibrils284.  
In AD three major Aβ deposits are present, namely vascular deposits and 
parenchymal diffuse or focal plaques. While diffuse plaques have a size of 
around 50 μm to several 100 μm, focal plaques show dense and spherical 
accumulations of the Aβ peptides and usually have a size of about 10-50 
μm285. The latter may lead to neurite breakage and loss of spine286. Further-
more, glial cells react prominently toward focal plaques287 and sparsely to-
ward diffuse ones288,289.   
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2.5.3.2 Tangles 
 
The second hallmark of AD is the presence of intraneuronal neurofibrillary 
tangles270. Contrary to the progression of the amyloid plaques, neurofibrillary 
tangles first appear in a small region of the entorhinal cortex. Also subcortical 
nuclei, in particular the nucleus basalis of Meynert, which harbours acetyl-
choline efferent fibers connecting it to the cortex290 and the locus coeruleus, 
that projects via noradrenergic efferences to the cortex291 are affected early 
in the disease progression. With time neurofibrillary tangles spread over the 
limbic system to neurons in the higher neocortex292.  
But what are tangles? They consist of non-soluble hyperphosphorylated tau. 
Under physiological conditions tau is a highly-soluble protein293,294, which is 
associated with axonal and also neuronal microtubules and is involved in the 
stabilization and assembly of them294,295. Its function is regulated by its de-
gree of phosphorylation293,296. Upon AD, tau becomes aberrantly phosphory-
lated by e.g. the cycline-dependent kinase 5 (Cdk5), which leads to a de-
tachment of tau from the microtubules, and results in their disruption296,297. 
Tau then assembles into paired helical filaments298. As the microtubuli disin-
tegrate, the axonal transport system collapses299, thereby contributing to neu-
ronal cell death300.  
2.5.3.3 Synapse and Neuron Loss 
 
Apart from extracellular plaque deposition and tangle formation, also neu-
ronal and synaptic losses are part of human AD pathology. Continuing neu-
ronal loss also accounts for brain atrophy and dysfunction301,302. Interestingly, 
neuronal loss takes place focally e.g. in layer II of the entorhinal cortex303, the 
CA1 region of the hippocampus304 and the superior temporal gyrus305. Even 
though neurons die, loss of synapses is most indicative for the intellectual 
deficit in AD306-309. Notably, neuronal as well as synapse loss but also tau 
pathology are additionally linked to the clinico-pathologic relationship of other 
dementias310 and are therefore not solely indicative for AD.  
Up to now, several theories on how AD progresses are discussed in the field 
of AD research. One of the leading hypotheses is the Aβ cascade hypothe-
sis, which will be discussed below. 
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2.5.3.4 Aβ Cascade Hypothesis 
 
Some familial AD cases carrying mutations in APP (about 36 mutations 
known) and all familial AD-patients with mutations in PS1 (about 180 muta-
tions known) or PS2 (about 20 mutations known) display elevated production 
of Aβ42284,311,312. In these patients either Aβ42 levels are increased or the 
Aβ40/Aβ42 ratio is shifted in favour of Aβ42313,314. This imbalance of Aβ gen-
eration and the enzymatically mediated Aβ clearance (e.g. by the insulin-
degrading enzyme)315 is believed to be the major cause of plaque deposition, 
leading to dementia with tangle pathology316. Recent findings led to modifica-
tions of the hypothesis. First, plaque load of patients does not correlate with 
memory loss and second because robust plaque deposition has been de-
tected also in non-demented individuals309,317-319,320. Third and most striking, 
a strong correlation between the presence of small soluble Aβ oligomers and 
cognitive decline was observed321,322. Therefore it is now believed that rather 
the small soluble Aβ oligomers may be the detrimental molecular component 
causing AD pathology with plaques serving as a potential reservoir312. How-
ever, one should keep in mind that many other hypotheses on how AD de-
velops are discussed and each of them consequently leads to a different 
therapeutic strategy. One problem in studying AD could be due to the fact 
that so far no mouse model resembles the complete human AD pathology 
but rather reflect selected features323. However, this at the same time is an 
advantage since isolated aspects and consequences of the very complex 
pathology can be investigated independently. Therefore, I chose to examine 
on two of the known mouse models, namely the APPPS1 and CK/p25 mice 
reflecting distinct aspects of AD pathology observed in patients. 
2.5.4 APPPS1- A Mouse Model with Plaque Deposition 
 
The APPPS1 mouse line expresses two mutations known to be a cause of 
familial AD under the postnatally active neuronal minigene promoter Thy1324. 
It carries the so called “swedish double-mutation” of the APP protein at posi-
tion 670 and 671 (KM670/671NL), which results in a switch from lysine to 
asparagine and methionin to leucine, respectively325. In humans this double-
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mutation leads to AD onset between 45 and 61 years of age and continues 
for approximately seven years. In addition, the APPPS1 mouse line ex-
presses a leucin to prolin point mutation in the PS1 gene, which is the most 
aggressive familial human AD mutation identified so far, the disease onset is 
around 24 years of age leading to death at the age of about 35. This PS1 
mutation leads to an strong increase in the Aβ42 amount, while Aβ40 and 
Aβ38 levels decrease326,327.  
Transgenic human APP expression in APPPS1 mice exceeds endogenous 
APP expression by approximately three times. The ratio of Aβ40/Aβ42 in the 
double-mutated APPPS1 mice changes from 1 to 1.6 prior to plaque deposi-
tion to 1 to 5 in mice with plaques. APPPS1 mice display neocortical extracel-
lular plaque deposition already apparent at three months of age, spreading 
later throughout the brain (Figure 2- 9). The initial plaques are small and 
dense. With age, amyloid plaque deposition progresses, resulting in an in-
crease of both, plaque size and number. The highest rate of new plaque for-
mation is detectable between four and five months of age (Figure 2- 9)328. At 
eight months of age, four types of plaques can be distinguished:  
1) Vascular amyloid (rare and restricted to the large pial vessels) 
2) Small, dense core plaques   
3) Larger plaques with a dense core and a large halo of diffuse amyloid, and   
4) Plaques with a dense core surrounded by a defined corona of diffuse amy-
loid324. The latter represents the plaque type mostly seen in human AD. In 
the vicinity of the plaques, dystrophic synaptic boutons, hyperphosphorylated 
tau-positive neuritic structures, an increase of microglial cell numbers and the 
presence of reactive astrocytes are observed. Furthermore, these mice ex-
hibit cognitive defects324, emphasizing the model’s value of reflecting several 
important aspects of AD pathology.  
In conclusion, APPPS1 mice exhibit progressive amyloid plaque deposition 
pathology but lack obvious neuronal death. Furthermore, tau pathology is 
restricted to areas around plaques and no tangle formation within neuronal 
cell bodies is detectable324,329. Therefore, this mouse model is suitable to 
study plaque-related glial reactions. Nevertheless, to gain insight into the glial 
cell reaction upon neuronal death and tangle pathology, I utilized an addi-
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tional mouse model the CK/p25 mice, which is described in the following sec-
tion. 
 
 
 
Figure 2- 9. Plaque Load at different Ages of APPPS1 Mice.  
Pictures (A-C) show sagital sections of APPPS1 mice at (A) 3, (B) 6 and (C) 9 months of 
age. The sections were immuno-stained with the 6E10 antibody, detecting human APP and 
Aβ. The plaque burden constantly increases with age, including more brain regions, while 
mostly sparing the cerebellum. Scale bar: 200µm. 
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2.5.5 CK/p25- A Mouse Model with Neuronal Loss  
 
The CK/p25 mouse line inducibly overexpresses human green flourescent 
protein (GFP)-tagged p25 (p25) under the control of the calcium/calmodulin-
dependent protein kinase II (CK) promotor, which restricts the transgene ex-
pression to neurons of the forebrain330,331. The p25 peptide is physiologically 
generated from the p35 peptide via a calpain cleavage taking place upon e.g. 
oxidative stress or presence of the Aβ peptide332-334. Both, p25 and p35 are 
regulatory subunits of the cycline dependent kinase 5 (Cdk5)335, with the 
subunit p25 leading to a longer lasting activation of Cdk5. Furthermore, the 
subunit p25 alters the Cdk5 substrate specificity and shifts its localisation 
from membrane-associated to nuclear and/or cytoplasmic. Upon regulatory 
subunit binding, the protein serine-threonine kinase Cdk5 becomes active 
and phosphorylates substrates on their serine and threonine residues336. As 
one of its targets includes the tau protein, Cdk5 was originally identified as 
the major tau kinase337,338. Upon human AD, p25 expression levels as well as 
Cdk5 activity are increased339-341 and associated with apoptotic cell 
death333,340.  
The CK/p25 mouse line expresses p25 in neurons using the doxycycline-
dependend Tet-OFF system (p25-TetOperon (TetO))331,342. After crossing 
these mice to mice expressing the transactivator domain (TTA) under control 
of the neuronal calcium/calmodulin-dependend kinase (CK) II promoter, with-
drawal of doxycycline results in ectopic expression of p25 in neurons of the 
cerebral cortex (Figure 2- 10).  
 
Figure 2- 10. CK/p25 Mouse Model. 
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CKp25 mice are generated via crossing the CK mice harbouring the transactivator domain 
(TTA) to the p25 mice, which expresses the p25 behind the Tet-Operon (Tet-O) promoter. 
Upon doxycycline (Dox) withdrawal, p25 becomes expressed specifically in CamKII-positive 
neurons in double-transgenic mice. Modified from330.  
 
 
As the p25 protein is fused to GFP (Figure 2- 10), staining for GFP confirms 
the expression of p25 in mature NeuN-positive neurons of double-transgenic 
mice 5 weeks after doxycycline withdrawal (Figure 2- 11A,B). At 2 weeks af-
ter doxycycline withdrawal, already apoptotic neurons are detectable, consis-
tent with the described apoptotic death of these neurons (Figure 2- 
11C,D)331. At the same time point, the cortical thickness is slightly reduced 
compared to control mice. At 5 weeks of doxycycline withdrawal the cerebral 
cortex of CK/p25 mice is obviously reduced compared to control animals 
(Figure 2- 11E). According to the literature, expression of p25 in CK/p25 mice 
for five weeks leads to progressive apoptotic cell death with a brain weight 
reduction of 15-20 %. After transgene expression for eight or twelve weeks 
the bitransgenic mice exhibit a 25 % or 40 % decrease in the cortical neu-
ronal density, respectively. In addition, hyperphosphorylation of tau can be 
detected in CK/p25 mice331. In addition, this transgenic mouse line exhibits 
intraneuronal accumulation of Aβ and the development of cognitive defects 
are present in this mouse line342,343. Consequently, within a few weeks of p25 
expression, massive neuronal death and GFAP activation is observed in this 
mice331,342. CK/p25 mice therefore represent a valuable mouse model reflect-
ing some features commonly observed upon human AD pathology.  
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Figure 2- 11. Phenotype of CKp25 Mice upon Different Durations of Doxycycline Withdrawal. 
 
As confirmation of the funtional mouse line, (A, B) show a staining for GFP, which detects 
p25 expression co-localising with NeuN-positive neurons. Staining for activated caspase 3 
(Casp. 3) in (C),  (D) shows an overlay of Casp.3 in a GFP labelled neuron. In (E) overview 
pictures of DAPI stained brain sections of control, CK/p25 2 weeks OFF and CK/p25 5 
weeks OFF treated animals at an equivalent Bregma level are presented. The cortical thick-
ness is reduced and the ventricular size is enlarged specifically 5 weeks OFF treated CK/p25 
animals. Scale bar indicates 50 µm in (E) and 20 µm in (A-D). 
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2.6 Glial Cells in Alzheimer’s Disease Pathology 
2.6.1 Astrocytes 
 
Upon Alzheimer’s diesease astrocytes become reactive and are mostly as-
sociated with focal plaques324,344-346. Astrocytes densely surround the 
plaques with their processes, thereby forming a barrier between plaque and 
brain tissue71,347. Astrocytes in the vicinity of plaques also become hyper-
throphic, while those located away from them were also shown to undergo 
atrophy348. In addition to these features upon AD, astrocytes overt altered 
gap junctional coupling and Ca-signaling, which may impair neuronal func-
tion349. Also the expression of glutamate transporters of astrocytes declines 
with increasing AD stage. This may additionally elevate the vulnerability of 
neurons toward excitotoxicity211,350,351. Importantly, changes in synaptic plas-
ticity appear to be worsened by astrocyte atrophy352. 
Upon AD pathology, some endogenous degradation of amyloid plaques 
takes place. In vivo imaging revealed that although most of the plaques seem 
to be relatively stable within a couple of months, a few of them decrease in 
size with time353. Similarly, analysis of human AD patient tissue shows that 
the most advanced AD cases (measured by Braak staging) have a slightly 
reduced plaque frequency than cases of a previous stage354. Strikingly, as-
trocytes are not only attracted by Aβ42355 but also are capable to take it up, 
accumulate it and degrade it in vitro355-357. Astrocytes that have taken up Aβ, 
may exert metabolic disturbances as well as a production of hydrogen perox-
ide, an oxidative stressor358. Some plaques may derive from the death and 
subsequent lyses of Aβ overloaded astrocytes357.  
In addition to the accumulation of Aβ, the expression of the Aβ-degrading 
enzyme neprilysin is induced in reactive astrocytes in mice, which exert ex-
tracellular plaque deposition359,360. However, neprilysin seems to be soley 
efficient for proteolytical degradation of soluble Aβ. The metalloproteinase 9 
(MMP9), which is additionally produced and released by astrocytes located in 
the vicinity of extracellular plaques, represents a more efficient enzyme to 
reduce the plaque burden formed by aggregated amyloid fibrils (fAβ)361.  
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As the inheritance of the ε4 allele of the apoE4 transporter is a major risk fac-
tor for sporadic AD, it is important to note that within the central nervous sys-
tem, APOE is highest expressed by astrocytes and microglia362. Upon aging, 
expression levels of APOE are increased in astrocytes103,363. Similarly, upon 
AD pathology APOE co-localizes with astrocytes as well as plaques and tan-
gles364. Furthermore, the expression of the apolipoprotein E in astrocytes 
seems to be crucial for their ability to accumulate Aβ, since in astrocytes 
where APOE is knocked out, this ability is lost365. According the the Aβ hy-
pothesis AD is caused by an imbalance of Aβ clearance and Aβ production. 
Therefore, astrocytes may have a crucial contribution to the development of 
AD since APOE dysfunction is involved in the clearance of Aβ by astrocytes. 
Summarizing, astrocyte atrophy, altered Ca-signalling or other AD-related 
disturbances may additionally account for the emergence of the pathology.   
3.6.2 Oligodendrocytes  
 
Myelination of the frontal lobe white matter proceeds until mid-age in healthy 
humans and then declines progressively. On the contrary, grey matter struc-
tures are linearly lost in normal ageing366. Furthermore, myelin maintenance 
may comprise a continuous myelin turnover105. Thus aging, the major risk 
factor of developing sporadic AD, is accompanied with increases in myelin 
aberrations369,370 and myelin breakdown371,372, which is exacerbated upon AD 
pathology371-373. In addition to the formation of plaques and tangles as well as 
focal neuronal degeneration, loss of myelin is additionally observed in human 
AD patients. The white matter is reduced in size and the expression of myelin 
proteins in the corpus callosum (CC) and frontal cortex white matter is low-
ered367,363. In addition, loss of oligodendrocytes in the white matter has been 
reported368. Also grey matter structures express less myelin proteins and 
show diminished levels of grey matter lipids369. Myelin loss and exacerbated 
myelin breackdown upon AD may lead to a failure of action potential conduc-
tance and trophic axonal support having a great impact in the progression of 
cognitive impairment. In the healthy brain, NG2+ cells comprise a cell source 
for myelin repair as observed in different pathologies such as multiple sclero-
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sis. Their reaction and reparative potential upon AD pathology remains to be 
elucidated170. 
3.6.3 Microglia  
 
Aβ is also a potent activator of microglial reactivity, resulting in an increased 
secretion of diverse molecules such as inflammatory cytokines, activated 
complement proteins, proteases and reactive oxygen species374,375. Microglia 
are closely associated with amyloid plaques and increase in number in a 
proportional manner376,377. Upon appearance of newly formed plaques, mi-
croglia rapidly extend their processes and migrate toward them within 1-2 
days378,379. Furthermore, they become activated, hyperthroph and exhibit a 
“proinflammatory phenotype” 370. Similar to astrocytes, microglia are able to 
engulf fAβ. After phagocytosis has occurred, Aβ is found in endosome-like 
cellular compartments381,38. Whether the up-taken fAβ is actually degraded 
within the microglia is still debated. There is evidence that activated microglia 
in culture are able to degrade internalized fAβ383, while other studies suggest 
only little degradation384,385. 
In a study conducted in 1989 in human patients with plaque deposition that 
had undergone a stroke, infiltrating macrophages into the brain had a greater 
capability to remove the amyloid. This finding indicates that invading macro-
phages may harbour a greater potential to phagocytose amyloid than the 
resident microglia present in the brain380,386. Also in mouse models of AD 
pathology, infiltrated blood-derived microglia are able to phagocytose fAβ 
and are associated with about 20 % of all plaques in the brain378,387,388. Al-
though ablation of resident microglia from the brain does not affect the 
plaque size, soluble Aβ40 and Aβ42 fractions are increased in this experi-
ment. Overall, this study reinforced the idea that resident microglia in the AD 
brain may be not efficiently degrading amyloid389. Therefore, how efficient the 
degradation of Aβ by resident microglia in an AD environment is remains de-
bated. Also the role and potential of blood-derived immune cells needs to be 
elucidated in more detail. Interestingly, at later stages of AD pathology in 
human and mouse models, blood brain barrier breakdown may facilitate the 
entry of these cells into the brain380,390,391.  
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Phagocytic functions of resident microglia may be impaired due to the pro-
inflammatory environment in AD pathology392,393. For example pro-
inflammatory molecules such as the liposccharide-binding protein (LPS) in-
hibit the fAβ up-take of microglia in vitro371. On the contrary, treatment of AD 
mice with anti-inflammatory drugs results in an reduced plaque burden394,395. 
Microglia also have a role in degrading soluble amyloid396, as they secrete 
the insulin-degrading enzyme with one of its substrates being soluble amy-
loid397.  
In conclusion, glial cells are also reacting toward AD, however the pathology 
is different from invasive injuries. Therefore, glial cells may exert very distinct 
functions and abilities compared to other injuries.  
2.7 Therapeutical Strategies  
 
Until now, no cure exists for AD. Rather therapies aim to improve a patient’s 
live. Thinking about the increasingly ageing society intensive care for AD pa-
tients is accompanied by enormous social costs. Development of new thera-
peutic approaches may contribute to improve a patient’s life quality and re-
duce this social burden.  
New therapeutics aim to decrease the production of Aβ, since according to 
the Aβ hypothesis, Aβ and/or its oligomers are the toxic component that initi-
ates AD pathology. However, few clinical trials were executed so far and their 
outcome remains to be elucidated372.  
The so called “cell-based therapies” may also represent a new alternative 
therapeutic strategy in neurodegenerative diseases. Here, the aim is to re-
place lost neurons as well as glial cells by cell transplantation into the af-
fected brain areas. In this regard e.g. embryonic stem cells or induced pluri-
potent stem cells from for example fibroblasts could comprise interesting cell 
sources. However, so far no stem cell therapy approach has proven to be 
beneficial enough to be suitable for routine use241,376. One concern is that the 
AD pathology may spread into the grafted cells as it has been shown in Park-
inson’s disease. When fetal nerve cells from the donor midbrain were trans-
planted into the striatum of patients with Parkinson’s disease these cells 
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could survive373. Long-term surviving patients first benefited from the trans-
plantation, but at later stages the transplanted cells developed Lewy pathol-
ogy reminiscent of Parkinson’s disease or dementia with Lewy bodies after 
11-16 years373. Such a spread of pathology from host to donor cells in Park-
inson’s disease was also observed by two other studies, further underlining 
the possibility of such a spread of pathology into transplanted cells also upon 
AD374,375. In addition, the suitability of cell transplantations into the brains of 
AD patients may also be questionable since the pathology occurs in a wide-
spread manner.  
Interestingly, glial cells respond to AD pathology and in principle they can 
exert both, beneficial and detrimental effects. Most importantly, glial cells 
such as astroglia or oligodendrocytes may essentially contribute to the de-
velopment and/or progression of AD pathology. Understanding of the glial 
cell reactivity may therefore help to elucidate new therapeutic strategies, by 
e.g. promoting positive and reducing detrimental effects.  
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2.8 Aims of the Study 
 
The main objective of this thesis is to better understand reactive gliosis upon 
AD pathology.  
As a first aim, I investigated the reaction and potential of reactive astrocytes 
in mouse models reflecting different aspects of human AD pathology. This 
was prompted by the recent discovery of a subset of astrocytes developing 
stem cell potential upon invasive injury. I therefore set out to determine to 
which extent this reaction also occurs in AD mouse models.  
Since upon human AD myelin diminutions are commonly observed and may 
also contribute to the progression of the disease, I set out to determine 
whether this feature is reflected in a mouse model with progressive plaque 
deposition. If so, the aim was to investigate the glial reactivity to determine 
possible attempts for remyelination. Toward this end I analyzed how cells of 
the oligodendrocyte lineage, and especially of the NG2+ progenitors, as a 
potential source for remyelination, react toward plaque deposition.  
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3  Results 
3.1 Reactive Gliosis 
 
Glial cells react toward injury and in this regard astrocytes are of special in-
terest because they harbour a great regenerative potential as upon acute 
lesion these cells are able to acquire a stem cell potential by forming self-
renewing multipotent neurospheres217. The great ability of these cells is fur-
ther underlined by the fact, that astrocytes can adopt a neuronal fate e.g. 
upon forced expression of neurogenic factors in vitro376-378 and in vivo after 
acute brain lesion116. Additionally, astrocytes exert inflammatory responses in 
concert with microglia, which represent the "immune cells" of the brain. Yet, 
reactive astrogliosis may differ in its characteristics, according to the dura-
tion, severity and type of injury. The most striking feature of astrocyte reactiv-
ity is the formation of the glial scar. Other prominent features include astro-
cytic hyperthrophy, up-regulation of intermediary filaments and extracellular 
matrix molecules as well as eventual proliferation48,95,187,215,216. To carefully 
determine the severity of astrogliosis in APPPS1 mice all these parameters 
were investigated and compared to an acute lesion paradigm such as stab 
wound injury.  
3.1.1 Hypertrophy and Up-regulation of Intermediate Filaments in APPPS1 
Mice 
 
To understand the astroglial cell reaction over time upon amyloid plaque 
deposition, I monitored the amyloid plaques with the anti-amyloid beta (Aβ) 
antibody directed against the amino acids 1 to 14 at the N-terminus of this 
protein; it therefore detects human Aβ (Fig. 3- 1A,B). Along with plaque 
deposition, reactive astrocytes were monitored by immunostaining of the in-
termediate filament GFAP, which has been shown to be up-regulated once 
protoplasmic astrocytes in the cortical grey matter become reactive95. The 
majority of the GFAP-positive astrocytes were located in the vicinity of 
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plaques in the 3 months old APPPS1 mice (Fig. 3- 1B). On the contrary, con-
trol mice exerted only subpially located or blood vessel-associated GFAP+ 
cells (Fig. 3- 1B). Between 6 and 11 months of age, GFAP+ astrocytes 
spread throughout the cerebral cortex of APPPS1 mice covering all layers 
(Fig. 3- 1B). Plaques accordingly further increased in density and volume as 
it has been described328 until at least 11 months of age. Several of the early 
as well as the later reacting astrocytes in the APPPS1 mice were also hyper-
trophic (Fig. 3- 1C).  
The majority of GFAP-positive reactive astrocytes additionally acquired im-
munoreactivity of the intermediate filament nestin, which was also observed 
after acute stab wound injury (Fig. 3- 2). Nestin is expressed by embryonic 
neuroepithelial and radial glial cells and may hence be indicative of a possi-
ble dedifferentiating response of astrocytes toward chronic and acute lesion 
paradigms (as observed after stab wound injury; Fig. 3- 2). 
Thus, astrocyte reactivity, studied by GFAP and nestin immunoreactivity 
started in association and further increased in parallel with the plaque pathol-
ogy in APPPS1 mice (Fig. 3- 1; 3- 2).  
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Figure 3- 1. Plaque Deposition and Astrocyte Reactivity in APPPS1 Mice.  
(A) depicts the plaque load at different ages in APPPS1 mice. (B) shows the up-regulation of 
GFAP upon amyloidosis according to increasing plaque deposition with increasing age while 
in control animals only subpial and blood vessel-associated GFAP-positive astrocytes were 
observed. (C) shows magnifications of single astrocytes in control and APPPS1 mice at dif-
ferent ages. Scalebar: 100 µm in (A,B) and 20 µm in (C).   
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Figure 3- 2. Nestin Immunoreactivity of Reactive Astrocytes.  
GFAP-positive reactive astrocytes in 6 months old APPPS1 mice acquire nestin immunore-
activity. Scale bar: 20 μm.  
 
3.1.2 Up-regulation of Extracellular Matrix Proteins  
In the healthy brain, the extracellular matrix molecules tenascin C (TNC) and 
DSD-1, are highest expressed in the neurogenic niches and can be secreted 
by astrocytes. Thus, these proteins may be localized intracellularly or at the 
membrane. After acute lesion, reactive astrocytes up-regulate and secrete 
these extracellular matrix molecules95,187,216. To study if these molecules 
would also be up-regulated in the APPPS1 mice, the expression of the gly-
coprotein TNC and the proteoglycan DSD-1 were investigated.  
For staining for the DSD-1 protein the antibody detecting the 473HD epitope 
was utilized. The 473HD epitope was detected at high levels extracellularly 
close to the acute stab wound, whereas its expression was low in the healthy 
brain parenchyma (Fig. 3- 3A,B). In addition, GFAP+ astrocytes showed an 
increase in membrane associated DSD-1 protein expression compared to 
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controls (Fig. 3- 3A`,B`). Also upon chronic amyloidosis DSD-1 protein ex-
pression was elevated in comparison to control levels but it was still lower 
compared to acute stab wound condition (Fig. 3- 3A-C).  
On the other hand, TNC expression was increased extracellularly as well as 
intracellularly within GFAP-positive astrocytes in stab wound and APPPS1 
mice compared to controls (Fig. 3- 3D-F). 
In conclusion, astrocytes became strongly reactive upon chronic amyloidosis. 
The up-regulation of extracellular matrix proteins as well as intermediate 
filaments, normally only expressed at low levels or in few cells in the healthy 
cortical grey matter but present at higher levels in the adult stem cells niche 
and stem cells, is indicative for the degree of dedifferentiation of reactive as-
trocytes in this lesion paradigm95. The data imply a similar severity (or degree 
of dedifferentiation) of reactive astrogliosis in the acute stab wound lesion in 
comparison to the APPPS1 mice.  
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Figure 3- 3. Expression of the 473HD Epitope and TNC after Stab Wound and Chronic Amy-
loidosis 
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Depicted are representative pictures for immunostainings of the extracellular epitope 473HD 
and GFAP-positive astrocytes in healthy (control; A), stab wounded (three days post lesion 
(3 dpi); B) and 6 months old APPPS1 mice (C), as well as higher magnifications of the indi-
cated inlays in (A`,B`,C`). The white arrowheads point toward membrane associated DSD-1 
protein expression. In (D-F) pictures of TNC immunostainings in healthy control (D), stab 
wounded (3 days post lesion; E) and 6 months old APPPS1 mice (F) are shown. Addition-
ally, higher magnifications of the equivalent immunostaining were added in (D`,E`,F`). The 
white arrowheads point towards double-positive cells, while the dark arrowhead shows a 
single positive cell. Scale bar: 20 μm.  
3.1.3 Increased Proliferation upon Chronic Plaque Deposition 
The severity of the reactive gliosis is supposed to gradually change accord-
ing to the severity of the insult. Along this line, astrocyte proliferation is a fea-
ture occurring after large invasive injury187. After acute stab wound injury 
about 50 % of the astrocytes resume proliferation103,217. To investigate the 
degree of proliferation upon chronic amyloid plaque deposition, I applied 5-
Bromo-2′-Deoxy-Uridine (BrdU) -a thymidin analogue that incorporates into 
the DNA during cell division-  for 2 weeks to the drinking water of APPPS1 
and age-matched control mice. First, I investigated the time course of prolif-
eration by analyzing animals at 3, 6, and 11 months of age. Interestingly in 
control mice, proliferation significantly decreased with age, while in APPPS1 
mice it increased from 3 to 6 months of age and then remained on a similarly 
elevated level. In comparison to control animals proliferation was markedly 
increased in APPPS1 mice from the age of 3 months on (Fig. 3- 4C). Of note, 
BrdU+ cells in 3 months old APPPS1 mice mostly accumulated in the vicinity 
of plaques (data not shown). However at 6 months of age, BrdU+ cells were 
also observed apart from plaques. Also at this time point proliferation was 
observed around plaques, stained with the 6E10 antibody detecting both hu-
man Aβ and APP, but also in plaque-free areas (Fig. 3- 4A,B).  
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Figure 3- 4. Proliferation in the Cerebral Cortex Grey Matter of APPPS1 Mice.  
(A,B) depict representative pictures of control and APPPS1 mice stained for BrdU and 6E10 
at 6 months of age. BrdU-positive cells at 6 months of age accumulated often but not neces-
sarily around plaques as shown in (B`,B``). (C) shows the quantitative analysis of BrdU+ 
cells per mm2 cortical grey matter at different ages. The proliferation in APPPS1 mice was 
significantly increased from 3 months of age on. The numbers within the column indicate the 
number of animals as well as the number of slices quantified (n of animals/n of slices). Data 
are presented as mean per slices ±SEM. Scale bar: 50 μm. 
 
 
To conclude, proliferation was already increased at 3 months of age. The 
most prominent elevation of BrdU+ cells in APPPS1 mice was detected at 6 
months of age and remained on a stable level afterwards. However, different 
glial cell types may start dividing upon chronic amyloidosis. Therefore, I co-
labelled BrdU-positive cells with different markers, namely S100b and/or 
GFAP, Iba1, and NG2 for the visualization of astrocytes, microglia and oli-
godendrocyte progenitors, respectively (Fig. 3- 5).  
Expectedly in control mice, the percentage of proliferating NG2+ cells was 
greatest, while only few astrocytes and microglia contributed to the total BrdU 
pool. On the contrary, microglia represented the major cell type proliferating 
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around the plaques at 3 months of age in APPPS1 mice. At this time point, 
the percentage of NG2+ progenitors among the total number of BrdU+ cells 
was already markedly decreased compared to control animals. At 6 months 
of age, the proliferative response of glial cells largely reflected the observa-
tions obtained from 3 months old animals (around the plaques. Interestingly, 
the percentage of astrocytes was similarly low between 6 months old control 
and APPPS1 animals (Fig. 3- 5A,B,C,E). It became clear that the cell popula-
tions that are proliferating are very distinct in the cortical grey matter in the 
healthy versus the chronic amyloidosis condition. 
To investigate if the decreased percentages of marker-positive cells over the 
BrdU population would also affect the total number of the proliferating cells in 
the APPPS1 mice, I quantified the number of Marker/BrdU double-positive 
cells per mm2 cortical grey matter. Since upon chronic amyloidosis mice pro-
liferation is most prominently increased at 6 months of age, I performed the 
quantification at this time point. Surprisingly, despite the decreased percent-
age of NG2+ glia over the BrdU population, the total number of NG2+BrdU+ 
cells was significantly increased (Fig. 3- 5D). In addition, even though the 
number of dividing astrocytes increased significantly in the APPPS1 mouse, 
the total amount of these cells was rather low (Controls had 1.3±0.3 
S100bGFAP+/BrdU+ cells per mm2, while APPPS1 had 3.1±0.5). Accord-
ingly, they constituted only to a small fraction of 2.5 % of the total BrdU pool 
in 6 months old APPPS1 mice (Fig. 3- 5D,E), respectively. Thus, despite the 
fact that astrocytes became reactive, which was proven by the increased ex-
pression of GFAP, nestin, 473HD and TNC, their proliferative response was 
limited. This is very different to what has been observed in the acute stab 
wound injury, since proliferation of astrocytes remarkably increased in this 
lesion paradigm103.   
In accordance with the high percentage of microglia over the BrdU pool, also 
their total number was elevated in APPPS1 mice (Iba1/BrdU double-positive 
per mm2), while in the healthy cortical grey matter microglial cells rarely di-
vided (Fig. 3- 5D,E).  
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Figure 3- 5. Proliferation of Glial Cells in APPPS1 Mice. 
(A) is an example of a BrdU+ astrocyte (S100b+ and GFAP+), while (B) depicts an accumu-
lation of proliferating Iba1+ microglia, (C) is an example of dividing NG2+ cells. (D) The total 
number of proliferating cell types was quantified in 6 months old animals per mm2 cortical 
grey matter by double-staining of BrdU-positive cells with NG2 for oligodendrocyte progeni-
tors, Iba1 for microglia and S100b and/or GFAP for labelling astrocytes. (E) Subdivision of 
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the cell types that proliferate in control and APPPS1 mice at the age of 3 and 6 months. 
NG2+/BrdU+, Iba1+/BrdU+ and S100b and/or GFAP+/BrdU+ cells were quantified as the 
percentage of marker-positive cells over the proliferating BrdU+ pool. The numbers behind 
the markers indicate the number of animals as well as the number of slices quantified (n of 
animals/n of slices) for controls – APPPS1 6 months of age. Data are presented as mean 
per slices ±SEM. For APPPS1 3 months of age in (E) the data are presented as mean per 
plaques (3/10 for NG2 staining; 5/73 for Iba1 staining and 3/19 for S100bGFAP staining) 
±SEM. Scale bar: 20µm. 
 
3.1.4 Neurosphere Forming Capacity of the Cortical Grey Matter in APPPS1  
 
Upon acute stab wound and focal laser lesion, some reactive glial cells have 
the potential to generate self-renewing, multipotent neurospheres in vitro. 
Interestingly, in acute stab wound lesion, reactive astrocytes were identified 
as the cell population responsible for neurosphere formation95,216,217. Since I 
observed a strong reaction of glial cells in chronic amyloidosis as well as a 
small but significant increase in astrocyte proliferation, I aimed to examine 
the potential of these reactive glial cells to generate self-renewing, multipo-
tent neurospheres.  
For this experiment, I dissected cortical grey matter tissue from APPPS1 and 
wild type control mice and compared it to grey matter tissue from wild type 
control mice which had undergone stab wound injury 3 days before. The data 
from the stab wounded animals were obtained in collaboration with Dr. Swet-
lana Sirko. As a further positive control, I isolated cells from the adult 
subependymal zone (SEZ), one of the neurogenic zones of the adult brain, 
where neurosphere formation has first been discovered51.  
From all tissue samples I plated an equal number of cells per well at clonal 
density (5 cells/µl) and quantified the number of primary neurospheres 
formed after 14 days in culture. As expected, most neurospheres had formed 
from SEZ tissue (Fig. 3- 6A, B). In addition, neurospheres did not form from 
the tissue of the intact and healthy cerebral cortex of young and aged healthy 
control mice. In further agreement with previous data, neurospheres formed 
from the stab wounded cerebral grey matter (Fig. 3- 6B). In line with the no-
tion, that the adult SEZ contains many neural stem cells the number of SEZ 
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neurospheres was 10 times (10 x) higher compared to the stab wound. Sig-
nificantly fewer primary neurospheres were generated from the cortical grey 
matter of APPPS1 mice, which were older than 6 months of age. 2 out of 9 
cultures of cells from the cerebral cortex of APPPS1 mice did not generate 
any neurospheres. To test for multipotency of the primary neuropheres, these 
were plated and differentiated for 7 to 10 days. Some of the neurospheres 
(33%, 5 out of 15), which had formed, were multipotent and generated neu-
rons, astrocytes and oligodendrocyte progenitors (Fig. 3- 6C), while the oth-
ers remained glial. 
3.1.5 Self-Renewal of Neurospheres 
Since neurospheres obtained from the APPPS1 mice were multipotent also 
their ability to self-renew was investigated. This was achieved by splitting and 
subsequent seeding at a clonal density of 5 cells per µl. The secondary neu-
rospheres were compared to secondary spheres obtained from acute stab 
wound lesion and SEZ tissue. Secondary neurospheres were counted 7 days 
after splitting. The number of secondary neurospheres increased in compari-
son to the primary neurosphere formation in all conditions. This is consistent 
with the idea of enrichment for self-renewing cells after passaging. Most sec-
ondary neurospheres were generated from the SEZ cells. Interestingly, 
APPPS1 mice generated significantly fewer secondary neurospheres com-
pared to both, SEZ tissue and acute stab wound. Thus, the capacity of neu-
rosphere self-renewal of cells from the cerebral cortex of APPPS1 mice is 
reduced compared to the acute lesion (Fig. 3- 6B).  
 
3.1.6 Neurosphere Formation after Acute Stroke 
 
As neurospheres were formed from the stab wounded cortical grey matter217, 
I wanted to determine, whether neurosphere formation would also take place 
after another acute lesion paradigm such as MCAO (middle cerebral artery 
occlusion). These experiments were performed in collaboration with Dr. Mar-
tin Dichgans, Dr. Christophe Heinrich and Steffen Tiedt. The MCA was oc-
cluded by a filament for 1 or 2 hours and tissue was collected 3 days after the 
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surgery. Interestingly, the formation of primary neurospheres in this model 
was well comparable to the stab wound injury model. A similar number of 
neurospheres as observed upon acute stab wound formed within 14 days in 
culture (Fig. 3- 6B).  
 
Figure 3- 6. Generation of Neurospheres. 
(A) shows representative pictures of neurospheres from different lesion paradigms such as 
stab wound, MCAO and APPPS1 mice, including SEZ as a positive control. (B) the cloured 
bars are the quantification of primary neurospheres (P.N.) per 10000 plated cells. Neuro-
sphere formation is significantly decreased upon chronic amyloidosis compared to acute 
stab wound. The quantification of secondary neurospheres (S.N.) is shown with the grey 
bars for the acute stab wound lesion, APPPS1 mice and SEZ as a positive control. Secon-
dary neurospheres were generated at a higher rate than primary neurospheres in all condi-
tions. The secondary neurosphere formation was decreased in APPPS1 mice compared to 
stab wound lesion (C) representative pictures of differentiated primary neurospheres of 
APPPS1 mice. βIIItubulin was used to detect neuronal, GFAP for astrocytes and NG2 for 
oligodendroglial progenitor cells. The number of the cultures analyzed are indicated within 
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the columns. Data are presented as mean per culture ±SEM. Scale bar: 50 µm in (A) and 20 
µm in (C).  
 
3.1.7 p25 Over Expressing Mice Exhibit Massive Neurodegeneration  
 
One reason for the decreased neurosphere forming capacity of APPPS1 
mice could be the virtual absence of neuronal cell death in APPPS1 mice 329. 
In contrast, profound cell death has been observed after both, stab wound 
and stroke injury189,379,380. To investigate the possible effect of this, I exam-
ined a mouse model of amyloidosis which additionally overts profound cell 
death and tau pathology. I used the CK/p25 mouse model, which inducibly 
expresses p25 in neurons using the doxycycline-dependend Tet-OFF sys-
tem. Ectopic p25 expression results in profound neuronal loss, up-regulation 
of GFAP in astrocytes, tau pathology and intraneuronal accumulation of amy-
loid (Fig. 2- 11 in introduction)331,342.  
To confirm neuronal loss, I stained brain slices from control animals, and 
from CK/p25 mice which expressed p25 for a period of 2 or 5 weeks. Already 
in 2 weeks OFF doxycycline treated animals a slight reduction in the cortical 
thickness could be detected. The profound reduction in NeuN-
immunopositive neurons was observed in 5 weeks OFF treated CK/p25 mice 
(Fig. 3- 7A). Neuronal loss affected all layers including the upper layers of the 
cerebral cortex, where Cux1-positive neurons were reduced (Fig. 3- 7B-E).  
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Figure 3- 7. Phenotype of CK/p25 Mice upon different Durations of Doxycycline Withdrawal. 
In (A) overview pictures of DAPI and the according NeuN stained brain sections of control, 
CK/p25 2 weeks OFF and CK/p25 5 weeks OFF treated animals at an equivalent Bregma 
level are presented. The cortical thickness is reduced in 5 weeks OFF treated CK/p25 ani-
mals. (B-E) are representative pictures of Cux1-positive neurons double-labelled with NeuN 
in control (B,C) and CK/p25 mice 5 weeks OFF doxycycline (D,E). (C,E) are the correspond-
ing higher magnifications of (B,C). Scale bar: 20 μm.  
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3.1.8 Reactive Gliosis in CK/p25 mice 
 
To investigate the time course of reactive astrogliosis along with neuronal 
loss in CK/p25 mice, I stained brain sections with 2 and 5 weeks of p25 ex-
pression for the intermediate filament marker GFAP. Notably in control ani-
mals, which were equally treated with doxycycline, few GFAP astrocytes 
could be detected mostly located at the pial surface. These cells extended 
long and fine processes (Fig. 3- 8A). On the contrary, in CK/p25 mice GFAP 
up-regulation and astrocyte hypertrophy was already detected after p25 ex-
pression for 2 weeks (2 weeks OFF doxycycline treatment) not only at the 
pial surface but also in most layers of the cerebral cortex grey matter (only 
sparring a band between layer 3 and 5; Fig. 3- 8A). CK/p25 mice 5 weeks 
OFF doxycycline showed a greater spread of the GFAP+ astrocytes (Fig. 3- 
8A). In addition, the degree of astrocyte hypertrophy increased compared to 
animals with p25 expression for 2 weeks (Fig. 3- 8A). Of note, also microglia 
became hyperthroph, which was already apparent 2 weeks after doxycycline 
withdrawal. Furthermore, they obviously increased in number after 5 weeks 
of p25 expression in double-transgenic mice (Fig. 3- 8B).  
To further characterize the reactive astrogliosis in CK/p25 mice, I examined 
the intermediate filament nestin as an additional intracellular marker for reac-
tive astrocytes. Nestin was already shown to be up-regulated upon stab 
wound as well as in APPPS1 mice. Also upon neuronal loss, the majority of 
GFAP-positive astrocytes acquired nestin immunoreactivity (Fig. 3- 9A). In-
vestigation of the extracellular matrix markers TNC and 473HD (Fig. 3- 
9B,C), showed an up-regulation similar to the observations obtained from 
stab wounded and APPPS1 mice (Fig. 3- 3).  
To conclude, astrocytes became similarly reactive in CK/p25 mice. As ob-
served in acute stab wound and APPPS1 mice, astrocytes became hyper-
throph and up-regulated markers characteristic for reactive astrocytes such 
as GFAP, nestin, TNC and 473HD. Also microglia became hyperthroph and 
increased dramatically in number.  
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Figure 3- 8. Astroglial and Microglial Hyperthrophy and Reactivity in CK/p25 Mice 
In (A) representative pictures of GFAP-positive astrocytes in control animals and CK/p25 
mice  2 and 5 weeks OFF doxycycline are depicted. In control animals, which were also 
raised on doxycycline, only non-hyperthroph subpial and blood vessel-associated astrocytes 
were labelled by GFAP. Up-regulation of GFAP is already apparent in 2 weeks OFF CK/p25 
mice. Astrogliosis worsens in 5 weeks OFF treated animals. Higher magnifications addition-
ally confirmed the astrocytic hyperthrophy in the double-transgenic mice. (B) depicts micro-
glial cells stained with Iba1. Microglial cells became hyperthroph and increase in number 
after doxycycline withdrawal of 2 and 5 weeks. Scale bar indicates 50 µm in the overviews 
and 10 µm in the higher magnifications.  
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Figure 3- 9. Up-regulation of Nestin, TNC and 473HD upon Massive Neuronal Death. 
Reactive astrocytes labelled with GFAP were co-localized with different markers characteris-
tic for reactive astrocytes. A significant number of GFAP+ cells co-expresses nestin. The 
extracellular matrix epitope TNC is additionally up-regulated extracellularly in CK/p25 mice 
after 5 weeks with doxycycline withdrawal. Also the 473HD epitope expression is elevated in 
these mice. Scale bar: 20 µm. 
 
3.1.9 Lack of Neurosphere Formation upon Neuronal Loss 
 
When CK/p25 mice were utilized for the neurosphere assay, strikingly, even 
fewer primary neurospheres than detected in APPPS1 mice formed from the 
cerebral cortex of CK/p25 mice 5 weeks after doxycycline withdrawal 
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(0.3±0.3 neurospheres/10000 cells). This suggested that neuronal cell death 
cannot be the trigger for neurosphere-forming reactive glial cells.  
According to what has been stated before187, reactive astrogliosis can differ 
profoundly between different lesion paradigms such as acute and chronic 
lesion. Therefore, whereas the lesioned area of acutely injured mouse mod-
els overts a stem cell capacity of a subset of cells, this ability is not present 
as pronounced upon chronic plaque deposition and neuronal loss despite 
prominent astrogliosis. Also upon heavy neuronal death, which was similarly 
accompanied with severe reactive gliosis, cells of the cortical grey matter 
showed an even further decreased ability to form neurospheres in vitro (Fig. 
3- 6). What might determine the different capacities of astroglia in the differ-
ent mouse models and injury paradigms tested? One possibility is that astro-
cyte proliferation may correlate to the neurosphere forming capacity, since 
stab wound injury as well as MCAO are accompanied by a high rate of proli-
feration of these cells and generate most neurospheres. In comparison, in 
APPPS1 mice neurosphere formation as well as astrocyte proliferation was 
decreased. Therefore, the question arises if astrocytes proliferate in CK/p25 
mice. 
3.1.10  Proliferation of Glial Cells in CK/p25 Mice 
 
To further evaluate the severity of reactive gliosis I examined the proliferation 
of glial cells by applying BrdU for 1 week via the drinking water. Control and 
CK/p25 mice were examined at 1 and 5 weeks after doxycyline withdrawal. 
Proliferation was most remarkebly increased after 2 weeks of p25 expression 
and the elevation was still observed after 5 weeks of doxycycline withdrawal 
(Fig. 3- 10A,B). Notably, in CK/p25 mice after 2 weeks of doxycycline with-
drawal some animals showed greater proliferation, while others showed 
much less indicating some heterogeneous phenotype at this early time point.  
To investigate in more detail which cell types would resume proliferation in 
CK/p25 mice, I examined the proliferation of reactive astrocytes by co-
staining the BrdU-positive cells with the astrocyte specific markers S100b 
and/or GFAP (Fig. 3- 11A-C). Surprisingly, despite the profound neuronal cell 
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death, astrocyte proliferation was only tendencially increased at 2 and 5 
weeks without doxycycline. Control animals had 1±0.4 BrdU+/S100b and/or 
GFAP+ cells per mm2 which constituted 1.3±0.4 % of the entire pool of BrdU-
labelled cells. In CK/p25 mice 2 weeks after doxycycline withdrawal the total 
number of BrdU/S100b- and/or GFAP was 2.7±0.7 double-positive cells per 
mm2 and hence not significantly different. At this time point astrocytes still 
constituted only a similarly small proportion amongst all proliferating cells as 
in the control (1.2±0.5 %). Thereafter, after 5 weeks of doxycycline with-
drawal astrocyte proliferation did not further increase in CK/p25 mice 
(1.7±0.6 double-positive cells per mm2 constituting to 0.9±0.3 % of the total 
BrdU pool). These results demonstrate that the proliferative response of re-
active astrocytes remained minor compared to acute invasive injury models 
and even diminished in regard to APPPS1 mice, which had a significant in-
crease in th number of proliferating astrocytes in the cortical grey matter (Fig. 
3- 11A-C).  
Given the hyperthrophy of microglia already present in 2 weeks OFF treated 
CK/p25 mice and the increased number in 5 weeks OFF treated CK/p25 
mice as described in Fig. 3- 8B, I examined microglia and their proliferative 
response to p25 over expression. Profound proliferation with an enormous  
increase in the number of BrdU-incorporating Iba1+ cells could be observed 
in both 2 and 5 weeks after doxycycline withdrawal in CK/p25 mice. Thus, 
microglia are activated in this injury model. Similarly to the APPPS1 mice 
microglia comprised the majority of proliferating cells thereby contributing 
most to the overall increase in proliferating cells after p25 overexpression 
(Fig. 3- 11A-C). When investigating the proliferation of NG2+ glia, interest-
ingly, no changes in the proliferation of NG2-positive cells were observed 
upon p25 induction causing heavy neuronal loss compared to control animals 
(Fig. 3- 11B,C).  
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Figure 3- 10. Proliferation in CK/p25 Mice. 
(A) shows representative pictures of BrdU-positive cells in the cortical grey matter. The 
quantification of BrdU+ cells per mm2 is depicted in (B). Proliferation is significantly in-
creased after 5 weeks of doxycycline withdrawal in CK/p25 mice. The numbers within the 
columns indicate the number of animals as well as the number of slices quantified (n of ani-
mals/n of slices). Data are presented as mean per slices ±SEM. Scale bar: 50µm. 
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Figure 3- 11. Proliferative Cell Types in CK/p25 Mice.  
Representative pictures of (A) BrdU+ Marker-negative cell the prominent overlay of BrdU 
and Iba1+ microglial cells in 2 weeks OFF treated CK/p25 mice. White arrowheads point 
toward BrdU+/Iba1+ cells while the dark arrowhead indicates a single potitive cell. (B) shows 
the total numbers of BrdU/Marker double-positive cells per mm2 cortical grey matter, while 
(C) depicts the according percentages of marker+ cells over the total BrdU pool. The num-
bers behind the markers indicate the number of animals as well as the number of slices 
quantified (n of animals/n of slices) for controls - CK/p25 2 weeks OFF - CK/p25 5 weeks 
OFF. Data are presented as mean per slices ±SEM. Scale bar: 20µm. 
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In conclusion, in contrast to stab wounded and APPPS1 mice, astrocyte pro-
liferation is not significantly increased in CK/p25 mice, which may also ac-
count for nearly absent capacity of the lesioned cortical grey matter to form 
neurospheres in vitro.   
But what determines the amount of astrocyte proliferation in the different in-
jury paradigms? One explanation is that signalling cascades that trigger as-
trocyte proliferation may be present in the stab wounded as well as (to a 
lesser extend) in the APPPS1 mice, which are absent in the CK/p25 mice. 
One such candidate is expression of the phosphorylated form of the immedi-
ate early gene cJun (pcJun), which has been shown to mediate astrocyte 
proliferation upon demyelination381.  
 
3.1.11 pcJun and pJNK Expression of Reactive Astrocytes in Different Lesion 
Paradigms 
 
To investigate if pcJun is expressed by reactive astrocytes in the lesion para-
digms that, I co-stained pcJun with GFAP and/or S100b to label reactive as 
well as non-reactive astrocytes. Quantification of the number of 
pcJun/S100bGFAP double-positive cells per mm2 cortical grey matter re-
vealed that their number is tendencially elevated upon stab wound and sig-
nificantly increased upon neuronal loss (CK/p25) compared to non-lesioned 
control animals. Upon chronic plaque deposition in the APPPS1 mice, pcJun 
expression was equally low as control levels (Fig. 3- 12A-H). However, the 
percentage of pcJun-positive astrocytes in regard to all labelled astrocytes 
showed that only a small proportion of about 2 % (1.7±0.5 % in stab 
wounded and 1.8±0.3 % in CK/p25 mice) expresses it (Fig. 3- 12I).  
These results were further evaluated by a staining for an upstream regulator. 
Since the phosphorylated form of the c-Jun N-terminal kinase (pJNK) was 
previously shown to phosphorylate cJun, an additional staining for pJNK was 
performed. Interestingly, pJNK was absent in control animals, but it was ex-
pressed by reactive GFAP-positive astrocytes upon stab wound or in CK/p25 
mice. On the contrary, pJNK expression was concentrated in plaque areas in 
APPPS1 mice, and only few processes of GFAP+ astrocytes in the vicinity of 
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plaques were stained (Fig. 3- 13A-D). Therefore, this observation was in line 
with the expression of pcJun in very few astrocytes in the respective lesion 
paradigms.  
 
 
  
Figure 3- 12. pcJun Expression of Astrocytes in Different Lesion Paradigms. 
Representative pictures of pcJun staining and co-staining of pcJun with GFAP-positive as-
trocytes in control (A), stab wounded (3 dpi) (B,C), APPPS1 at 6 months of age (D,E), and in 
CK/p25 mice 5 weeks after doxycycline withdrawal (F,G). A magnification of the overlay are 
shown in (C,E,G), respectively. The full arrowheads highlight double-positive cells, while the 
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dark arrowhead depict a single-positive cells. (H) reflects the quantification of the total num-
ber of pcJun/S100b and/or GFAP double-positive cells per mm2 cortical grey matter. In (I) 
the percentage of astrocytes expressing pcJun are presented. The numbers underneath the 
columns indicate the number of animals as well as the number of slices quantified (n of ani-
mals/n of slices). Data are presented as mean per slices ±SEM. Scale bar: 20μm. 
 
Figure 3- 13. Expression of pJNK in Different Lesion Paradigms.  
Representative pictures of pJNK staining and co-staining of pJNK with GFAP-positive astro-
cytes in control (A), stab wounded (3 dpi) (B), APPPS1 at 6 months of age (C), and in 
CK/p25 mice 5 weeks after doxycycline withdrawal (D). Magnifications of the inlays 
(A`,B`,C`,D`) are shown in (A``,B``,C``,D``), respectively. Scale bar: 20μm. 
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3.1.12 Expression of Olig2 in Astrocytes in Different Lesion Paradigms 
 
The transcription factor Olig2 is a further interesting candidate in regard to 
proliferation of astrocytes. Olig2 is expressed largely in the oligodendrocyte 
lineage, but also a subset of astrocytes expresses it105,116,121. After stab 
wound injury, astrocytes are known to up-regulate Olig2. Notably, when Olig2 
expression was deleted after injury, astrocyte proliferation was re-
duced116,382,383.  
Double staining for Olig2 and S100b and/or GFAP, to label reactive and non-
reactive astrocytes (Fig. 3- 14A-H) showed that the number of 
Olig2/S100bGFAP double-positive cells per mm2 cortical grey matter was 
significantly increased 3 days after stab wound lesion as well as in 6 months 
old APPPS1 mice and CK/p25 mice in comparison to 6 months old control 
animals (Fig. 3- 14I). However, the number of double-positive upon stab 
wound injury (24.4±3 per mm2) was increased compared to the other lesion 
paradigms tested. Moreover, the total number of double-positive cells per 
mm2 was tendencially increased in APPPS1 mice (19.3±2.6 per mm2) com-
pared to CK/p25 mice (13.9±2.7 per mm2). Investigation of the percentage of 
astrocytes expressing Olig2 in regard to all labelled astrocytes revealed that 
about 8.9±1 % in stab wounded expressed this transcription factor, being 
significantly more compared to controls (4.1±0.8 %) and CK/p25 mice (4.3±1 
%) (Fig. 3- 14J). APPPS1 mice with 6.5±0.9 % of all astrocytes expressing 
Olig2 showed still an elevation compared to controls. This showed that Olig2 
expression is decreased in CK/p25 mice compared to stab wound injury and 
APPPS1.  
Therefore, it appears that different signalling cascades are present in the dif-
ferent AD-related mouse models, while in stab wounded animals both signal-
ling candidates were present at an elevated level.  
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Figure 3- 14. Expression of Olig2 in Astrocytes after Different Lesion Paradigms. 
Representative pictures of co-staining of Olig2 with S100b/GFAP-positive astrocytes in con-
trol (A,B), stab wounded (3 dpi) (C,D), APPPS1 at 6 months of age (E,F), and in CK/p25 
mice 5 weeks after doxycycline withdrawal (G,H). Magnifications of the inlays in (A,C,E,G) 
are shown in (B,D,F,H), respectively. The filled arrowheads highlight double-positive cells, 
whereas the dark arrowheads point toward single-positive astrocytes. (I) reflects the quantifi-
cation of the total number of Olig2/S100b GFAP double-positive cells per mm2 cortical grey 
matter. The numbers within the columns indicate the number of animals as well as the num-
ber of slices quantified (n of animals/n of slices). Data are presented as mean per slices 
±SEM. Scale bar: 20μm. 
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3.1.13 Increased Expression of Cyclin D1 in Astrocytes in Different Lesion 
Paradigms 
 
Since astrocytes in APPPS1 and CK/p25 mice did not resume proliferation 
but  up-regulated distinct signalling cascades involved in it, I aimed to 
understand if astrocytes in AD-related mouse models become activated 
sufficiently strong to re-enter at least early stages of the cell cycle. Astrocytes 
in the healhy brain mostly are in the Gap 0 (Go) phase, which is a resting 
phase where cells stopped dividing. In accordance with that few astrocytes 
proliferate in the non-lesioned healthy grey matter103,116. After e.g. initial 
proliferative triggers, cells may re-enter the cell cycle by progressing into the 
gap 1 (G1) phase, in which they usually grow in size and prepare for DNA 
synthesis. One protein typically expressed at the end of the G1 phase is 
Cyclin D1, which is also involved in cell cycle progression into the DNA 
synthesis (S)-phase384. Notably, BrdU, which was used as a marker for 
proliferation in the previous experiments, incorporates into the DNA in S-
phase385. After successful DNA replication, cells pass through another gap 
phase (Gap 2; G2) followed by the mitosis386.  
Therefore, I analyzed the expression of the protein cyclin D1 in astrocytes to 
understand if astrocytes may become activated enough to re-enter cell cycle. 
Quantification of the number of cyclin D1/S100b and/or GFAP double-
positive cells showed a significant elevation in all lesion paradigms tested 
(Fig. 3- 15A-I). Interestingly, about 32.6±2.9 % of all astrocytes expressed 
cyclin D1 upon stab wound injury, whereas in APPPS1 (16.3±1.8 %) and 
CK/p25 mice (12.8±1.8 %) their percentage was significantly less. 
Interestingly, however the percentage of cyclin D1-positive astrocytes was 
still elevated in the AD-related mouse models compared to control levels 
(5.1±0.9 %; summarized in Fig. 3- 15I).  
This showed that upon chronic plaque deposition and neuronal loss the 
number of astrocytes re-entering cell cycle increases, however most of these 
cells fail to perform S-phase. For example in APPPS1 mice 16.3 % of the 
astrocytes expressed cyclin D1 while only 2.5 % actually incoporated BrdU. 
On the contrary, upon stab wound injury 32.6 % of the astrocytes expressed 
cyclin D1 3 days after lesion and about 50 % of the astrocytes re-entered cell 
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cycle until 7 days after injury103, which implicates that most of the cyclin D1+ 
astrocytes actually perform S-phase in this lesion paradigm.  
Therefore, other factors may contribute to the different amounts of astrocyte 
proliferation observed upon stab wound, in APPPS1 and in CK/p25 mice. 
One such difference may be different ongoing inflammatory processes.  
 
Figure 3- 15. Cyclin D1 Expression of Astrocytes in Different Lesion Paradigms,  
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Representative pictures of co-staining of cyclin D1 with S100b/GFAP-positive astrocytes in 
control (A), stab wounded (3 dpi) (B,C), APPPS1 at 6 months of age (D,E), and in CK/p25 
mice 5 weeks after doxycycline withdrawal (F,G). Magnifications of the inlay in (B,D,F) are 
shown in (C,E,G), respectively. The white arrowheads highlight double-positive cells, while 
dark arrowheads point toward single-positive cells. (H) shows the quantification of the total 
number of cyclin D1/S100b and/or GFAP double-positive cells per mm2 cortical grey matter. 
In (I) the percentage of astrocytes expressing cyclin D1 are presented. The numbers under-
neath the columns indicate the number of animals as well as the number of slices quantified 
(n of animals/n of slices). Data are presented as mean per slices ±SEM. Scale bar: 20μm. 
 
3.1.14 Invasion of Blood-derived Cells in APPPS1 and CK/p25 Mice 
 
Since upon stab wound injury, blood-derived immune cells participate in the 
inflammatory process, I investigated if such cells would invade the brain upon 
AD-related chronic plaque deposition or neuronal loss in CK/p25 mice. To 
examine this, I stained brain sections with CD45, which is a protein ex-
pressed at highest levels by blood-derived cells. However, as CD45 is also 
expressed by resident microglia and increases in expression in activated res-
ident microglia, I co-stained CD45 with Iba1, expressed in non-activated and 
activated microglia. To ensure localization outside blood vessels, I took ad-
vantage of the β-dystroglycan antibody, which outlines blood vessels.  
In control animals, high CD45-immunostaining was nearly absent with the 
exception of CD45-positive cells located within blood vessels (Fig. 3- 16A,B). 
In APPPS1 mice, resident Iba1-positive microglia up-regulated CD45 expres-
sion. In addition, Iba1-negative CD45-positive immune cells invaded the 
brain, since they localized away from blood vessels (Fig. 3- 16C,D).  Similar-
ly, in CK/p25 mice invading immune cells away from blood vessels were also 
present (Fig. 3- 16E,F). This indicates that, as observed in stab wound le-
sion, also in the AD-related mouse model blood-derived cells have the ability 
to enter the brain parenchyma. One reason for the presence of these cells 
within the brain parenchyma could be an opening of the blood brain barrier.  
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Figure 3- 16. CD45-positive Cells in the Cortical Grey Matter of APPPS1 and CK/p25 Mice. 
Representative pictures of a triple-staining of β-dystroglycan for blood vessels, with Iba1 for 
microglia and CD45 for invading blood-derived immune cells. Lower magnifications of control 
in (A), APPPS1 in (C) and CK/p25 in (E). In (B) is the magnification for the inlay for control 
and in (D,E) for APPPS1 and CK/p25 mice, respectively. The arrowheads highlight single 
CD45-positive cells. Scale bar: 20μm. 
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3.1.15 Unchanged Blood Brain Barrier Integrity in APPPS1 and CK/p25 Mice 
 
To test for the blood brain barrier integrity of APPPS1 and CK/p25 mice, I 
first performed a stab wound as a positive control in one hemisphere of these 
mice, as it is known that the blood brain barrier is ruptured in this lesion pa-
radigm. Afterwards, a fluorescent coupled dextran of 3000 dalton (Da) was 
injected into the tail vein. As expected, stab wound lesion resulted in a 
spread of the fluorescent dye into the brain parenchyma in the AD-related 
mouse models. However, on the contralateral, non-lesioned side, the blood 
brain barrier integrity remained intact in APPPS1 and CK/p25 mice for mole-
cules of a size of 3000 Da (Fig. 3- 17).  
These data indicate a dramatic difference between acute stab wound (as well 
as MCAO) and the AD-related mouse models investigated. They further open 
the possibility that factors released from the blood may represent an essen-
tial trigger for astrocytes to proliferate and/or form neurospheres.  
 
In addition to the differences observed in the astrocyte proliferation and neu-
rosphere formation in different lesion paradigms, also differences in the reac-
tion of NG2+ glia could be detected. These cells specifically reacted toward 
amyloid plaque deposition, whereas their reactivity was absent in CK/p25 
mice. To understand the reaction of oligodendroglial cells over time upon 
chronic amyloid plaque deposition, I analyzed the APPPS1 mouse line in 
more detail324. These mice reflect certain clinical aspects of Alzheimer’s dis-
ease (AD) like a progressive amyloid plaque deposition already present at 3 
months of age in the cortical grey matter. However, tangle pathology and 
overt neuronal loss are absent in this mouse model, contrary to the human 
pathology324,329. As it has been pointed out before, human AD is normally 
accompanied with myelin diminutions 367,369,387,388 and focal demyelination389. 
Moreover, also white matter lesions are often associated with AD390,391. In the 
healthy brain, myelin insulates axons allowing the propagation of action po-
tentials at high velocity. Disruption of the myelin sheaths upon AD, may 
therefore also contribute to cognitive impairment, since action potential con-
ductance may become slower or completely disturbed. 
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Figure 3- 17. Blood Brain Barrier Integrity in AD-related Mouse Models. 
Depicted are the positive stab wound control of stab wounded control, APPPS1 and CK/p25 
mice. The contralateral side was evaluated for the integrity of the blood brain barrier. Scale 
bar: 50 µm. 
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3.2 Reactivity of Oligodendrocyte Progenitors upon Chronic 
Amyloid Plaque Deposition 
 
3.2.1 Focal Loss of Myelin in Plaque Core Areas 
 
First, I carefully investigated to which extend these myelin diminutions and/or 
aberrations can be reproduced in APPPS1 mice resembling plaque deposi-
tion as the only feature of the human AD pathology. To analyze changes in 
the myelin in the aged APPPS1 mice, I stained brain sections of transgenic 
and control littermates at different ages (3, 6, 9 and 11 months) for the myelin 
associated glycoprotein (MAG), while plaques were labelled with the 6E10 
antibody that detects both, human Aβ and the human APP. Additionally, I 
performed a Gallyas silver impregnation to label myelin in a quantitative and 
antigen independent manner. Interestingly, I observed focal demyelination in 
the plaque core areas of the cerebral grey as well as white matter with both 
staining techniques. This result is similar to the observations in humans or 
other mouse models of plaque deposition389, and it shows that plaques alone 
are sufficient to induce demyelination, while neuronal loss and tangle pathol-
ogy, as occurring in human pathology, is not necessary (Fig. 3- 18).  
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Figure 3- 18. Myelin in the Cortical Grey and White Matter.  
Overview of the myelin by the Gallyas impregnation for myelin in the white and grey matter 
at 6 months of age in control and APPPS1 mice. The arrowheads indicate plaque core areas 
being devoid of myelin. Immunostainings of the cortical grey matter for MAG and 6E10 at the 
same age. The inlay depicts a magnification of a plaque core area devoid of MAG staining. 
Scale bar: 200 μm (in A, D) 100 μm (in A`, C, F) 50 μm (B, D`, E) and 20 μm in (G).  
 
3.2.2 Analysis of Myelin Protein Amounts 
To analyze the amount of myelin, I performed a western blot analysis on the 
cerebral cortex of control and APPPS1 mice with an antibody directed 
against the 2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNPase), which 
was already shown to be expressed at reduced levels in human AD pa-
tients388. Notably, apart from the localization in the non-compact myelin, the 
CNPase protein is also expressed in mature oligodendrocytes. To have a 
precise readout, I examined the ratio between CNPase and NF70 protein to 
evaluate the amount of CNPase present per axons (Fig. 3- 19A). Interesting-
ly, a significant decrease in the ratio could be detected in 6 months old 
APPPS1 mice compared to age matched controls (Fig. 3- 19B). As neuronal 
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loss can be excluded329 the data indicate a decreased amount of CNPase 
present per axon in 6 months old APPPS1 mice. Surprisingly, at 9 months of 
age, controls and APPPS1 mice display equal CNPase/NF70 ratios (Fig. 3- 
19B). This result is suggestive of myelin repair mechanisms taking place be-
tween 6 and 9 months of age in APPPS1 mice. However, as this analysis 
only examined the total amount of myelin but not its integrity, I proceeded to 
perform electron microscopic analysis.     
  
 
Figure 3- 19. Western Blot Analysis of CNPase and NF70 in the Cerebral Cortex.  
To examine total protein amounts of NF70 and CNPase, western blot analysis was per-
formed on cerebral grey and white matter of APPPS1 mice at different ages compared to 
age-matched controls. (A) is a representative picture taken from one western blot. As it is 
originally two-colored the single channels were adjusted first and then the colored blot was 
converted into greyscale picture. (B) is the ratio between the total pixels of CNPase divided 
through NF70, which shows a significant decrease specifically in 6 months old APPPS1 mice 
compared to age-matched controls. The numbers within the columns indicate the number of 
animals as well as the number of datapoints quantified (n of animals/n of datapoints). Data 
are presented as mean of all data points ±SEM for a minimum of 2 independent western 
blots. 
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3.2.3 Increase in Myelin Aberrations in APPPS1 Mice 
 
To analyze the myelin integrity, I performed electron microscopy of the corti-
cal grey (GM; Fig. 3- 20B-F; Fig. 3- 20A wild type control) and white matter 
(WM; Fig. 3- 20H-L; Fig. 3- 20G wild type control) of APPPS1 mice at differ-
ent ages. Myelin aberrations were classified according to392,393: 
a) An axon surrounded by two myelin sheaths, separated by a space (Fig. 3-  
     20D, J), 
b) Excess cytoplasm in the inner loop (Fig. 3- 20K),  
c) Degenerated sheaths (Fig. 3- 20E),  
d) Balooned myelin (Fig. 3- 20F,L) 
e) Abnormal myelin outfoldings (Fig. 3- 20C,J) – these are areas of the  
     internode where the myelin sheath protruded away from the axon surface 
or  
f) Other myelin abnormalities (Fig. 3- 20B,H).  
Interestingly, the compaction of the aberrant myelin looks normal without ob-
vious irregularities (inlay Fig. 3- 20H). Myelin aberrations could be detected in 
APPPS1 mice in both cortical GM and WM, however the quantitative analysis 
was focused on the WM, since the GM has a much lower number of myeli-
nating axons. The percentage of defects was counted per number of axons. 
At 6 months of age, APPPS1 mice revealed a significantly higher proportion 
of dysmyelinated axons compared to control littermates (Fig. 3- 20M). In con-
trast, in 9 months old animals no significant difference in myelin aberrations 
was detectable indicating no further increase in myelin aberrations with age 
and plaque deposition in the APPPS1 mice. Most strikingly, these data fur-
ther indicate a potential repair, regarding also the aberrations, taking place 
between 6 and 9 months of age in APPPS1 mice. Along with myelin aberra-
tions in APPPS1 mice, also activated microglia that phagocytized myelin-like 
structures in the cortical grey and white matter were present (Fig. 3- 20N).   
Apart from differences between transgenic and control animals, interestingly, 
a significantly elevated number of myelin aberrations was observed in 9 
months old control animals compared to control mice of 6 months of age (Fig. 
3- 20N). This age-related increase in myelin aberrations has also been ob-
served in rhesus monkeys394 and was absent in APPPS1 mice, which had 
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reached the maximum of myelin aberrations already in 6 months of age. In 
summary, APPPS1 mice exhibited an increase in the disruption of myelin 
integrity at 6 months of age and then remained on a similar level, unlike in 
control mice, which showed no signs for a further increase in myelin aberra-
tions until 6 months of age.  
To exclude a developmental effect on myelin integrity in APPPS1 mice, 
where the mutations in APP and PS1 are overexpressed from late embryonic 
stages to early postnatal stages on. I also analyzed myelin formation and 
integrity in 20 days old animals (postnatal day 20, P20). This is the peak of 
myelination in the mouse. Neither the Gallyas silver impregnation that spe-
cifically stains myelin nor immunostaining with MAG revealed any obvious 
differences between control and APPPS1 mice (data not shown). Accord-
ingly, also analysis of myelin integrity in the white matter at the ultrastructural 
level further confirmed no differences in myelin aberrations between control 
and APPPS1 mice at this age. The number of myelin aberrations was higher 
than at later stages. This is likely a result of the developmental myelination 
process since at p14  numerous myelin sheaths with a loosely built structure 
were shown to be present395. Even though the number of myelin sheaths in-
creases continuously thereafter, at P28 (and as well at p21), the presence of 
both thick, compact and thin, loosely structured myelin sheaths, which were 
included in this quantification, are still present and suggestive for a still ongo-
ing myelination395. Therefore, the myelin aberrations observed in 6 months 
old animals were not due to a developmental failure of myelination (Fig. 3- 
20M). 
To investigate if early plaque deposition is sufficient to induce the myelin ab-
errations, I additionally analyzed animals at 3 months of age. Only few myelin 
aberrations were present at this time point (Fig. 3- 20M) in both, control and 
APPPS1 mice, indicating that the myelin aberrations are a rather late effect 
that appears secondary to the plaque formation. 
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Figure 3- 20. Analysis of the Myelin Integrity in the Cortical Grey and White Matter. 
(A) depicts a field of view of the cortical grey matter in control mice. (G) represents the cor-
tical white matter of control animals. This transverse section contains closely packed myeli-
nated nerve fibers with a range of sizes. Grey matter and white matter aberrations observed 
in APPPS1 mice are depicted in (B-F and G-L). Among them are such aberrations as an 
axon surrounded by two myelin sheaths, separated by a space (9D,J), balooned myelin (F,L) 
degenerated sheaths (E), excess cytoplasm in the inner loop (K) and abnormal myelin out-
foldings (C,I) or other myelin abnormalities (B,H). The insert in (H) shows the normal myelin 
compaction. The quantification of myelin defects per axons is shown in (M) with a significant 
increase of myelin aberrations at 6 months of age in APPPS1 mice and in 9 months old con-
trol mice. (N) is an example of a microglia located in the grey matter phagocytozing myelin 
sheath-like structures. The according magnifications are indicated within the pictures. Arrow-
heads point toward aberrations while (#) indicates a blood vessel and (*) dystrophic neurites. 
(M). The numbers within the columns indicate the number of animals as well as the number 
of pictures quantified (n of animals/n of pictures). Data are presented as mean per pictures 
±SEM. 
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3.2.4 Transient Increase in the Number of Olig2-positive Cells  
 
At the age of 6 months, myelin integrity but not myelin amounts were signifi-
cantly disturbed in APPPS1 mice. At this stage, plaques are spread all over 
the cortical grey matter (Fig. 3- 1A). Given the increase in the quantification 
of myelin aberrations specifically at 6 months of age, I aimed to study the 
effect on the cells of the oligodendrocyte lineage, because new remyelinating 
oligodendrocytes can be generated from oligodendrocyte progenitors 
(OPCs)170,237. As Olig2 is expressed throughout the oligodendrocyte line-
age115,396,397, it represents a valuable marker to test if cells of the oligoden-
drocyte lineage are reacting towards chronic plaque deposition. Furthermore, 
the number of Olig2-positive cells has been shown to increase in different 
lesion paradigms including APPPS1 mice116. Therefore, I quantified the num-
ber of Olig2-positive cells present in the cortical GM at different ages, namely 
3, 6 and 11 months of age. No change in the number of Olig2+ cells was ob-
served between control and APPPS1 mice at 3 months of age (Fig. 3- 21B). 
With increasing age and plaque deposition, at 6 months of age, the number 
of Olig2 positive cells was significantly increased in APPPS1 mice (Fig. 3- 
21A,B). At 11 months of age the number of Olig2+ cells was still increased in 
APPPS1 mice compared to controls, however this was not significantly dif-
ferent anymore. This result was mostly due to an increase in Olig2+ cells in 
control animals. Interestingly, the increase in the number of Olig2-expressing 
cells may be correlated with an increase in myelin aberrations present in con-
trols at 9 months of age, which may indicate some ongoing myelin repair 
mechanisms also in healthy aging mice. In addition, it can be concluded that 
the onset of amyloid plaque deposition precedes the increase of Olig2+ cell 
number with a transient elevation at 6 months of age in APPPS1 mice.  
Since Olig2 is expressed in a variety of cell types and this composition can 
vary enormously between different lesion types116, I assessed which cell 
types were responsible for the increase in number of Olig2+ cells in the grey 
matter of 6 months old APPPS1 mice. I costained Olig2 with antibodies di-
rected against the chondroitin sulfate proteoglycan NG2 (NG2) to label 
OPCs, with glutathione S-transferase pi (GSTpi) for mature oligodendrocytes 
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and the calcium binding protein S100 b and/or the GFAP (S100bGFAP) to 
label astrocytes.  
The number of S100bGFAP+/Olig2+ cells were about 20 cells per mm2  and 
a significant increase was detectable between controls and APPPS1 mice, 
however they constituted only about 6 % of the total Olig2+ cells (Fig. 3- 14). 
Amongst the remaining cells there was an increase in the NG2/Olig2 double-
positive cell population while the GSTpi/Olig2 double positive population was 
tendencially increased (Fig. 3- 21C). 
 
 
Figure 3- 21. Olig2+ Cells in the Cortical Grey Matter.  
Staining for BrdU, GSTpi and Olig2 is depicted in (A) for control and APPPS1 mice at the 
age of 6 months. In (B) the number of Olig2-positive cells was quantified at different time 
points showing a transient increase of APPPS1 mice at 6 months of age. The histogram in 
(C) shows the composition of the Olig2+ cells at the age of 6 months. The numbers within 
the columns indicate the number of animals as well as the number of data points quantified 
(n of animals/n of slices). Data are presented as mean per slices ±SEM. Scale bar: 100 μm. 
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3.2.5 Proliferation Analysis of Olig2- positive Cells  
 
The transient increase of Olig2+ cells in the cortical grey matter of 6 months 
old APPPS1 mice could be a result of an increase in the proliferation of these 
cells. To test this hypothesis, the animals received BrdU in the drinking water 
for 2 weeks. With this protocol all dividing cells including slow and fast prolif-
erating cells as well as cells that have divided and became post mitotic within 
this labelling time period are detectable. I determined the number of 
Olig2/BrdU double-positive cells per mm2 at different ages (3, 6 and 11 
months), to see possible changes in proliferation upon chronic amyloidosis. 
At 3 months of age, the number of proliferating Olig2+ cells was comparable 
between control and APPPS1 mice (Fig. 3- 22). In contrast, a significant in-
crease in the number of Olig2+/BrdU+ cells was observed in the cortical grey 
matter of APPPS1 mice at 6 as well as at 11 months of age compared to age 
matched controls (Fig. 3- 21A,Fig. 3- 22). Thus, the increase in the number of 
Olig2/BrdU double-positive cells per mm2 is indeed the result of, at least in 
part, enhanced proliferation of these cells in APPPS1 mice.  
The proliferative oligodendroglial reaction was delayed compared to plaque 
deposition and coincided with the increase in myelin aberrations. Most inter-
estingly, the number of proliferating Olig2+ cells was still increased in 
APPPS1 mice at 11 months of age compared to control mice. As the number 
of myelin aberrations, detected with electron microscopy, did not further in-
crease between 6 and 9 months old APPPS1 mice the proliferating Olig2+ 
cells may serve to generate an increased number of oligodendrocytes for 
repair. Conversly in controls, the number of BrdU/Olig2 double-positive cells 
decreased with age (between 3 and 9 months) which correlated to a signifi-
cant increase in myelin aberrations in controls. These data indicate that with 
age myelin aberrations develop possibly due to a lack of new oligodendro-
cytes, which may hint to a decreased myelin repair capacity in normal age-
ing.  
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Figure 3- 22. Proliferation of Olig2+ Cells per mm2.  
Proliferation of Olig2-positive cells was investigated by the number of cells that incorporated 
BrdU, when BrdU was given into the drinking water for 2 weeks. Quantification of BrdU/Olig2 
double-positive cells per mm2 shows an elevation in APPPS1 mice at 6 and 11 months of 
age. The numbers within the columns indicate the number of animals as well as the number 
of slices quantified (n of animals/n of slices). Data are presented as mean per slices ±SEM. 
 
Despite the significant increase in the number of Olig2/BrdU double-positive 
cells per mm2 at 6 and 11 months of age in APPPS1 mice, I noted a simulta-
neously decreased percentage in proliferating Olig2+ cells amongst the total 
BrdU-incoorporating cells in APPPS1 mice (Fig. 3- 23A). In the healthy adult 
cortical grey matter mostly Olig2+ cells proliferated, which is in line with pre-
vious observations103,105. However, upon chronic amyloid plaque deposition 
other cell types, which normally did not divide, started to proliferate. This ef-
fect was already apparent at 3 months of age, when plaque deposition has 
just started.  
Along this line, also age seemed to initiate proliferation of non-Olig2+ cells, 
since the percentage of Olig2-positive cells over the BrdU population de-
creased with age. Control as well as APPPS1 mice exhibited a significantly 
lower percentage of Olig2+ cells over the total BrdU population between 6 
and 11 months of age (Fig. 3- 23A).  
Even though Olig2+ cells mostly constituted to the proliferating cell popula-
tion in control mice, these cells represented only a subpopulation of about 
10-20 % of all Olig2+ cells. Also in APPPS1 mice only a subpopulation of 
Olig2+ cells resumed proliferation (Fig. 3- 23B). Therefore, I focused further 
on this dividing subpopulation of the Olig2+ cells of the oligodendrocyte line-
age, which co-localizes with the chondroitin sulfate proteoglycan NG2103,105. 
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Figure 3- 23. Olig2+ Cell Percentage over the BrdU Pool and Total Proliferation of Olig2+ 
Cells. 
(A) represents the percentage of Olig2+ cells over the total BrdU population at 3, 6 and 11 
months of age in APPPS1 mice compared to control animals. With age the percentage de-
creased in control animals and upon chronic amyloidosis. (B) depicts the percentage of the 
proliferating Olig2+ cells over the total Olig2+ population at different time points in control 
and APPPS1 mice. With age, proliferation of these cells decreased in the control as well as 
in the condition of chronic amyloidosis. The numbers within the columns indicate the number 
of animals as well as the number of slices quantified (n of animals/n of slices). Data are pre-
sented as mean per slices ±SEM. 
 
3.2.6 Increase in Proliferation of Oligodendrocyte Progenitors and 
Differentiation into Mature Oligodendrocytes in the Cortical Grey 
Matter 
 
As I already observed a tendency of specifically NG2+ cells to be elevated in 
the Olig2+ cell composition and given the fact, that NG2+/Olig2+ cells are the 
most proliferative cell type in the healthy cortical grey matter103,105,116, I aimed 
to investigate the increase of Olig2+/NG2+ cells in more detail. Therefore, 6 
months old animals received BrdU for 2 weeks. Interestingly, the number of 
NG2+/BrdU+ cells was increased about 2-fold in the cortical grey matter of 
APPPS1 mice (Fig. 3- 24A,B). This reaction of NG2+ oligodendrocyte pro-
genitor cells could be a response toward the focal loss of myelin and increas-
ing plaque load in the grey matter. As OPCs have the ability to differentiate 
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further to become mature oligodendrocytes within the oligodendrocyte line-
age, I aimed to follow the differentiation of these cells as well. Therefore, I 
applied BrdU for 2 weeks to the animals and then left them on normal water 
for another 4 weeks, to be able to look for the maturation of the previously 
dividing cells. Interestingly, I observed a significant 2-fold increase in the 
generation of mature GSTpi+ oligodendrocytes in the APPPS1 mice (Fig. 3- 
24C,D).  
This increased maturation of oligodendrocyte progenitors may serve to repair 
the focal demyelination or myelin aberrations observed in the grey matter. 
 
Figure 3- 24. Proliferation and Differentiation of Olidodendrocyte Progenitors in the Cortical 
Grey Matter.  
Proliferation and differentiation of grey matter cells was investigated by different BrdU pulses 
(A) BrdU was applied for 2 weeks into the drinking water for studying proliferation or (B) it 
was applied for 2 weeks followed by a 4 weeks differentiation period. This allowed following 
the differentiation of the cells that previously incorporated BrdU. The identity BrdU-labelled 
cells cells was characterized by NG2 as shown in (B) with representative immunostainings 
for BrdU and NG2 and their overlay in 6 months old control mice and APPPS1 mice. In (C) 
the quantification of GSTpi/BrdU double-positive cells per mm2 is represented and examples 
are shown in (D). The white arrowheads indicate double-positive cells, while the dark arrow-
heads point toward single positive cells.The inlay is a magnification of the according cell in 
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(D). The numbers within the columns indicate the number of animals as well as the number 
of slices quantified (n of animals/n of slices). Data are presented as mean per slices ±SEM.  
Scale bar: 50 μm and 20 μm for the inlay in (D).  
3.2.7 Proliferation and Differentiation of Oligodendrocyte Progenitors in the 
Cortical White Matter  
 
The above analysis showed an increased proliferation of oligodendrocyte 
progenitors and a subsequent increased generation of mature oligodendro-
cytes in the GM. Yet, quantitative analysis for the integrity of the myelin was 
performed in the cortical white matter and focal demyelination could also be 
observed in this particular brain region. However, cortical grey and white mat-
ter may respond differently. Therefore, I next examined the above described 
parameters in the WM. The proliferation of NG2-positive cells in the white 
matter of control mice that had incorporated BrdU (after 2 weeks) was 4 
times higher in the WM than in the GM in control animals. To investigate dif-
ferentiation of the proliferating NG2+ cells, I added a retaining period of 4 
weeks to the 2 weeks BrdU labelling. The number of GSTpi/BrdU double-
positive cells is also increased by 2.5-times in the WM compared to the GM 
of control mice. This underlines the strong differences in the density of prolif-
erating or differentiating cells between GM and WM (Fig. 3- 24A,C;Fig. 3- 
25A,B).  
To analyze if these cells would react similarly to the cells in the GM toward 
plaque deposition, I quantified the total number of NG2+/BrdU+ cells in the 
white matter of APPPS1 mice. Also in the WM, an increase of NG2+/BrdU+ 
cells per mm2 could be observed in APPPS1 mice compared to control mice 
(Fig. 3- 25A). Subsequent analysis of the newly generated mature oligoden-
drocytes (BrdU+/GSTpi+ cells) in white matter of APPPS1 mice revealed a 2-
fold increase comparable to what was observed in the grey matter (Fig. 3- 
25B,C).  
Thus, myelin aberrations correlated to an elevation in proliferation of oli-
godendrocyte progenitors and a consequent increase in the differentiation 
into mature oligodendrocytes in both GM and WM. This could further explain 
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the stable number of myelin aberrations observed between 6 and 9 months 
old APPPS1 mice.   
 
 
Figure 3- 25. Proliferation and Differentiation of Oligodendrocyte Progenitors in the White 
Matter.  
Proliferation and differentiation of white matter cells was investigated by different BrdU 
pulses (A) 2weeks for studying proliferation and (B) 2 weeks followed by 4 weeks label re-
taining period. Retaining allows following the differentiation of the cells that previously incor-
porated BrdU. (A) depicts quantification of NG2+/BrdU+ double-positive cells per mm2 (B) 
the differentiation of the oligodendrocyte progenitors investigated by staining for GSTpi/BrdU 
double-positive cells. (C) is a representative picture of a GSTpi/BrdU immunostaining, with 
the inlay (D) representing a magnification of a double-positive cell. The numbers within the 
columns indicate the number of animals as well as the number of slices quantified (n of ani-
mals/n of slices). Data are presented as mean per slices ±SEM. Scale bar: 20μm. 
3/16                      3/16 
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3.2.8 Olig2-positive Cells Do not Transdifferentiate into Astrocytes 
 
From the data presented above it became clear that cells of the oligodendro-
cyte lineage specifically react to amyloid plaque deposition. Yet, these cells 
may also generate astrocytes as observed upon e.g. cortical cryolesion229. 
Therefore, I asked the question if after such a chronic and persistent lesion 
paradigm as present in APPPS1 mice, Olig2-positive cells would also give 
rise to astrocytes.  
To monitor cells of the oligodendrocyte lineage I utilized Olig2::CreERTM x 
CAGGFP mice that express GFP specifically in Olig2-positive cells after in-
duction with tamoxifen (Fig. 3- 26A)105,115,398. Mice were analyzed at different 
time points after induction at 5 months of age, namely 9, 30 and 90 days after 
induction. As you can see in Fig. 3- 26B,C already at 9 days after induction, 
mostly mature GSTpi-positive oligodendrocytes or NG2+ oligodendrocyte 
progenitors were recombined and thus expressed GFP. In line with previous 
reports, that find a small overlap of S100b expressing NG2+ cells121, also a 
small fraction of S100b and/or GFAP-positive astrocytes could be visualized. 
However, there were no significant differences between control and APPPS1 
mice observed at any time point tested. Therefore, Olig2+ cells did not react 
divert from but rather stayed within their lineage, the oligodendrocyte lineage, 
upon chronic amyloid plaque deposition. Notably, the increased maturation of 
OPCs into GSTpi+ cells was not observed with this approach, which is pos-
sibly due to the specific Olig2+ cell population that is fate mapped, since 
about 20 % of all Olig2+ cells recombine (data not shown)105. 
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Figure 3- 26. Fatemapping of Olig2+ Cells in the Cortical Grey Matter. 
(A) shows the schematic drawing of the generation of the mouse line. (B) are representative 
pictures of reporter (GFP) positive cells in APPPS1-Olig2::CreERTM x CAGGFP mice at 6 
months of age, which are double-positive with different cell markers such as GSTpi, NG2 
and S100b and/or GFAP. (C) quantification at different time points after recombination of 
reporter+ cells in the cortical grey matter are shown. No changes concerning the oligoden-
drocyte lineage can be detected between 9, 60 and 90 days after induction (dpi). n=4 NG2 
and S100bGFAP staining controls 30 dpi and APPPS1 NG2 staining 90 dpi, n=5 APPPS1 
S100bGFAP staining 90 dpi and n=3 for all other quantifications in (C). Data are presented 
as mean per animal normalized to 100 % ±SEM. Scale bar: 20µm. 
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3.2.9 Decrease in the Number of OLIG2+ cells in Human Alzheimer’s 
Disease 
 
The previous results indicated a specific response of cerebro-cortical grey 
matter oligodendrocyte progenitors and a subsequent increase in generation 
of mature oligodendrocytes in a chronic amyloid plaque deposition mouse 
model. Interestingly, the cells belonging to the oligodendrocyte lineage have 
not been investigated in human AD in detail so far. In order to examine 
whether a similar response of OLIG2+ cells that I observed in mice is also 
present in human AD pathology, I assessed the number of OLIG2-expressing 
cells in the grey and white matter of post mortem neurologically healthy hu-
man and AD tissue (8 subjects for each condition; for detailed information to 
the human material used look at table 6- 3 in material and methods). Since in 
the APPPS1 mouse model I mainly investigated the somatosensory cortex, I 
decided to also study this area in human material (Fig. 3- 27). Surprisingly 
and in contrast to the mouse data, I observed a significant decrease in the 
number of OLIG2+ cells in both GM (Fig. 3- 27A,C) and WM (Fig. 3- 27B,D) 
of AD patients. Since the sensory-motor cortex is not predominantly affected 
in human AD patients, I also quantified the number of Olig2+ cells in the Su-
perior Temporal Gyrus (STG; Fig. 3- 27E,F) and Mid Frontal Gyrus (MFG; 
Fig. 3- 27G,H), regions known to be affected already early upon AD. Also in 
these cortical regions I detected a decrease in the number of OLIG2+ cells 
as observed in the sensory-motor cortex, except for the white matter of the 
MFG (Fig. 3- 27H). To further confirm that the observed overall reduction of 
OLIG2 expressing cells upon AD pathology are not due to neuronal and sub-
sequential loss of oligodendrocytes, I quantified the percentage of OLIG2+ 
cells per DAPI+ cells in the human grey and white matter. The percentage of 
Olig2+ cells over DAPI was significantly reduced upon AD in SSC, STG and 
MFG. The only exception was the white matter of the MFG, where the per-
centage of OLIG2+/DAPI+ cells was similar between normal and AD cases 
(Fig. 3- 28).  
In summary, these data indicate a loss of oligodendrocytes in different brain 
regions including both cortical grey and white matter upon human AD pathol-
ogy.  
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Figure 3- 27. OLIG2-positive Cells in Human Cortical Grey and White Matter. 
(A,B) representative pictures of OLIG2+ cells in the cortical grey and white matter of healthy 
control patients and human AD patients. (C-H) histograms depicing the total number of 
OLIG2+ cells per mm2 in different areas of the cortical grey and white matter of human con-
trol and AD patients. The numbers within the columns indicate the number of animals as well 
as the number of pictures quantified (n of patients/n of pictures). Data are represented per 
mean of spictures ±SEM. Scale bar: 100µm.  
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Figure 3- 28. Percentage of OLIG2-positive Cells Amongst the Total Number of DAPI-
positive Cells. 
(A,C,E) indicate the percentage of OLIG2+ cells over the total number of DAPI+ cells in dif-
ferent brain regions of the cortical grey matter. (B,D,F) indicate the percentage of OLIG2+ 
cells over the total number of DAPI+ cells in different brain regions of the cortical white mat-
ter. The numbers within the columns indicate the number of animals as well as the number 
of pictures quantified (n of patients/n of pictures). Data are represented per mean of pictures 
±SEM.  
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4 Discussion 
4.1 Reactive Gliosis in Different Lesion Paradigms 
4.1.1 Differences in the Neurosphere Forming Capacity of Reactive Glia 
between Acute Injury and upon AD Pathology 
 
Despite the strong glial reactivity, the neurosphere forming capacity of the 
lesioned cortical grey matter (GM) tissue is significantly lower in AD-related 
mouse models compared to large invasive injuries such as stab wound. In-
terestingly, this stem cell capacity in vitro is correlated to proliferation of cells 
after injury in vivo, which is higher in stab wound and lower in APPPS1 mice, 
with many neurospheres generated in the former and few in the latter (table 
4- 1)217. Similarly in another invasive injury paradigm such as stroke, induced 
by an occlusion of the middle cerebral artery (MCAO), neurosphere formation 
is present to the same extent as observed in stab wound. Interestingly, this 
ability was accompanied as well by a similarly enhanced astrocyte prolifera-
tion218,399. In further support of this idea, in CK/p25 mice the failure of neuro-
sphere formation also correlates with the absence of increased proliferation 
of macroglial cells (table 4- 1). 
One possible explanation for the decreased number of neurospheres ob-
tained from APPPS1 mice could be the age of the animals. APPPS1 mice 
were 6 months or older, while stab wound or MCAO were performed in 2 to 3 
months old animals (data not shown). With age, proliferation is known to de-
crease in the neurogenic niches and cortical GM (Fig. 3- 4)400. In line with this 
suggestion, I also observe a decrease in the neurosphere forming capacity in 
6 months old stab wound animals (data not shown). However, age does not 
explain the fact that no neuropheres are generated in CK/p25 mice, as they 
were 2-3 months old.  
Another interesting feature which could play a role in the neurosphere form-
ing capacity is the “in vitro senescence“ present in astrocytes isolated from 
AD patients401. These cells can only undergo about 7 cell cycles in culture 
before proliferation decreases and finally stops. At late stages, astrocytes 
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start to express senescence markers, such as cyclin D1 and are prone to 
undergo apoptosis when they stop dividing401. Such an up-regulation of cyclin 
D1 in the absence of proliferation in astrocytes is also observed in the AD-
related mouse models utilized in this study (Fig. 3- 15)401. Therefore, astro-
cytes may particularly lose their proliferative ability during aging or in mouse 
models reflecting certain aspects402.  
Besides the link between proliferation and neurosphere forming potential, it is 
unclear which cell type is giving rise to the neurospheres observed in 
APPPS1 mice. In principle, both postnatal cortical astroglia and NG2+ cells 
are able to generate multipotent and self-renewing neurospheres in vi-
tro403,404. However after the second postnatal week, the potential of these 
cells located in the cortical GM is lost217,403. Recent rodent data reveal that 
after stab wound injury, adult GM astrocytes re-gain their developmental po-
tential to generate self-renewing, multipotent neurospheres103,217. In contrast, 
other glial progenitors such as NG2+ cells that actively proliferate as well in 
this lesion paradigm are not capable to do so95,116,217. In this study mouse 
models reflecting different injury paradigms are used. As glial cells may re-
spond differently toward distinct lesion paradigms the neurosphere formation 
observed in APPPS1 mice may still be attributable to both, astroglia and 
NG2+ glia, since both cell types seem to harbour some developmental poten-
tial to generate neurospheres. One indication that also adult NG2+ cells har-
bour the potential to generate multipotent neurospheres arises from the fact 
that their formation is observed after isolation of unlesioned human adult cor-
tical white matter405. 
Thus, in principle both cell types appear to be potent to generate neuro-
spheres, I cannot exclude the possibility that also NG2+ glia may retain the 
ability to generate neurospheres after certain lesion conditions like chronic 
amyloidosis.  
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4.1.2 Striking Differences in the Glial Cell Proliferation in Response toward 
Different CNS Pathologies 
 
As it has been pointed out above, the degree of astrocyte proliferation is 
strikingly different between acute invasive and non-invasive mouse models of 
AD pathology. Factors contributing to these differences in proliferation may 
be present at the cellular level or may be determined by the specific injury 
environment. All data obtained in this study are summarized in table 4-1. 
 
 
Table 4- 1. Overview over the Specific Features of Reactive Gliosis in Different Lesion Para-
digms.  
The table summarizes data obtained in this study. The AD-related mouse models used 
(APPPS1 and CK/p25) are compared to available data for acute invasive injuries such as 
stab wound and MCAO. Studies referred to are (a)406; (b)218; (c)407; (d)399; (e)408; (f)409; (g)410; 
(h)411; (i)412; (j)187; (k)189. The increased potential in forming neurospheres after stab wound 
and MCAO is indicated by the green background. 
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4.1.2.1 JNK/c-Jun pathway 
 
The discrepancy in the astrocyte proliferation may be mediated by differently 
activated signalling cascades. One candidate represents the activation of the 
c-Jun N-terminal kinase (JNK). An increase in JNK phosphorylation has been 
demonstrated in reactive astrocytes in different injury paradigms such as epi-
lepsy and demyelination381,413. Also my observations indicate an activation of 
the JNK after stab wound injury as well as in the AD-related mouse models 
(Figure 3- 13). The JNK is expressed in astrocytes after stab wound and in 
CK/p25 mice, while in APPPS1 mice only plaque-associated areas are im-
munostained. In support of the latter result, the JNK pathway has been 
shown to be active also in other plaque depositing mouse models of AD, 
such as the Tg2576 and Tg2576/PS1P264L mice414,415 (table 4- 2). In accor-
dance with my observations, both mouse models show an elevation of phos-
phorylated JNK expression mostly in plaque areas and in dystrophic neurons 
in the peri-plaque regions414,415.  
It has also been previously described that reactive astrocytes upon lesion 
show increased phosphorylation of a downstream target of JNK, namely c-
Jun, an immediate early gene416-418. Phosphorylation of c-Jun (pcJun) is fur-
ther implicated in the modification of astrocyte proliferation after demyelina-
tion381. In accordance with the activation of the JNK in GFAP-positive astro-
cytes upon stab wound and in CK/p25 mice, pcJun is detected in a small 
subset of reactive astrocytes in these lesion models (Fig. 3- 12). Other pcJun 
positive cells in this study, mostly detected in stab wounded and CK/p25 
mice, likely comprise neurons, since pcJun is linked the induction of apop-
tosis after lesion419,420. However, not all pcJun positive neurons die, which 
indicates that pcJun expression may have broader and even protective func-
tions in neurons after lesion421. The total amount of pcJun expression is ac-
cordingly higher in stab wound and CK/p25 mice (data not shown), with 
prominent neuronal death189,331, while in APPPS1 mice the total number of 
pcJun-positive cells is lower correlated to the lack of cell death in this 
model329. These results are also in line with the results obtained in Tg2576 
mice (table 4- 2), where expression of pcJun remains at control levels415. In-
terestingly, also in human AD pathology, pcJun positive neurons, which often 
carry paired helical filaments (PHF), can be identified422. In addition, pcJun-
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positive GFAP+ astroglia as well as neurons, both located in the vicinity of 
plaques are present in the cortex, hippocampus and enthorinal cortex of AD 
patients422. This further supports the idea that tangle pathology as well as 
neuronal loss may be important triggers for pcJun expression in astrocytes. 
 
4.1.2.2 Olig2 
 
A transcription factor possibly involved in astrocyte proliferation after injury is 
the expression of the Olig2, a basic helix loop helix repressor, which is mostly 
expressed within the oligodendrocyte lineage117. However, also a small sub-
set of astrocytes expresses it (Fig. 3- 14). Upon cortical stab wound lesion 
and in APPPS1 mice the number of Olig2 expressing cells is known to in-
crease105,116. Olig2 is also up-regulated most prominently in astrocytes upon 
stab wound injury and in APPPS1 mice, which is in line with my own obser-
vations (Fig. 3- 14)116. Introduction of Olig2 via retroviruses into the lesion 
area of spinal cord-injured adult rats, results in massive proliferation of the 
transduced cells. However, only small subsets of these cells are astro-
cytes423. Also in human gliomas, Olig2 is strongly expressed, yet again 
mostly in cells of the oligodendrocyte lineage. One possible mechanism how 
Olig2 mediates its pro-proliferative function may be repression of p21, a tu-
mor suppressor and inhibitor of stem cell proliferation424. Accordingly, repres-
sion of p21 would then lead to an increase in proliferation. Since Olig2 is fre-
quently implicated in proliferation and tumor formation, it is likely that Olig2 is 
also involved in proliferation of astrocytes after injury. Indeed, genetic dele-
tion of Olig2+ cells after cortical contusion injury, results in a reduced prolif-
eration of astrocytes382. In line with this idea, Olig2+ astrocytes are highest 
after stab wound injury and lowest in CK/p25 mice, which is in accordance 
with the absence of astrocytes resuming proliferation in the latter mouse 
model (see Fig. 3- 11). Therefore the results indicate that only specific pa-
thologies lead to a strong induction of Olig2 expression in astrocytes and the 
signals mediating this in astrocytes still need to be determined383. 
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4.1.2.3 Cyclin D1 
 
Astrocytes in AD pathology attempt to re-enter the cell cycle but fail to com-
plete it. Along this line, I observe an increased number of reactive astrocytes 
in APPPS1 mice as well as CK/p25 mice that express cyclin D1. Expression 
of this protein, as a delayed early gene in the gap 1 (G1) phase of the cell 
cycle, is induced by e.g. growth factors and integrins384,425,426. D-type cyclines 
control the re-entry into DNA-synthesis (S)-phase, when the DNA is repli-
cated, by regulating the phosphorylation status of the retinoblastoma pro-
tein386,427,428. Upon phosphorylation, the retinoblastoma protein releases the 
E2F transcription factor that then activates genes important for G1 to S 
phase transition. Cyclin D1 exerts its cell cycle-related functions by forming a 
holoenzyme with the cyclin dependend kinases (CDK) 4 and CDK6, however 
its expression has to be significantly downregulated for progression into S-
phase384,429. The increase in expression of this protein indicates that astro-
cytes upon chronic plaque deposition (APPPS1) and heavy neuronal loss 
(CK/p25) become reactive and additionally attempt to re-enter cell cycle. De-
spite this increase in cyclin D1 expression, however, astrocytes do not incor-
porate BrdU to an extent observed upon stab wound injury103,217. Interest-
ingly, after neurodegeneration in the retina, similar results are obtained. The 
Müllerglia in the retina fail to proliferate after a neurodegenerative insult but 
increase in the expression of cell cycle markers such as cyclin D1430. 3 days 
after stab wound injury, significantly more astrocytes express cyclin D1 com-
pared to the AD-related mouse models. However, for proliferation to occur 
cyclin D1 expression has to be downregulated. At the time point where most 
proliferation of astrocytes is detectable upon stab wound (7 dpi) cyclin D1 
expression is likely to be reduced compared to 3 dpi (Fig. 3- 15)103.  
However, cyclin D1 may also exert functions independent of CDK4 and 
CDK6, since different signalling pathways may converge on the cyclin D1 
promoter. Interestingly, amongst such candidates are inflammatory signalling 
pathways e.g. the NF-κB (nuclear factor κB)/IKK (inhibitor of NF-κB) pathway 
or cytokines431,432. NF-κB resides in the cytoplasm in an inactive state due to 
the presence of members of the IκB family. Upon activation of this signalling 
pathway, IκB becomes phosphorylated and subsequently degraded. This 
allows the NFκB to translocate into the nucleus thereby activating or repress-
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ing target genes431,433. NF-κB signalling is involved e.g. in the immune re-
sponse toward injury, cell proliferation and cell death433 and has been addi-
tionally implicated in the induction of cyclin D1 expression434,435.   
On the other hand, cytokines, which play an important role in the immune 
response, bind to cell surface receptors initiating signalling via the JAK-STAT 
pathway. The Janus activated kinase (JAK) e.g. upon binding to ligand-
bound cytokine receptors, phosphorylates activators of transcription (STAT) 
transcription factors. Upon phosphorylation, STAT translocates into the nu-
cleus436. Cytokines such as interleukin-3 or interleukin-6 are shown to stimu-
late the cyclin D1 promoter via STAT3 and STAT5 mediated signalling432,437-
439. Since brain injury is accompanied by inflammation, cyclin D1 expression 
may be induced by inflammatory processes independently of a cell cycle 
function. However, one should keep in mind that so far most of the studies on 
that issue are conducted in other cell types. If such an inflammatory activa-
tion of cyclin D1 expression would also take place in astrocytes is not known 
yet.  
 
4.1.2.4 Immune Response 
 
The immune response taking place upon acute stab wound or MCAO injury 
may be different compared to the one taking place upon progressive amyloi-
dosis (APPPS1) or induced neuronal loss (CK/p25). In general, the brain’s 
immune response is mediated by astrocytes440 and microglia which cooper-
ate and influence each other383,441. In response to stimulation with cytokines, 
murine astrocytes up-regulate genes involved for example in innate immunity 
(e.g. IL-6, INF-β, IL-15, interferon-inducible GTPases), genes involved in 
adaptive immunity (e.g. MHC class I and II molecules) but also genes in-
volved in signalling (NF-κB)442. Furthermore, other genes are down regulated 
such as CNTF (cilliary neurotrophic factor) as well as NT-3 (neurotrophin 
3)442. This shows that astrocytes change their gene expression profile upon 
injury and it may be that different injury paradigms may lead to up- or down-
regulation of distinct sets of genes. In support of this idea it has been shown 
that distinct astrocytes such as GM and WM astrocytes respond differently 
toward stroke443,444. One explanation for this may be that astrocytes repre-
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sent a heterogenous cell population, since e.g. astrocytes cultured from dif-
ferent brain regions are diverse in their release of chemokines and cytokines 
or by the induction of the expression of nitric oxide (NO) synthase-2 (NOS-
2)445,446,447. 
Also microglia produce numerous factors such as pro- and anti-inflammatory 
cytokines, growth factors and neurotrophins252. They furthermore rapidly mi-
grate toward the lesion side243, adopt an amoeboid shape and proliferate. 
Upon e.g. large invasive injuries or AD pathology they additionally acquire 
the ability to phagocytose and may produce reactive oxygen and nitrogen 
species177,448.  
A similar time course in microglial proliferation is observed upon stab wound 
and MCAO injury. At an early time point, 3 days after stab wound lesion, mi-
croglial cells constitute to most of the proliferating cells, whereas this reaction 
diminishes with time103. Similarly, upon MCAO in rats, activated microglia are 
observed 1 day after stroke and increase in number by day 2. Afterwards, 
this reaction subsides and resumes control levels around 14 days after 
MCAO449,450. In addition, peripheral leucocytes, including neutrophils, macro-
phages and T-cells invade into the lesioned area, thereby contributing to-
gether with the activated microglia to the increased production of cytokines 
including TNFα following ischemia451. However, certain immunomodulatory 
factors may react faster and more temporary, as it has been shown in acute 
traumatic spinal cord injury, where an increase of interleukin 1ß (IL1ß), inter-
leukin 1α (IL1α)  and tumor necrosis factor α (TNFα) transcripts are observed 
as early as 30 minutes after lesion. Other cytokines such as interleukin 6 (IL-
6) and transforming growth factor-As (TGFAs) are also increased after spinal 
cord injury, however transcript up-regulation occurs later in time. 24 hours 
after spinal cord trauma the presence of these molecules starts to diminish, 
while simultaneously the number of microglia/macrophages increases452. 
Similar to stroke injury, after acute stab wound injury platelet-derived growth 
factor (PDGF) and TGFß are present early at the lesion side, since they are 
generated by platelet lyses453,454. The expression of TGFß is mostly present 
at the lesion side between 1 and 3 days after lesion. Thereafter, the TGFß 
protein expression decreases and becomes mostly located at the glial 
scar454. All the above described immunomodulators are expressed by infiltrat-
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ing blood-derived immune cells but also by resident microglia and reactive 
astrocytes after lesion. Even though expression of e.g IL-6 and TGFß pro-
teins can still be detected 12 to 14 days after lesion, the great inflammatory 
response toward the CNS insult endures relatively short in acute invasive 
injuries, which is in contrast to a more persistent chronic inflammatory re-
sponse in AD pathology453,455. 
Aβ is a potent activator of microglial reactivity resulting in increased secretion 
of e.g. inflammatory cytokines, activated complement proteins, proteases and 
reactive oxygen species456,457. Microglia becoming reactive upon AD pathol-
ogy are often associated with compact amyloid plaques, as also observed in 
different mouse models with plaque deposition324,359,456 but also neurons with 
tangles or phosphorylated tau as well as aberrant neurites can be associated 
with reactive microglia456. Interestingly, the total numbers of microglial cells is 
well comparable between APPPS1 and CK/p25 mice. Furthermore, the pro-
liferative response of microglial cells in CK/p25 mice with inducible neuronal 
cell death, follows a time course similar to acute invasive lesions, even 
though these changes were observed in longer periods of time. For example, 
at an early stage after onset of the pathology, microglia constitute about 60% 
of the total BrdU pool. At later stages of the pathology, the percentage ad-
justs to 50 % (Fig. 3- 11). This indicates an initial increase in microglial prolif-
eration also in CK/p25 mice. In conclusion, regardless of the lesion paradigm 
microglial cells are one of the first cell types (together with NG2+ cells in 
APPPS1 mice) to increase in proliferation.  
In addition to proliferation upon acute invasive injury, an invasion of blood-
derived immune cells takes place, which may contribute to the immune re-
sponse458,459. These infiltrating cells seem to exert important functions, since 
their ablation after spinal cord lesion impairs functional recovery460. Interest-
ingly, such blood-derived cells are also detectable in APPPS1 and CK/p25 
mice, however the density of these cells is rather low in comparison to acute 
injury paradigms (Fig. 3- 16). Since these cells together with microglia are a 
major source of TNFα451, which also promotes astrocyte proliferation461, this 
may be an additional candidate to mediate differences in proliferation be-
tween stab wound and AD-related mouse models.  
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The inflammatory response has been shown to exert both, beneficial effects 
as well as detrimental effects for the regenerative outcome after injury. For 
example, immediately after a stroke injury, the inflammatory process con-
veyed by microglia seems to be beneficial for neuronal survival, since abla-
tion of proliferating microglia until 48-72 hours after stroke results in an in-
crease in the size of the lesion and in the number of cells undergoing apop-
tosis462. Later in time, microglia may exert more detrimental effects on brain 
repair, as reduced microglial proliferation from 4 days after stroke on results 
in improved functional recovery after the insult463. Also in AD pathology, mi-
croglia may exert both beneficial as well as detrimental effects. For example, 
microglia migrate toward amyloid plaques and have the ability to phagocy-
tose Aβ, thereby contributing to Aβ clearance. On the other hand, the in-
creased expression of pro-inflammatory cytokines may enhance Aβ deposi-
tion455. Therefore it is believed that the immune response needs to balance 
beneficial versus detrimental effects and this balance seems to be of critical 
importance in terms of brain repair456,464. Interestingly, chronic inflammation 
may be a result of an imbalance of the presence of such inflammatory media-
tors, conveying the inflammatory response, and inflammatory regulators (in-
clude anti-inflammatory mediators), which down-regulate inflammation456. An 
imbalance of these different mediators upon aging465 or chronic inflammatory 
stimulation may lead to an exacerbated pathology456. One observation sup-
porting this suggestion is the observation that AD patients show a greater 
number of reactive microglia than non-demented patients bearing high 
amounts of plaques as well456,466. In addition to this possible imbalance of the 
inflammatory reaction, detrimental actions of activated microglia may pre-
dominate in AD pathology455,467.  
Therefore, microglia are activated in various pathologic conditions and may 
exert different functions depending on the specific CNS insult. Furthermore, 
they may release different sets of pro- and anti-inflammatory cytokines, 
growth factors and neurotrophins as well as different amounts of reactive 
oxygen and nitrogen species, which may also influence astrocyte and NG2+ 
cell reactivity differently.  
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4.1.2.5 Extracellular Matrix 
 
In addition to the possible differences in the immune response upon different 
brain injuries, also other molecules present in the injury environment may 
support astrocyte and NG2+ cell proliferation in acute invasive injuries, 
whereas they may be less-supportive in AD-related mouse models. Along 
this line, the expression of the extracellular matrix proteoglycan DSD-1, 
which can be secreted from astrocytes, is increased in APPPS1 and CK/p25 
mice95,216 as detected with the 473HD antibody50,468 (Fig. 3- 3, 3- 9)92,93. The 
473 epitope recognizes the chondroitin sulfate proteoglycan (CSPG) phos-
phacan, which is expressed in the neurogenic niches of the healthy non-
lesioned brain48. CSPGs have been shown to bind various growth factors 
that may promote cell division in the neurogenic niches as well as glial prolif-
eration after lesion47,95. In addition to the DSD-1 proteoglycan also the ex-
tracellular matrix (ECM) glycoprotein tenascin C (TNC) is up-regulated and 
secreted from reactive astrocytes upon e.g. acute stab wound or laser le-
sion95,216,469. TNC is highly expressed by radial glial cells in the developing 
brain470 and within the SVZ throughout postnatal and adult life contributing to 
the stem cell niche by e.g. modulating growth factor signalling49,50. In princi-
ple both of the above described molecules may be supportive for astrocyte 
proliferation but are obviously not sufficient as they are also up-regulated in 
APPPS1 and CK/p25 mice despite the lack of astrocyte proliferation. Notably, 
the extracellular matrix after lesion includes many more molecules than the 
DSD-1 and TNC, which may additionally influence the lesion environment 
and exert different effects on glial cells according to the different lesion condi-
tions. 
4.1.3 Upregulation of Intermediate Filaments 
 
Another hallmark of reactive gliosis upon acute invasive brain injuries, like 
stab wound and stroke, includes the up-regulation of intermediate filaments 
such as GFAP and nestin95,216,218,406. Similar to the observations obtained 
from acute invasive injury, astrocytes up-regulate the intermediate filaments 
GFAP and nestin upon chronic plaque deposition (Fig. 3- 2; 3- 8; 3- 9). This 
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is in line with previous reports demonstrating that reactive astrocytes in an 
AD environment up-regulate GFAP and that they are mostly associated with 
focal plaques324,344-346. Furthermore, these reactive astrocytes in the vicinity 
of plaques become hyperthrophic, similar to the observations in APPPS1 
mice (Fig. 3- 1)348. In addition to GFAP up-regulation, also increased expres-
sion levels for nestin have been observed upon human AD pathology and in 
neurodegeneration471.  
In contrast to APPPS1 mice, the CK/p25 mice do not show extracellular 
plaque deposition; however they show intraneuronal accumulation of Aβ, tau 
pathology and neuronal loss. Also these features were previously demon-
strated to induce GFAP up-regulation which could in principle be due to ei-
ther tau pathology or neuronal loss331,336. For example neurofibrillary tangle 
(NFT) pathology in mice leads to severely degenerated neurons as well as 
astrogliosis visualized with GFAP immunostaining472.  
In conclusion, on the one hand reactive gliosis upon AD pathologies shares 
many similarities with invasive injuries. On the other hand, certain aspects 
such as astrocyte proliferation, neurosphere formation are strikingly different 
comparing invasive and non-invasive injury paradigms.  
4.1.4 Blood Brain Barrier Integrity  
 
A very prominent difference observed in this study is the “open” versus 
“closed” blood brain barrier (up to a molecule size of 3000 Dalton) upon 
acute invasive and AD-related mouse models, respectively (Fig. 3- 17). No-
tably, this might be different in human AD pathology or in very old APPPS1 
mice, since the blood brain barrier (BBB) has been suggested to be 
leaky473,474. Yet a possible leakiness is still is a matter of debate. A compro-
mised blood brain barrier, however, is considered a feature of human AD pa-
thology475. One difference of human AD pathology and APPPS1 (6 months of 
age) or CK/p25 mice (5 weeks OFF) is the presence of vascular amyloid de-
posits in human and its virtual absence (except for large pial vessels at late 
stages) in the mouse models324,331,342. Therefore, the absence of vascular 
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amyloid deposits within vessels may account for the unchanged blood brain 
barrier integrity in the AD-related mouse models I tested.  
Given the rupture of the BBB upon acute invasive injuries, this can have 
dramatic influences on the specific lesion environment. For example, it is 
known that upon acute brain injury fibromeningal cells invade into the brain 
and take part in the generation of the glial scar199,200. In addition, factors that 
promote astrocyte and NG2+ cell proliferation as well as neurosphere form-
ing capacity may be released from the blood entering the brain. Rupture of 
blood vessels and their astrocyte’s contact may further trigger astrocyte pro-
liferation upon large invasive injuries. Yet, the BBB and blood vessels remain 
intact in APPPS1 and CK/p25 mice and therefore this strong re-enforcement 
of proliferation may be missing. However, it should be noted that plaque 
deposition in APPPS1 mice is sufficient to elicit an increase in glial cell prolif-
eration and neurophere forming capacity similar to age-matched stab 
wounded animals. However, it still needs to be elucidated what cell type gen-
erates these neurospheres and what are the factors leading to that response.  
4.2     Reactivity of Cells of the Oligodendrocyte Lineage toward 
Chronic Plaque Deposition 
4.2.1 Transient Increase in Disruption of Myelin Integrity in APPPS1 Mice 
 
I could demonstrate that the percentage of myelin aberrations per axon upon 
chronic amyloid plaque deposition are significantly increased at the age of 6 
months in APPPS1 mice, an age when in these mice plaque formation is al-
ready visible. In contrast to this observation, in another mouse model reflect-
ing distinct aspects of human Alzheimer’s disease, the 3xTg mice (table 4- 
2), myelin sheath aberrations are detectable even before plaque deposition 
starts476. One explanation for the discrepancy in the onset of myelin aberra-
tions may be that 3xTg mice express mutations in APP, PS1 and tau, 
whereas APPPS1 mice specifically reflect the plaque pathology by overex-
pressing only APP and PS1 mutations (table 4- 2). Furthermore, in 3xTg 
mice the expression of the PS1 mutation starts prenatally477, meaning that 
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the expression of the PS1 mutation starts earlier than in APPPS1 mice, 
where the PS1 mutation is postnatally expressed324. Above that, the different 
γ-secretase mutations of the two mouse models may also account for the 
discrepancy in the onset of myelin aberrations, since PS1 may be crucially 
involved in myelination. It has been shown that PS1 cleaves the insulin-like 
growth factor 1 (IGF-1) receptor478 as well as the structurally homologous 
insulin receptor479,480, which both are receptor tyrosine kinases. The corre-
sponding ligand of these two receptors, IGF-1, is a strong promoter of myeli-
nation480-483 as for example, knockout mice for IGF-1 show a marked reduc-
tion in the size of WM structures in brain and spinal cord484. As in the 3xTg 
mouse line the expression of the PS1 mutation starts before myelination on-
set, it could be that in these mice IGF-1 receptor is not efficiently cleaved by 
PS1. This may result in problems of IGF1-mediated signalling resulting in 
inefficient myelination. In accordance with this, APPPS1 mice do not show 
effects on myelination as examined at postnatal day 20 or 3 months of age, 
but rather on myelin integrity at later stages (6 months of age; Fig. 3- 20). 
However, the function of the PS1-mediated cleavage of the IGF1 receptor is 
not well known and it could be that different PS1 mutations differently affect 
IGF-1 receptor function479. 
Interestingly, also the ErbB4 signalling pathway is affected by the γ-
secretase-mediated cleavage480,485. This pathway is known to be important 
for myelination in the peripheral nervous system (PNS) determined by in vivo 
studies486,487. For example, transgenic mice expressing a dominant-negative 
ErbB receptor in myelinating Schwann cells of the PNS have a delayed onset 
of myelination, thinner myelin, shorter internodal length and smaller axonal 
caliber in adulthood487. One signalling cascade involved in this phenotype is 
neuregulin-1 (NRG1) mediated via the ErbB receptors, which was similarly 
shown to be important for Schwann cell myelination in the peripheral nervous 
system (PNS)488. Similar to the NRG1 heterozygous mice, also BACE1 
knock-out mice show severe hypomyelination in the PNS489-491. In the ab-
sence of BACE1, uncleaved full-length NRG1 accumulates resulting in this 
phenotype489,490. Therefore, it is possible that the cleavage of Erb can be 
mediated by both the γ-secretase and the β-secreatse, which may in princi-
ple affect myelination in the PNS. However, in the adult central nervous sys-
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tem (CNS) the function of neuregulin-ErbB4 signalling seems conflictive, be-
cause ErbB4 knockout mice show no effect on myelination in the CNS492. On 
the other hand, a selective blocking of Erb signalling in oligodendrocytes is 
followed by hypomyelination, neuronal dendritic arborisation changes and 
interfered with dopaminergic neurotransmission493. Upon activation of Erb 
signalling the intracellular domain is released and translocates into the nu-
cleus promoting the expression of the myelin basic protein (MBP) in oli-
godendrocytes494. Therefore, mutations or alterations in APP-related secre-
tases may greatly influence myelin integrity480.  
Besides PS1, also overexpression of APP may affect myelination. The 
PDAPP mice495, which overexpresses exclusively mutated APP under a 
mostly neuronal promotor (see table 4- 2), shows myelin loss by a reduction 
in the size of the corpus callosum, fornix and hippocampus. The length of the 
corpus callosum (CC) is reduced at the age of 40 days, as a result of an im-
paired WM development. No further change in the CC size can be detected 
until 21 months of age496. These morphological changes can be correlated to 
the gene dose of the mutant gene as homozygous animals have a greater 
reduction than heterozygous animals497. One difference between the mouse 
lines is again the onset of transgene expression prenatal in PDAPP and 
postnatal in APPPS1 mice324,498. In addition to the distinct onset of APP 
transgene expression in the two mouse lines, the overexpressed mutation is 
different (table 4- 2), which may distinctively affect myelination324,495.  
Apart from the possible involvement of APP mutations in myelin reductions, 
the APP-N-terminus has been recently shown to serve as an activator of the 
death receptor 6 (DR6). This receptor mediates axonal degeneration and 
neuronal loss via the activation of different caspases (caspase 3 and 6)499. 
Interestingly, another recent study demonstrates an involvement of DR6 also 
in the regulation of oligodendrocyte survival via caspase 3 activation. This 
study, however, does not observe any caspase 3 activation, when the oli-
godendrocytes are treated with the APP-N-terminus, which implies different 
effects of APP-N-terminus on the DR6 in different cell types500. Mutations in 
APP may still alter the activation of the DR6 in a way that affects survival of 
axons or myelin maintenance in different APP-mouse lines.  
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In summary, the above mentioned effects of different mutations were dis-
cussed in regard to myelination. Yet, in my study I could not detect myelina-
tion effects, but rather effects on myelin integrity. However, there is also evi-
dence that oligodendrocyte cultures obtained from PSM146VKI (AD-
associated PS1 mutation) mice show increased vulnerability towards different 
stressors such as glutamate and Aβ, which may in general account for 
changes in the observed myelin integrity477,501-503. Contrary to the 
PSM146VKI mouse line (table 4- 2), in APPPS1 mice the PS1-mutation is 
only neuronally expressed. However, also application of Aβ 42 to rat oli-
godendrocyte cultures reduces the survival of mature oligodendrocytes and 
even inhibits myelin sheath formation, while not affecting OPCs504. These 
results raise the possibility that the Aβ production could also result in death of 
oligodendrocyte progenitors thereby affecting myelin integrity APPPS1 mice.  
Therefore, specific APP as well as PS1 mutations may result in disturbances 
of both, myelin production and myelin integrity. Yet, also extracellular plaque 
deposition influences myelin, since focal demyelination can be observed in 
plaque core areas389. In conclusion, the myelin aberrations I observed in 
APPPS1 mice may be the result of mutant transgene overexpression as well 
as extracellular plaque deposition.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 Discussion 115
 
Mouse-
line 
Pro-
moter 
Start of  
Promotor  
Expres-
sion 
APP                     PS1           Tau 
                      Mutation 
Onset of 
Plaque and 
Tau/Tangle 
Pathology 
APPPS1 
324 
Thy1; 
neuronal 
Postnatal KM670/671NL 
(Swedish double-
mutation) 
L166P  Plaques: 
2-3 months of 
age 
La Ferla 
(3xTg)505 
Thy1: 
Neuronal 
PS1: 
neuronal 
and glial 
(knock-
in) 
Postnatal: 
App, Tau 
Prenatal: 
PS1 
(knock-in) 
KM670/671NL 
(Swedish double-
mutation) 
M146V 
Knock-
in477 
P301L Plaques: 
6 months of 
age 
Tangles: 
12-15 months 
of age 
NFT-tg472 Tau 
promo-
tor; 
neuronal 
During de-
velopment  
  K257T/
P301S 
Tangles: 
6 months of 
age 
PDAPP495 PDGFß; 
mostly 
neuronal 
506 
 
Prenatal: 
Aß produc-
tion from 
embryonic 
E16 cul-
tures 
V4717F   Plaques: 
6-9 months of 
age 
PS1 
M146VKI 
477,503 
 
neuronal 
and glial 
(knock-
in) 
Prenatal 
(knock-in) 
 M146V 
Knock-
in 
 No gross 
phenotype 
Tg2576507 Hamster 
Prion 
Protein 
(PrP); 
neuronal 
and glial  
From 
E13.5 on508 
KM670/671NL 
(Swedish double-
mutation) 
  Plaques: 
9-11 months 
of age 
Tg2576/ 
PS1P264L  
507,509,510 
Hamster 
Prion 
Protein 
(PrP); 
neuronal 
and glial  
From 
E13.5 on508 
KM670/671NL 
(Swedish double-
mutation) 
P264L 
Knock-
in 
 Plaques: 
2-3 months of 
age 
 
Table 4- 2. Overview on Different AD-Related Mouse Lines. 
 
The characters indicate mutated amino acids: F = Phenylalanine; K= Lysine; L= Leucine; M 
= Methionine; N = Asparagine; P = Proline; S = Serine; V = Valine. The numbers refer to the 
location of the mutation.  
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4.2.2 Indications for Myelin Repair upon Chronic Plaque Deposition 
 
Possibly as a reaction to the above observed aberrations, I reported an in-
crease in the generation of mature oligodendrocytes and no further defects 
on myelin in APPPS1 mice compared to controls, respectively. This could 
hint toward some myelin repair mechanisms taking place in APPPS1 mice at 
this age. Remyelination is commonly observed after demyelination, where 
axons that lost their myelin, redistribute axonal sodium channels along the 
axon, formerly only located at the node of Ranvier232. This results in a non-
saltatory and therefore slower conduction of action potentials. Upon remyeli-
nation, saltatory conduction is functionally re-acquired233. Yet, the remyeli-
nated axons have thinner myelin sheaths with less compaction511,512, which is 
most obvious for large diameter axons but not easy to detect for corpus cal-
losal axons170. Therefore, when only morphology of myelin is taken into ac-
count, it is difficult to evaluate whether remyelination has taken place in the 
latter area in APPPS1 mice. However, there are some indications that myelin 
repair mechanisms might be ongoing. 
In the spinal cord it has been shown that an increase of cells expressing the 
transcription factor Olig2 occurs in response to demyelination. A slower and 
delayed increase in the number of Olig2+ cells could be correlated to in-
creasing age237,513. Also APPPS1 mice show an elevated number of Olig2-
expressing cells in the GM at 6 months of age, when most myelin aberrations 
are observed. The majority of them belong to the oligodendrocyte lineage. At 
the latest time point tested (11 months of age) still a tendency toward an in-
crease in the number of Olig2+ cells is detectable between control and 
APPPS1 mice. Furthermore, at 6 months of age, the increased number of 
Olig2-expressing cells in APPPS1 mice correlates to an enhanced Olig2+ cell 
proliferation, assessed by BrdU incorporation. At this time point, I could fur-
ther attribute the increase in the number of Olig2+/BrdU+ cells to an increase 
in OPC proliferation. Strikingly, at 11 months of age, I still observe an in-
crease in the number of proliferating Olig2/BrdU double-positive cells. Maybe 
this phenomenon indicates some ongoing myelin repair mechanisms still 
present at 11 months of age in APPPS1 mice, as these proliferating 
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Olig2/BrdU double-positive cells may serve as a reservoir for new myelinat-
ing oligodendrocytes.   
Interestingly, the Olig2/BrdU double-positive cells are only a minority of all 
dividing cells in APPPS1 mice, whereas they are the majority in control mice. 
This is in line with previous observations in wildtype mice describing that 
Olig2+ cells represent the major cell population dividing outside the neuro-
genic niches103,105. In addition to this observation, the percentage of prolifer-
ating Olig2+ cells over the total Olig2 pool implies that only a subpopulation 
has the capacity to divide (Figure 3- 23)105.  
The major cell type mediating myelin repair upon demyelination of the cortical 
grey and WM are the Olig2+/NG2+ OPCs237,514,515,103,170. Upon demyelination 
these cells proliferate and are located around the lesion side, before differen-
tiation into myelinating oligodendrocytes is observed170,236-238. Therefore, the 
increase in OPC proliferation and the consequent increase in the generation 
of mature oligodendrocytes upon chronic amyloid plaque deposition could 
hint to a remyelination attempt.  
In line with this suggestion, the ratio of the myelin protein CNPase divided 
through the axonal marker NF70 is significantly decreased at 6 months of 
age in APPPS1 mice and it reaches control levels again at 9 months of age 
(Fig. 3- 19D). As axonal loss can be largely excluded329, the decreased ratio 
indicates that less myelin is present per axon. As CNPase is additionally ex-
pressed in mature oligodendrocytes, the ratio indicates a transient decrease 
in rather both, myelin as well as mature oligodendrocytes at 6 months of age.  
Amyloidosis may inhibit the further differentiation of mature oligodendrocytes 
into myelinating oligodendrocytes, since Aβ application to oligodendorcyte 
cultures exhibits an effect on myelin formation, while leaving NG2+ cells un-
affected. Dystrophic neurites as observed in plaque areas of the APPPS1 
mice (Fig. 3- 20 and323), are usually rarely remyelinated170. 
However, not only demyelination stimuli can lead to an increased maturation 
of OPCs. For example, axonal degeneration without myelin pathology can 
also cause an increase in the proliferation of NG2+ OPCs516. Interestingly, 
activated microglia alone may mediate a response of NG2+ OPCs517 and 
microglia are known to become reactive upon chronic plaque deposition518. 
Also after stab wound injury, an increase in NG2+ glia is detectable103,105. I 
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can therefore not exclude that the response of the NG2+ cells is only due to 
the myelin defects I observed in APPPS1 mice.  
4.2.3 Heterogeneity of Cells of the Oligodendrocyte Lineage in the White 
and Grey Matter 
 
OPC proliferation is significantly increased in the GM and WM of APPPS1 
mice. However,  GM and WM OPCs differ in their physiological properties519 
and WM OPCs display a higher rate of proliferation (see Fig. 3- 24; 3- 25). 
Previous fatemapping of Olig2+ cells revealed that WM OPCs are able give 
rise to myelinating oligodendrocytes in the adult healthy rodent brain. In con-
trast, few OPCs in the GM differentiate into mature oligodendrocytes and 
most do not progress to myelinating oligodendrocytes105. In another study, 
however, a greater proportion of proliferating GM NG2+ cells matures into 
GSTpi-positve oligodendrocytes, which is in line with my own observations 
(Fig. 3- 24)103. Notably, when the Olig2::CreERTM mouse is used, about 50 % 
of the recombined cells are proliferating, while in the healthy cortical GM only 
about 10 % of the Olig2+ cells proliferate (Fig. 3- 23)105. Therefore, 
Olig2::CreERTM supposedly labels the NG2+ cells with the highest levels of 
Olig2. Consistent with the role of Olig2 in proliferation as discussed above, 
NG2+ glia with the highest levels of Olig2 may proliferate most. These cells 
may then take longer to differentiate into mature oligodendrocytes105.  
Also my data indicate a greater number of NG2+/Olig2+ cells differentiating 
into mature oligodendrocytes in the GM compared to the white matter. In the 
WM an additional recruitment from the SVZ and RMS to the local OPCs may 
also explain the higher number of cells maturating observed in this brain re-
gion compared to the GM (Fig. 3- 24, Fig. 3- 25) 242,520. However, also a pos-
sible migration of OPCs from the GM to the WM cannnot be excluded105. 
When I investigated the Olig2::CreERTM mouse line (Fig. 3- 26), however, I 
could observe no increase in the generation of mature oligodendrocytes in 
the cortical GM. This is likely due to the employment of a different reporter, 
since I observe already shortly after recombination of about 50 % GSTpi-
positive cells in the cortical GM, while with the other reporter (Z/EG) about 80 
% were NG2+105.  
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In conclusion, both GM and WM OPC maturated more extensively into ma-
ture oligodendrocytes upon chronic plaque deposition, indicating some pos-
sibly ongoing myelin repair mechanisms present in this pathology.   
4.2.4 Comparison of APPPS1 Mice to Human Aging and Human     
Alzheimer ’s Disease  
 
Myelin diminutions are frequently observed in AD tissue samples both in cor-
tical GM and WM367,369,387,388,520. In APPPS1 mice, I observed a transient re-
duction in the ratio CNPase/NF70. While myelin is analyzed in post-mortem 
human samples, mice are analyzed at adult stages that do not represent the 
last period of a mouse’s lifespan. However, these different time points may 
be of great importance for the obtained results, when taking into account that 
myelin amount and myelin integrity changes with age. For example in hu-
mans, myelination of the WM increases until mid-life (45 years of age) and 
then decreases, while myelin of the GM is constantly lost throughout life521. 
These damaged and lost sheaths may be constantly turned over103,105,125,480. 
Furthermore, ageing leads to deterioration of WM integrity522-525, while also 
the efficiency of remyelination decreases with age170. Therefore upon AD, in 
addition to myelin reductions also exacerbated myelin breakdown is ob-
served520,526. This suggests that even if myelin could be repaired at early 
stages, increasing age may confuse the issue of AD-associated myelin repair 
and may result in oligodendrocyte loss.  
In support of this idea I observe less OLIG2+ cells in human AD patients in 
comparison to age-matched controls, while in APPPS1 mice (6 months of 
age) the number of Olig2+ cells is increased. However, in mice I cannot ex-
clude that at later time points the number of Olig2+ cells would also decline, 
since the latest time point analyzed was 11 months of age. Indeed, in another 
AD mouse model, the Tg2579 mice (see table 4- 2) the number of Olig2+ 
cells is decreased at the age of 15-20 months527. 
Interestingly, studies in humans suggest that OPCs continue to divide in the 
adult as observed in mice103,124. These cells may serve as a potential source 
for new myelinating oligodendrocytes. However, the proliferation is known to 
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decrease with age and may also account for the decreased number of Olig2+ 
cells observed in this study400.  
Another explanation for the severity of the myelin reductions observed only in 
human pathology, could be the different evolutionary stati of the oligodendro-
cytes in humans and mice. Oligodendrocytes in humans are more complex 
and evolved later in time. Thus, these cells may respond different to patho-
logic insults such as Aβ accumulation. In vitro studies on rat oligodendro-
cytes already suggest a generally high toxicity of Aβ for oligodendro-
cytes528,529. Possibly, human oligodendrocytes or aged oligodendrocytes may 
be more vulnerable to Aβ toxicity than healthy or younger ones. Apart from 
the myelin aberrations focal demyelination is present in plaque core areas in 
the APPPS1 mouse models as well as in human AD389.   
Interestingly, similar to human aging, in the rodent model, I observe progres-
sive deterioration of WM myelin integrity with age in control animals (Fig. 3- 
20). In contrast, APPPS1 mice show an increase in the number of effects 
already at the age between 3 and 6 months (Fig. 3- 20). One explanation for 
this result is that normal aging of myelin may be exacerbated upon amyloid 
plaque deposition, as it has been suggested for AD pathology520,526.  
In conclusion, myelin in mice is a vulnerable target upon chronic amyloid 
plaque deposition both, in terms of myelin aberrations at an early stage of the 
pathology and focal demyelination. APPPS1 mice additionally display possi-
ble endogenous repair mechanisms at early stages of the pathology. In hu-
man AD patients, on the contrary, a loss of oligodendrocytes manifests, indi-
cating an inefficient or no myelin repair. 
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4.3 General Considerations 
4.3.1 Differences between APPPS1 and CK/p25 mice 
 
The proliferation of astrocytes and NG2+ glia as well as the neurosphere 
forming capacity is increased in APPPS1 mice compared to CK/p25 mice. 
Interestingly in APPPS1 mice, at 3 months of age, proliferation is mostly lo-
cated around the plaques. Previous work showed that mostly astrocytes sur-
rounding plaques are immunoreactive for acidic FGF530,531  and basic FGF as 
well as FGF receptor 1 (FGFR-1) in human AD pathology532,533. Acidic and 
basic FGF are considered to represent strong mitogens and their presence 
may initiate proliferation of reactive astrocytes as well as NG2+ glia in 
APPPS1 mice534, while CK/p25 mice that lack the hallmark of plaque deposi-
tion also lack increases in proliferation of these cells.  
In addition to the differences in proliferation, astrocytes seem to initiate dif-
ferent signalling pathways upon different aspects of AD pathology. While in 
APPPS1 mice Olig2 is more promiently up-regulated in astrocytes compared 
to CK/p25 mice116 (see also table 4- 2), pcJun expression in astrocytes 
seems to be a specific hallmark only present in CK/p25 mice. A possible ex-
planation for these differences in astrocyte proliferation as well as astrocyte 
signalling between APPPS1 and CK/p25 mice is that neurons die via apop-
tosis in CK/p25 mice, whereas virtually no cell death is observed in APPPS1 
mice329. However, cells in the vicinity of extracellular plaques in the latter 
mouse model eventually undergo necrosis. Thereby, mitogenic factors could 
possibly be released. For example, upon traumatic or ischemic pathologies, 
massive amounts of purine (ATP, ADP) and pyrimidine (UTP, UDP, UDP-
sugars) nucleotides are released due to e.g. increased excitotoxic neuro-
transmission or liberation from dying cells244. Purines and pyrimidines exert 
their functions by e.g. activating the G-protein-coupled P2Y receptors on as-
trocytes, which results in up-regulation of GFAP and proliferation535,536. This 
mechanism may therefore be specifically involved in astrocyte signalling, and 
possibly glial proliferation in general, in APPPS1 mice, since CK/p25 mice 
show apoptotic cell death331.  
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In addition to astrocyte proliferation another hallmark of severe astrogliosis is 
glial scar formation, which is observed upon stab wound injury as well as 
MCAO187. In plaque-depositing APPPS1 mice, astrocytes densely surround 
the plaques with their processes, thereby also possibly forming a glial-scar-
like barrier between plaque and brain tissue71,347. Also I observed that astro-
cytes close to plaques polarize toward them (Fig. 3- 1). However, glial scar 
formation is absent in CK/p25 mice, even though severe neuronal death 
takes place.  This may be due to the widespread occurrence of the neuronal 
loss. A further indication for this scenario is that astrocytes do not polarize 
and become extremely hyperthroph in CK/p25 mice (Fig. 3- 8). 
Another difference between the AD-related mouse models is the increase in 
the proliferation of NG2+ OPCs specifically in the APPPS1 mice, but not in 
CK/p25 mice. OPCs are known to increase in proliferation upon various in-
sults, however, this proliferative response is often attributed to demyelina-
tion537,538. Furthermore, OPCs have the ability to remyelinate demyelinated 
axons237,242. In support of this idea, focal demyelination is present in plaque 
core areas and myelin integrity is disturbed in APPPS1 mice (Fig. 3- 20; 3- 
18)331,342,389. Therefore, demyelination and aberrant myelin integrity may be 
the trigger for OPC proliferation specifically in APPPS1 mice. However, one 
should consider that also possible differences in the immune response be-
tween APPPS1 and CK/p25 mice may account for these discrepancies, since 
it has been shown that specific inflammatory stimuli can force NG2-glia pro-
liferation517. However, in terms of microglial proliferation APPPS1 and 
CK/p25 mice show great similarities. In addition, in both of the AD-related 
mouse models some invading blood-derived immune cells are observed, 
which may contribute to the immune response (Fig. 3- 16).  
This study provides evidence that astroglia and NG2-glia react distinctly to-
ward different aspects of AD pathology. In general, it seems that extracellular 
plaque deposition triggers their reactivity more prominently than a combina-
tion of neuronal loss, tau pathology and intracellular amyloid accumulation. 
Furthermore, in APPPS1 mice, NG2+ glia may contribute to myelin repair 
and additionally astrocytes resume proliferation and reactive glia exhibit stem 
cell capacity in vitro. In CK/p25 mice, astrocytes fail to divide and also NG2+ 
glia do not react in terms of increases in cell proliferation. This further under-
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lines that astrocytes and NG2-glia exert very different reactivity’s and poten-
tials depending on the specific injury. Therefore, the question arises what 
signalling pathways may be further involved in the reaction and proliferation 
of these two cell types? 
4.3.2 Activation of Signalling Pathways Upon Injury 
 
One interesting approach to identify such signalling pathways considers the 
different signalling pathways normally involved in stem cell signalling, since a 
hallmark of these cells is proliferation. Notably, many of these pathways are 
re-activated in glial cells after injury and therefore represent interesting can-
didates in identifying factors involved in glial cell proliferation and/or neuro-
sphere formation95. Active signalling pathways of astroglia-like stem cells in 
the adult neurogenic zones include sonic hedgehog (Shh) and Wnt signal-
ling95,539-541. In the cortical GM these pathways are present in a small subset 
of astrocytes. After lesion, Wnt signalling increases in astrocytes and its ex-
pression correlates to the newly (by proliferation) born cells542,541,543. Like-
wise, the mitogen sonic hedgehog is produced in reactive astrocytes after 
acute cortical cryoinjury inducing cell proliferation544. A synthesis and possi-
ble release of Shh and/or Wnt may explain the great proliferation of astro-
cytes also upon acute stab wound lesion. Furthermore, Amankulor et al. 
(2009) describes that specific inflammatory processes of macrophages seem 
to trigger Shh release of astrocytes, since ablation of these cells abrogates 
Shh expression 544. As the inflammatory processes may be very different be-
tween acute and AD-related pathologies (as discussed above), these could 
also dramatically affect Shh signalling. Another interesting candidate pathway 
is growth factor signalling, which is also present at high levels in the stem cell 
niches. In the healthy non-lesioned cortical GM the basic fibroblast growth 
factor receptors (FGFRs)95 are expressed at low levels by astrocytes545-547. 
After e.g. WM demyelination or focal brain injury an up-regulation in FGF ex-
pression in astrocytes is observed,  possibly inducing the expression of FGF 
receptors548,549. The expression of another receptor for a different growth fac-
tor, the epidermal growth factor receptors (EGFRs), is absent in astrocytes 
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populating the healthy adult GM550-553. Yet, upon injury, astrocytes up-
regulate the expression of EGFR, which may be important for astrocytes to 
become reactive550,554,555.  
In summary, astrocytes seem to up-regulate many signalling pathways, 
which are also active in adult neural stem cell niches. This may also explain 
the potential of reactive astrocytes to develop stem cell features after acute 
brain lesion95. Furthermore, all the above described signalling pathways may 
represent interesting candidates to test for in regard to their presence or ab-
sence in APPPS1 and CK/p25 mice, since astrocytes show different proper-
ties in these lesion paradigms. 
However, also NG2+ cells increase in proliferation after injury and may also 
harbour the potential to generate neurospheres in APPPS1 mice. Similar to 
GM astrocytes, a small subset NG2+ cells expresses Wnt signalling-related 
molecules, while after lesion Wnt signalling increases and corresponds to cell 
proliferation541. Also FGFRs95 are expressed by both, astrocytes and NG2+ 
cells545-547 and after e.g. WM demyelination NG2+ glia up-regulate them, 
similar to astrocytes548. EGFR expression is absent in NG2+ cells in the 
healthy adult GM550-553 and upon brain lesion it is not yet determined if NG2+ 
cells are able to express this receptor547. Furthermore, one study so far sug-
gests that NG2+ glia seem not to be a source for the mitogen Shh, yet this 
has to be determined in more detail544. Thus, the signalling pathways of 
NG2+ glia after injury still need to be elucidated, but so far interesting candi-
ate signalling pathways after injury such as in FGF and Wnt signalling show 
an overlap to astrocytes. Yet, different signalling molecules may affect astro-
cytes and NG2+ glia differently as they comprise distinct cell populations.  
4.3.3 General Differences between Astrocytes and NG2-Positive Cells 
 
One important difference between astrocytes and NG2+ glia may be that the 
developmental neuroepithelial cells first transform into radial glia, which then 
directly transform into astrocytes. Besides that these neuronal progenitors 
transform into adult neural stem cells as well as ependymal cells35,40,68,547,556-
560. A subset of astrocytes is also generated from either subventricular or cor-
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tical progenitors as well as NG2+ cells during development70,129,561,562. Con-
versely, an early neuroepithelial origin for NG2+ glia is not observed so far. 
There is evidence obtained from fatemapping of ventral radial glial cells indi-
cating some direct transformation of these cells into into NG2+ cells29. In the 
dorsal telencephalon, however, NG2 glia are mostly generated from commit-
ted intermediate progenitors29,40,100,547,563. This indicates that NG2+ glia may 
divert from the astroglial cells, since the latter are directly derived from neural 
stem cells. However, as NG2+ cells also give rise to certain astrocyte sub-
types may indicate some overlap between these two cell population.  
The close relationship of adult parenchymal astrocytes with neural stem cells 
is further underlined by the shared expression of specific markers. Amongst 
them are e.g. the beta subunit of the calcium binding protein S100 (S100b), 
the excitatory amino acid transporter 2 (also known as GLT1) or the gluta-
mine synthetase (GS)74. Furthermore, parenchymal astrocytes retain the ex-
pression of stem cell-related markers such as Sox2, Sox9 and Musashi, 
which are not expressed by NG2+ glia399,547,564-568. Other molecular features 
reminiscent of the stem cell niches are downregulated in parenchymal astro-
cytes (e.g. Tenascin C, nestin, DSD-1) but can be re-expressed after le-
sion48,95,216. 
In addition, the neurogenic potential of adult astroglia-like stem cells is well 
established569,570, while the neurogenic potential of NG2+ glia remains de-
bated. Some studies claim the generation of interneurons in the olfactory 
bulb from NG2+ cells located in the subventricular zone, which are fate 
mapped utilizing the 2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNPase) 
promoter571,572, while fate mapping studies of NG2+ or Olig2+ glia do not re-
veal such neurogenic potential69,70,105,121,129.  
In the adult, a subset of NG2-glia expresses astrocytic proteins121, while 
some astroglia-like stem cells in the adult subependymal zone were shown to 
express the Plateled Derived Growth Factor receptor alpha (PDGFRα)573, 
which is most commonly expressed by NG2+ glia125. Yet another study does 
not confirm the co-expression of PDGFRα in GFAP+ neural stem cells574. 
Apart from the discrepancies concerning the PDGFRα expression, still some 
overlap in the expression of certain markers between these two cell types 
exists. Yet, despite this small overlap in expression of markers, in APPPS1 
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mice fate mapping of Olig2+ cells of the oligodendrocyte lineage shows that 
they do not overt the potential to transdifferentiate into astrocytes, as ob-
served after cortical cryolesion229,230. These cells rather stay within their line-
age upon chronic plaque deposition, which is in line with observations ob-
tained from stab wounded animals105,231 Therefore, the ability of NG2-glia to 
generate astrocytes seems to depend on the specific lesion paradigm or may 
be due to the transgenic mouse lines utilized.  
One striking difference of these two cell populations in the adult healthy corti-
cal GM is that astrocytes are quiescent103,217 and may only resume prolifera-
tion after large invasive injury, while NG2+ glia continuously divide in the 
healthy brain and further increase in proliferation after e.g. acute stab wound 
injury and in APPPS1 mice but not in CK/p25 mice (Fig. 3- 5; 3- 11)103,105. 
This indicates that after lesion these cell types may be more similar, as they 
both respond with an increase in proliferation after injury. Interestingly, after 
acute stab wound lesion only astrocytes have the ability to give rise to multi-
potent neurospheres217. However, the generated neurospheres from 
APPPS1 mice may be derived from both astrocytes or NG2+ glia, which both 
hold a certain potential (see above).  
 
This study provides evidence that astrocytes exert different potentials be-
tween acute invasive and AD-related pathologies. Furthermore, also different 
aspects of AD pathology influence the extent of astroglial cell reactivity. Fur-
ther investigation of signalling cascades involved in the brain’s reaction to-
ward injury may give new ideas how to promote astrocyte proliferation also in 
APPPS1 and CK/p25 mice. In addition to that, another glial cell type, the 
NG2+ glia react only in the APPPS1 mice, while in CK/p25 mice this reaction 
does not take place. Upon AD pathology NG2+ glia seem to exert their func-
tions while remaining in their lineage. However, signalling molecules that in-
duce that response in APPPS1 mice may be important to be investigated 
with the aim to increase myelin repair mechanisms that seem to be ongoing 
upon extracellular plaque deposition. This is of special importance in light of 
the finding that in human AD oligodendrocytes are lost. 
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In summary, all data indicate dramatic differences between the glial cell reac-
tivity toward different pathologies. In addition to that, the different glial cell 
types exert very distinct functions. The glial cell reactivity in such a complex 
pathological disease as AD is determined by different aspects of the pathol-
ogy, which may induce different beneficial as well as detrimental glial cell 
responses.  
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5 Material 
5.1 Equipment 
Table 5- 1. List of Equipment: 
Description 
 
Company 
Geldoc™ XR BIO-RAD 
Heat sealing device Vacuplus Petra electrics 
Incubator Memmert 
Incubator Binder 
Laminar flow Bdk 
Magnetic stirrer IKAMAG® RCT Bachofer 
Magnetic stirrer IKACOMBIMAG RET Jahnke & Kunkel GmbH and  
CoKG IKA-Wok 
Microscope Axiovert 40CFL  
(fluolamp HXP120: Kübler) 
(camera A640: Canon) 
Zeiss 
Microscope LSM700  
(confocal microscope)  
Zeiss 
Microscope Fluo Olympus BX61 
(fluorescence microscope) 
Olympus 
 
Microscope Leica MZ6 
(light microscope) 
Leica 
Microwave  Privileg 
Odyssey Scanner  LI-COR 
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Description 
 
Perfusion pump  
Company 
 
Gilson 
pH meter WTW inoLab 
Refrigerator Privileg 
Refrigerator Liebherr 
 
Semi-Dry Transfer Cell  
Trans-Blot® SD  
 
BIO-RAD 
Shaker IKA-Vibrax-VXR Electronic 
Shaker RM5 (rotary shaker) Assistant 
Shaker Duomax 1030  Heidolph 
Shaker Vortemp56EVC  Uniequip 
Spectral photometer Prim advanced  Secoman 
Stereotactic apparatus  Stoelting 
Thermocycler 3000  Biometra 
Thermomixer comfort  Eppendorf 
Ultrathorax Sonopuls  Bandelin 
Vibratome VT1000S  Leica 
Vortex-Genie  Bender & Hobein AG 
Water bath  Haake 
Water bath (cell culture) Memmert 
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5.2 Consumables 
 
Table 5- 2. List of Consumables: 
Description 
 
Company 
Augen- und Nasensalbe  Bepanthen 
BC assay reagent A  Uptima 
BC assay reagent B Uptima 
Cell culture flask with filter lid  
Cellstar® (T25,T75, T175), PS red 
Greiner bio-one 
CELLSTAR 
Cell strainer  BD Falcon (70 μm) 
Coverslips Roth 
Drill  Foredom 
Filaments (Vicryl) Ethicon 
Filter/strainer 70 μm  BD Transduction Laboratory 
Filter tips Biosphere 
Gloves  Diana Baronin von Schaezler 
Gloves  NeoTouch 
Gloves Nitra-Tex® (nitrile)  Ansell 
Insulin needles, U-100, 1 ml  BD Micro Fine (PZN: 324870) 
Microscope slides Roth 
Microscope slides Superfrost Thermo Scientific 
Pasteur pipettes (glass)  VWR 
Parafilm PM-996  Parafilm 
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Description 
 
Reaction tubes for PCR 
Company 
 
Eppendorf 
Reaction tubes 
(0.5 ml; 1.5 ml; 2 ml) 
Plastibrand 
Reaction tubes safelock 
(1.5 ml; 2 ml) 
Eppendorf 
Reaction tube (15 ml; 20 ml) Greiner 
Serological pipettes 
(5 ml; 10 ml; 15 ml) 
Sarstedt 
Syringe (10 ml; 30 ml) Braun 
V-LanceTM Knife, 19 Gauge  Alco © Surgical  
Well-plate (24) Orange Scientific 
5.3 Chemicals 
 
Table 5- 3. List of Chemicals: 
Chemical Company 
 
Aceton Roth 
Acetic acid  Roth 
Acetic acid anhydride Sigma 
Acrylamid 30 % BioRad 
Agarose  Serva 
Ammonium nitrate Sigma 
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Chemical 
 
Ammonium Persulfate (APS) 
Aprotinin 
Company 
 
BioRad 
BioMol 
Araldit Kit Fluka 
BCA Assay Uptima Interchim 
Bromphenol blue Sigma 
5-Bromo-2′-Deoxy-Uridine (BrdU) 
Cacodylic acid 
Sigma 
Sigma 
Calcium chloride dihydrate 
Citric acid monohydrate 
Sigma 
Roth 
Corn oil Sigma 
4′,6-diamidino-2-phenylindole,  
dilactate (DAPI) 
Invitrogen 
dNTPs PeqLab 
Dimethylarsinic acid sodium salt tri-
hydrate 
Edetate disodium 
Merck 
 
Sigma 
Ethanol Roth 
Ethanol 70 % Roth 
Ethidiumbromid Roth 
Ethylene glycol Sigma 
Ethylenediamine-tetraacetic acid 
(EDTA) 
Sigma 
Formaldehyde (Formol) Roth 
Formamide Roth 
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Chemical  
 
Glutaraldehyde 25 %  
Company 
 
Serva 
Glycerol Sigma 
Glycine Sigma 
Goat Serum 
Leupeptin 
Gibco 
BioMol 
Ketaminhydrochlorid (Ketavet) 100 
mg/ml 
Pfizer 
 
Magnesium sulphate heptahydrate Sigma 
Magnesium sulphate hexahydrate 
Methanol 20 % 
Merck 
Merck 
2-Mercaptoethanol Sigma 
Mounting solution (AquaPolymount) Polysciences 
Mounting solution (DPX) Fluka 
0,9% NaCl solution (Saline) Braun 
Osmium tetroxide solution 4 % Sigma 
Paraformaldehyd Sigma 
PCR Reaction buffer 10 x NEB 
PCR Reaction buffer 10 x 
Pefabloc 
Pepstatin 
Quiagen 
BioMol 
BioMol 
2-Propanol (Isopropanol) Roth 
Proteinkinase K Roth 
Potassium chloride Sigma 
Potassium dihydrogen phosphate Merck 
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Chemical 
 
Potassium phosphate 
Company 
 
Sigma 
Potassium hydroxide Sigma 
Potassium permanganate Fluka 
Potassium phosphate Sigma 
Pyridine Sigma 
Q- solution Qiagen 
Sucrose Merck 
Silicotungstic acid  Sigma 
Silver nitrate 
Sodium acetate trihydrate 
Sigma 
Roth 
Sodium bicarbonate Sigma 
Sodium carbonate Fluka 
Sodium chloride Sigma 
Sodium citrate dehydrate Sigma 
Sodium dodecyl sulphate (SDS) Sigma 
di-Sodium hydrogen phosphate di-
hydrate 
Merck 
Sodium hydroxide Fluka 
Sodium hydroxide pellets Sigma 
Sodium nitrite Fluka 
Sodium phosphate Sigma 
Sodium thiosulfate Sigma 
5-Sulfosalicylic acid dihydrate Roth 
Tamoxifen Sigma 
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Chemical 
 
Taq Polymerase 
Company 
 
NEB/ self-made 
TEMED BioRad 
Triethanolamine Hydrochloride Sigma 
Triton X-100 Sigma 
TRISbase 
TRISHCL 
Sigma 
Sigma 
Tween20 Sigma 
Xylazinhydrochlorid (Rompun) 2% Bayer 
Xylene cyanole 
 
Sigma 
 
5.4 Buffers and Solutions 
5.4.1 Mouse DNA Preparation 
Tris- HCl 10mM for DNA (1l) 
1.211 g TRISbase 
  ad 1l H2Odd, pH 8.5 
 
Lysis Buffer for Tail Biopsies 
         1 M NaCl 
         1 M TRISHCl pH 8.5 
      10 % SDS 
      0.5 M EDTA 
10 mg/ml Proteinase K  
(freshly added) 
 ad H2Odd 
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10 x PCR Buffer (uni) 
500 mM Potassium chloride 
100 mM TRISHCl 
 pH 8.7 
 
 
dNTP Mix 
 
2.5 mM each dATP, dTTP, 
dGTP, dCTP 
 in H2Odd 
 
50 x TAE 
    242 g   TRISbase 
   32.2 g Edetate disodium 
57.1 mg Acetic acid (100 %) 
 ad 1l H2Odd ,  
pH 8.0 
 
Ethidiumbromid 
100 mg Ethidiumbromid 
    2 ml H2Odd 
 
4 x DNA Loading Buffer 
 20 ml   100 % Glycerin 
   1 ml   50 x TAE 
200 μl Bromphenol blue 
500 μl Xylene cyanol solu-
tion 
 ad 50 ml H2Odd 
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5.4.2 Electron Microscopy 
 
Cacodylat Solution 
 
 0.2 M Cacodylate 
21.4 g Dimethylarsinic acid 
sodium salt trihydrate
0.22 g Calcium chloride de-
hydrate 
 ad 500 ml H2Odd, 
pH 7.2 
 
Karnovski Fixative for Perfusion 
2.5 % Glutaraldehyde 
   2 % PFA 
0.1 % Cacodylate solution 
 in H2Odd 
 
Storing Solution for Electron Microscopic Tissue Samples 
  4 % PFA 
2.5 % Sucrose 
 in H2Odd 
 
Washing Solution 
0.1 % Cacodylate 
   2 % Sucrose 
 in H2Odd 
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Osmication Solution 
       2 % Osmium tetroxide 
solution 
0.002 % Calcium chloride 
         2% Sucrose 
 in 0.2 %  
Cacodylate buffer 
 
5.4.3 Western Blot 
 
Lysis buffer for Tissue Samples 
50 mM  
  
TrisHCl,  
pH 7.4 
     1 %   TritonX 100 
   10 % Glycerin 
   5 mM   EDTA  
                    
Protease Inhibitors:  
 4.2 µM Leupeptin 
100 nM   Aprotinin 
 5.8 µM Pepstatin 
1.7 mM Pefabloc 
 
20% Tween 
  50 ml  Tween 20 
200 ml H2Odd 
 
TBS Buffer (10 x)  
12.1 g  TRISbase 
87.8 g Sodium chloride 
 ad 1l H2Odd 
 pH 8.0; autoclave 
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TBST Buffer (1 x) 
100 ml TBS 10x 
  10 ml Tween20 
 ad 1l H2Odd 
 
Electrophoresis Buffer (Elpho buffer) 
30.3 g TRISbase 
 144 g Glycine 
   10 g SDS 
 ad 1l H2Odd  
pH 8.45  
 
APS (10%) 
100 mg Ammonium  
Persulfate 
 in 1 ml H2Odd 
 
 
Stacking Gel Solution (4 % Acryalamid) 
 
1.86 ml 0.5M TrisHCl pH 6.8 
37.5 20% SDS 
0.98 ml Acrylamide 
37.5 μl 10% APS 
  7.5 μl TEMED 
4.58 ml H2Odd 
 
Running Gel Solution (12 % Acryalamid) 
 
  7,5 ml 1,5M TrisHCl pH 8.8 
0,15 ml  20% SDS 
12,0 ml Acrylamide 
0,15 ml  10% APS 
0,02 ml  TEMED 
10.2 ml H2Odd 
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Transfer Buffer  
3.03 g TRISbase 
 0.1 % SDS 
14.4 g Glycine 
  20 % Methanol 
 ad 1 l H2Odd 
 
4x Loading Dye 
   2 ml 1M TrisHCl pH 8.5 
   8 ml 20 % SDS 
   5 ml Glycerin 
1.6 ml β-Mercaptoethanol 
50 mg  Bromphenol blue 
3.4 ml H2Odd 
 
5.5 Tissue Preparation for Immunohistochemistry 
Anesthesia Solution 
2.5 ml Saline 
   1 ml  Ketamin 
0.25 ml  Rivapoun 
Prepare freshly. 
 
Tamoxifen 
40 mg/ml Tamoxifen 
       10 %   Ethanol 
 in corn oil 
For preparation of the solution shake 3-4 h at 37 °C 
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BrdU – Drinking Water 
1 mg/ml BrdU 
     10 %   Saccharose 
 in H2O 
 
20 % Paraformaldehyd (PFA) Stock 
       67 g di-Sodium hydrogen 
phosphate dihydrate 
in 800 ml H2Odd 
     200 g PFA 
ca. 10 ml Sodium hydroxide 
 pass through paper 
filters 
 ad 2 l H2Odd, 
 pH 7.4  
 
4 % Paraformaldehyd 
100ml PFA 20 % 
 ad 500 ml H2Odd 
 
10 x Phosphate Buffer 0.25M (400 ml) 
  5 N Hydrochloric acid  
(approximately 2 ml) 
15 g NaOH 
65 g Sodium phosphate 
 pH 7.2-7.4 
 
30 % Saccharose Solution for Cryoprotection 
15 g Sucrose 
 ad 50 ml 1 x PBS 
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Storing Solution for Free Floating Brain Tissue Sections 
     4 M Glycerol 
  5.4 M  Ethylenglycol 
25 mM Phosphate buffer  
pH 7.2-7.4 
 
5.6 Immuno-histochemistry/cytochemistry 
 
10 x Phosphate Buffered Saline (PBS)  
    1.5 M Sodium chloride 
  0.03 M  Potassium chloride 
0.080 M di-Sodium hydrogen 
phosphate dihydrate 
0.010 M Potassium dihydro-
gen phosphate  
pH 7,5 
 in 1l H2Odd, pH 7.4 
 
4 % Agarose Solution for Embedding of Vibratome Sections 
4 %   Agarose 
 in 1 x PBS 
 
Blocking Solution for Brain Tissue Sections 
0.5 %   TritonX100 
 10 % goat or donkey se-
rum 
 in 1 x PBS  
 
Blocking Solution (cells) 
0.1 %   TritonX100 
 10 % goat or donkey se-
rum 
 in 1 x PBS  
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Citric Acid Solution 
2.1 g Citric acid  
monohydrate 
 ad 1 l ddH2O; pH 6 
 
 
4′,6-Diamidino-2-phenylindol (DAPI) Stock 
10.9 mM DAPI, dilactate 
 in H2Odd 
 
Sodium Citrate Buffer 0,1 M 
29.41 g sodium citrate 
 ad 1l H2Odd, pH 6.0  
 
Storing solution for Free Floating Brain Tissue Sections 
     4 M Glycerol 
  5.4 M  Ethylenglycol 
25 mM phosphate buffer 
 pH 7.2-7.4 
 
 
5.7 Immunohistochemistry of Human Brain Tissue 
 
Citric Acid Solution 
 
10.5 Citric acid  
monohydrate 
15.36    Sodium dihydrogen-
phosphate 
 ad 500 ml ddH2O;  
pH 4.5 
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50 % Methanol Solution (10 ml) 
 
5 ml Methanol 
333 µl    H2O2 
4.66 ddH2O 
 
 
0.4 M PO4 buffer 
 
46 g Sodium dihydrogen-
phosphate 
9.07 g Sodium phosphat 
 ad 1 l ddH2O  
 
 
DAB solution (25 ml) 
 
12.5 mg DAB 
18.75 ml    H2O2 
0.4 M  
PO4 buffer 
250 µl   
6.25 ml 
 
H2O2 (1 %) 
 
 
Glycerin yelly for coating of glass slides 
3 g Gelatin 
60 ml    dH2O 
 
 
 
70 ml 
0.25 g 
dissolve in beaker 
placed in waterbath 
 
glycerin 
phenol crystals 
 
Nickel/DAB Staining 
0.4 ml 
 
Nickel-ammonium 
sulphate (1 %) 
10 ml 
200 µl 
DAB solution 
H2O2 
incubate for about 
10 min 
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5.8 Gallyas Impregnation for Myelin 
 
Incubation Solution 
1 g Ammonium nitrate 
1 g Silver nitrate 
 solve in 1 l H2Odd 
3 ml Sodium hydroxide 
(pH 7.4- 7.6) 
 
Physical Development Solution A 
50 g Sodium carbonate 
 in 1 l H2Odd 
 
Physical Development Solution B 
2 g Ammonium nitrate 
2 g Silver nitrate 
10 g Silicotungstic acid  
 in 1 l H2Odd 
 
Physical Development Solution C 
2 g Ammonium nitrate 
2 g Silver nitrate 
10 g Silicotungstic acid 
7 ml Formol (37 %) 
 in 1 l H2Odd 
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5.9 Cell Culture 
5.9.1 Cell Culture Media and Components 
Table 5- 4. List of Consumables and Media for Cell Culture: 
Description 
 
Company 
B27 Gibco 
basic fibroblast growth factor (FGF) Gibco 
Bovine serum albumin (BSA) Sigma 
DMEM/ F12 + GlutaMAX™ Gibco 
DMEM/ F12 Gibco 
D-Glucose (45%) Sigma 
Earle`s Balanced Salt Solution (EBSS) Life Technologies 
Hank’s Balanced Salt  Solution (HBSS) Gibco 
Hepes 1M Gibco 
Human epidermal growth factor (EGF) Gibco 
Hyaluronidase Sigma 
L-Glutamine 200mM Gibco 
Neurobasal A Gibco 
Penicillin/Streptomycin 100x Gibco 
poly-L-Lysine (PDL) Sigma 
Sucrose Sigma 
TripleLExpress Gibco 
Trypsin/ EDTA 0.05% Gibco 
Trypsin  Sigma 
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5.9.2 Solutions and Media 
 
Solution 1 (HBSS-Glucose) 
 50 ml HBSS 
   9 ml D- Glucose 
7.5 ml Hepes (1 M) 
 ad 0,5 l H2Odd ,  
pH 7.5 
 
Dissociation Medium 
    10 ml Solution 1 
13,3 mg Trypsin (Sigma) 
     7 mg Hyaluronidase 
 
Solution 2 (Sucrose-HBSS) 
  25 ml HBSS 
 154 g Sucrose 
475 ml H2Odd, 
 pH 7.5 
 
Solution 3 (BSA-EBSS-Hepes) 
    20 g BSA 
  10 ml Hepes 
490 ml  EBSS 
 pH 7.5 
 
Neurosphere Differentiation Medium 
   1 ml B27 
500 μl Glutamate 
500 μl Hepes 
 48 ml  Neurobasal A 
500 μl Penicillin/Streptomycin
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Neurosphere Medium 
              1 ml B27 
            48 ml  DMEM/ F12 
           500 μl Glutamate 
            8 mM Hepes 
100 units/ ml Penicillin/ 
Streptomycin 
     10 μg/ ml EGF 
     10 μg/ ml FGF 
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6 Methods 
6.1 Animals 
6.1.1 Mouse Strains 
All animal procedures were performed in accordance with the policies of the 
use of Animals and Humans in Neuroscience Research, revised and ap-
proved by the Society of Neuroscience and the state of Bavaria under licence 
number 55.2-1-54-2531-144-07 and 55.2.-1-54-2531-152-10. 
The following mouse lines were used for experiments: 
APPPS1, overexpresses the Swedish double mutation as well as a PS1 mu-
tation under the neuronal promotor Thy1316 
CAG-CAT-EGFP (refered to as CAGGFP) reporter mouse line, expressing 
the CMV-β-actin promoter and the loxP flanked chloramphenicol acetyl-
transferase (CAT) gene upstream of the EGFP cassette377  
CK/p25 mouse line, inducible overexpression (tetOFF) of the p25-GFP fusion 
protein under the control of the neuronal CAMKII promotor323,364 
GLAST::CreERT2, expressing a Cre recombinase estrogen receptor fusion 
protein in the GLAST locus378 
Olig2::CreERTM expresses a Cre recombinase estrogen receptor fusion pro-
tein in the Olig2 locus115 
6.1.2 Genotyping 
To maintain colonies of experimental mice, animals were tagged with num-
bered ear clips (0001-9999). Small tail biopsies of less than 0.5 mm length 
were taken to isolate the DNA. The tail pieces were transferred into a 1.5 ml 
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eppendorf tube and incubated in 500 μl lysis buffer, shaking at 55°C over 
night. After lysis, centrifugation at 10000 rpm for 5 minutes (min) resulted in 
sedimentation of tissue residues. The supernatant was transferred into a new 
1.5 ml tube. Precipitation of DNA was achieved by addition of 0.5 ml isopro-
panol for 5 min and pelleted by centrifugation of 10 min for 10000 rpm. The 
supernatant was removed and the pellet was dried by turning the tube upside 
down for 1 hour (hr) at room temperature. Dissolving of the dried DNA was 
accomplished by addition of 200 μl 10 mM Tris buffer followed by 1-2 hrs 
shaking at 55 °C. The extracted DNA was kept at 4 °C until further process-
ing. For PCRs 1-2 μl of DNA were mixed with 10 mM dNTPs in 30 μl reaction 
tubes. The final concentration of the primers was 10 pM in the reaction mix. 
The precise PCR conditions and reaction mixes are described in detail for 
each mouse line below. After the PCR, the reactions were mixed with load-
ingbuffer and loaded on a 2 % agarose gel (with 1 x TBS buffer), to detect 
the PCR products. 
6.1.2.1 APPPS1 
 
APP-PCR 
Primer sequences: 
APP (forward): GAA TTC CGA CAT GAC TCA GG 
APP (reverse): GTT CTG CTG CAT CTT GGA CA 
Reaction mix 
  2.5 μl 10 x buffer (Quiagen) 
  0.6 μl dNTPs 
  0.5 μl each Primer 
  0.3 μl Taq Polymerase 
19.1 μl H2O 
     1 μl DNA 
6 Methods 151
 
Cycling conditions (PCR program): 
         95°C    4 min 
34 x  95°C  45 sec 
         58°C  45 sec 
         72°C  45 sec 
         72°C    5 min 
 
Band size: about 270 basepairs 
 
PS1-PCR 
Primer sequences: 
PS1 (forward) : CAG GTG CTA TAA GGT CAT CC 
PS1 (reverse): ATC ACA GCC AAG ATG AGC CA 
 
  2.5 μl 10x buffer (Quiagen) 
  0.6 μl dNTPs 
  0.5 μl each Primer 
     1 μl Taq Polymerase 
18.4 μl H2O 
  1.5 μl DNA 
Cycling conditions (PCR program): 
         94°C    5 min 
35 x  94°C  45 sec 
         58°C  45 sec 
         72°C  45 sec 
         72°C  10 min 
 
Band size: about 270 basepairs 
 
Due to cointegration of the APP and PS1 transgenes316, for routine analysis 
genotyping for APP was performed. PS1 genotyping was conducted sporadi-
cally as an additional control. 
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6.1.2.2 CAGGFP (CAG-CAT-EGFP) 
 
Primer sequences: 
CAG-CAT-EGFP (forward) 5’-CTG CTA ACC ATG TTC ATG CC-3’ 
CAG-CAT-EGFP (reverse) 5’-GGT ACA TTG AGC AAC TGA CTG-3’ 
 
Reaction mix 
  2.5 μl 10x buffer (uni) 
  3.0 μl Magnesium chloride 
(25mM) 
  0.5 μl dNTPs 
     5 μl  Q-Solution (Qiagen) 
     1 μl each Primer 
  0.5 μl Taq Polymerase 
10.5 μl H2O 
     1 μl DNA 
 
 
Cycling conditions (PCR program): 
         94°C    5 min 
29 x  94°C  30 sec 
         55°C  30 sec 
         72°C    1 min 
         72°C  10 min 
 
Band size: 350 basepairs  
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6.1.2.3 CK/p25 
 
CK-PCR 
Primer sequences: 
 
tTA-JC6:  5’-GCT GCT TAA TGA GGT CGG-3’ 
tTa-HC6: 5’-CTC TGC ACC TTG GTG ATC-3’ 
Reaction mix:  
2.5 μl PCR buffer (NEB)  
0.5 μl dNTPs 
1.8 μl each Primer 
0.4 μl Taq Polymerase 
(NEB) 
16 μl H2O 
  2 μl DNA 
 
Cycling conditions (PCR program): 
         94°C   5 min 
34 x  94°C 45 sec 
         55°C 45 sec 
         72°C   1 min 
         72°C   1 min 
 
Band size: 480 basepairs 
 
 
ZEG-PCR for p25-GFP 
Primer sequences:  
ZEG (forward): 5’-TTC ACC TTG ATG CCG TTCT-3’ 
ZEG (reverse): 5’-GCC GCT ACC  CCG ACC AC-3’ 
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Reaction mix:  
2.5 μl 
 
0.5 μl 
 
PCR buffer (uni)  
 
Magnesium chloride 
(25mM) 
 
0.5 μl dNTPs 
   1 μl each Primer 
0.5 μl Taq Polymerase  
   4 μl Q- solution 
 14 μl H2O 
   1 μl DNA 
 
Cycling conditions (PCR program): 
         94°C   5 min 
34 x  94°C 45 sec 
         55°C 45 sec 
         72°C   1 min 
         72°C   1 min 
 
 
Band size: 400 basepairs 
 
 
 
 
6.1.2.4 GLAST::CreERT2 
 
The protocol for genotyping was adopted from Mori et al. 378 
Primer sequences: 
Glast F8 (forward): 5’-GAG GCA CTT GGC TAG GCT CTG AGG A-3’ 
Glast R3 (reverse): 5’-GAG GAG ATC CTG ACC GAT CAG TTG G-3’ 
CER 1 (CreERT2 specific primer):  
                               5’-GGT GTA CGG TCA GTA AAT TGG ACA T-3’ 
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Reaction mix:  
 2.5 μl 10x buffer 
 2.5 μl Magnesium chloride 
(25mM) 
 0.5 μl dNTPs 
    5 μl  Q-Solution (Qiagen) 
    1 μl each Primer 
 0.5 μl Taq Polymerase 
    9 μl H2O 
    2 μl DNA 
 
Cycling conditions (PCR program): 
         94°C 2 min 
35 x  94°C 20 sec 
         55°C 20 sec 
         72°C 30 sec 
         72°C 5 min 
 
Band size: wildtype 700 basepairs, Glast::CreERT2 recombinant: 400 base-
pairs 
6.1.2.5 Olig2::CreERTM 
 
The protocol for genotyping was adopted from115. 
 
Primer sequences: 
Olig2 sense (forward)         5’-TCG AGA GCT TAG ATC ATC C-3’ 
Olig2 antisense (reverse)   5’-CAC CGC  CGC CCA GTT TGT CC-3’ 
Olig2KICreER                      5’-AGC ATT GCT GTC ACT TGG T-3’ 
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Reaction mix 
  2.0 μl Magnesium chloride 
(25mM) 
  2.5 μl 10 x buffer (uni) 
  0.6 μl dNTPs 
     1 μl each Primer 
     4 μl Q-solution 
  0.5 μl Taq Polymerase 
11.4 μl H2O 
     1 μl DNA 
 
Cycling conditions (PCR program): 
         94°C    9 sec 
36 x  94°C  20 sec 
         58°C  30 sec 
         72°C  30 sec  
         72°C  10 min 
 
Band size: wildtype 247 basepairs, Olig2KICreER recombinant 367 base-
pairs 
6.1.3 Tamoxifen Administration 
 
Tamoxifen was applied to mice which were older than 2 months of age either 
orally (p.o.; 3 times 250 μl) every second day or by intraperitonal injection 
daily 2 times for 5 consecutive days (100 μl; 1 mg per injection). 
6.1.4 Doxycycline Administration 
 
Doxycycline (0.05 %) was applied to CK/p25 mice via the drinking water con-
taining 1.5 % succrose until 6 weeks of age. Mice received doxycyline prena-
tally through application of doxycycline water already to matings or later via 
the milk of the mother. Doxycycline is light sensitive, therefore, it was applied 
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in bottles impervious to light and was additionally exchanged 3 times a week. 
Doxycycline drinking water was finally exchanged with normal drinking water 
after 2 or 5 weeks, to achieve overexpression of p25-GFP. 
6.1.5 BrdU Labelling 
The DNA-base-analogue 5-Bromo-2′-deoxy-Uridine (BrdU) was applied to 
the animals for 1 or 2 weeks to the drinking water at a concentration of 1 
mg/ml. 1 % sucrose was added and stirred for at least 1 hr at room tempera-
ture. Every 3rd day BrdU drinking water was exchanged and the bottles con-
taining BrdU water were protected from light. The BrdU solution was stored in 
the fridge for maximal 1 week. 
6.1.6 Anesthesia 
To anesthetize the mice for perfusion an anesthesia solution was prepared. 1 
ml ketamin (10 %) were mixed with 0.25 ml xylazine hydrochloride (2 %) and 
2.5 ml saline (0.9 %). The injection of the anesthesia was performed intrap-
eritoneally with an insulin syringe and the volume of the injection depended 
on the animal’s weight, since 5 µl per 1 g were injected. Afterwards, the ani-
mals reflexes (e.g. eye blink reflex and the reflex after pinching the hindpaw) 
were checked until they disappeared. In case of an unsufficient anesthesia 
an additional amount of about 20 µl anesthesia solution was injected intrap-
eritonally.  
For stab wound injuries another anesthesia solution was prepared for intra-
peritoneal injection. 300µl of a mixture of 0.5 mg/kg Medetomidin with 5 
mg/kg Midazolam and 0.05 mg/kg Fentanyl were injected. To wake animals 
up after the operation 250 μl of an antisedate were applied intraperitoneally 
(2.5 mg/kg antisedan with 0.5 mg/kg flumacenil and 1.2 mg/kg naloxone).     
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6.1.7 MCAO – A Mouse Model of Stroke 
These mice were used and analyzed in collaboration with Dr. Christophe 
Heinrich and Steffen Tiedt from my lab and Prof. Dr. med. Martin Dichgans. 
The MCAO lesion was performed in the lab of Martin Dichgans.  
The protocol was performed as described in Vosko et al. (2006). In short, 
mice were anesthetized by isoflurane inhalation. Initial anesthesia contained 
5 % isoflurane (< 1 min) and 2 % isoflurane in a mixture of 70%/30% of 
N2O/O2 were used to maintain it. The body temperature was keept between 
37 °C and 38 °C with a DC temperature regulation system (FHA, Bowdoin, 
USA). After successful anesthesia, a fiberoptic probe (Perimed, Järfäla, 
Sweden) was placed over the MCA territory + 2 mm posterior and + 6 mm 
lateral to bregma, while the regional cerebral blood flow (rCBF) was con-
trolled with a laser Doppler flowmetry (Perimed, Järfäla, Sweden). Focal 
cerebral ischemia was induced by occlusion of the middle carotid artery 
(MCA). After ventral midline neck incision, the left common and external ca-
rotid arteries were ligated utilizing an intraluminal filament. The internal ca-
rotid artery (ICA) was temporarily clipped with a microvascular clip (Aesculap, 
Germany). A silicon-coated 8-0 nylon monofilament (Ethicon, Johnson & 
Johnson, Belgium) was gently advanced into the ICA until resistance was 
felt. Successful occlusion of the MCA reduced the rCBF baseline by > 70 %. 
After ischemic induction, laser Doppler probes were removed, and the mice 
returned to their cages, where they woke up. During the 1 to 2 hrs of ische-
mia, mice were placed in a cage in the incubator (Babytherm 4200, Dräger-
werk AG Lübeck, Germany) to keep the body temperature stable. After 1-
2 hrs the animals were anesthetized again and the filament was removed. 
Animal care and all experimental procedures were performed in accordance 
to the German and National Institutes of Health animal legislation guidelines 
and were approved by the local animal care and use committees379. 
6.1.8 Stab Wound Mouse Model 
 
Another mouse model utilized in this study as an acute lesion paradigm is the 
stab wound. To perform a stab wound lesion, the animals were first anesthe-
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tized with the opoid anaesthesia. After all reflexes disappeared the mice were 
placed in a sterotactic apparatus. The skin above the scull was cut with a 
razor blade and then turned in a way that the skull above the brain becomes 
accessable. A unilateral small hole located behind bregma but before lambda 
was then drilled with a dental drill through the skull, while leaving the men-
inges intact. Afterwards, the somatosensory cortical grey matter was 
scratched with a V-LanceTM knife. The scratch was 0.5 to 0.6 mm deep and 1 
to 2 mm long and did not touch the white matter. After stab wound, the ani-
mals were removed from the stereotactic apparatus and the skin incision was 
stiched. Stab wound lesion results in a rapid onset of glial reaction, rupture of 
the blood brain barrier and cell death in the lesion area. These mice are used 
in collaboration with Dr. Swetlana Sirko in my lab. 
6.2 Electron Microscopy  
The animals were deeply anesthetized with ketamin/xylazine and perfused 
with the Karnovski-fixative (see solutions electron microscopy). The perfusion 
was performed with high pressure and 200 ml fixative were used per animal. 
Afterwards, the brains were dissected and post-fixed over night at 4 °C in the 
same fixative. Then, the brains were transferred  into the storing solution and 
kept at 4 °C until further processing. Prior to cutting, brains were washed in 
washing solution over night at 4 °C. Coronal vibratome sections were then 
cut at the vibratome at a thickness of 500-600 μm. Small pices of the area of 
interest (grey matter and white matter including the corpus callosum) were 
carefully dissected using a razor blade. The following osmication was per-
formed in the dark by adding the osmication solution for 2 hrs to the speci-
men in a small glass ware. Importantly, the incubation was conducted on a 
metal plate, which has been cooled down to -20°C before the experiment 
was started. Glutaraldehyd, which was used for the perfusion is a fixative to 
preserve structures, however it does not stabilize lipids, the major component 
of myelin, sufficiently. Therefore, osmium was needed for lipid stabilization. 
Osmium reacts as oxidant mainly with unsatured lipids thereby labelling lipid 
rich structures, such as myelin, since it renders the tissue black in its reduced 
state575. After osmication, sections were transferred to a 24-well-plate and 
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were washed in 0.1 M cacodylat for 20 min. A graded series of ethanol for 
hydration of the tissue samples followed. Every 20 minutes the sections were 
transferred into the next ethanol solution (70 %, 80 %, 90 %, 96 %, 100 %, 
and 100 %). Finally, sections were transferred again into glass vials to wash 
them in propylenoxide for 30 min. Incubation in a 1:1 mixture of araldid in 
propylenoxide was carried out over night at 4 °C thereafter. In the last step 
the sections were embedded in araldit epoxy using an araldit epoxy embed-
ding kit (Fluka) according to the manufacturer’s protocol. Polymerization of 
the araldid epoxy was achieved at 60 °C for 2 days. The araldit blocks were 
sent to the LMU Anatomy Institute for contrasting and cutting semi-and ultra-
thin sections. Semithin cross-sections of 0.5 µm in thickness were cut for 
light microscopy inspection, whereas ultrathin sections of 65-85 nm were cut 
for electron microscopy analysis. Grids were then analyzed at a transmission 
electron microscope belonging to the LMU Anatomy Institute.  
6.2.1 Quantification of Myelin Integrity  
Pictures were taken randomly in the white matter at 11440 x for quantification 
at the electron microscope. Analysis of the pictures took place by two inde-
pendent persons, namely Dr. Leda Dimou and myself. Myelin aberrations 
were classified according to Peters et al. (2000) and Thurnherr et al. (2006): 
a) An axon surrounded by two myelin sheaths, separated by a space  
b) Excess cytoplasm in the inner loop   
c) Degenerated sheaths  
d) Balooned myelin 
e) Abnormal myelin outfoldings– these are areas of the  
     internode where the myelin sheath protruded away from the axon surface 
or  
f) Other myelin aberrations 
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6.3 Western Blot 
6.3.1 Tissue Lysis  
 
Brain tissue containing cortical grey and white matter as well as the hippo-
campus was dissected in HBSS medium. Then the tissue pieces of interest 
were collected in a 1.5 ml eppendorf tube, immediately frozen in liquid nitro-
gen and stored at -80 °C until further processing. After defrosting at 4 °C, 500 
μl of lyses buffer (solutions western blot) were added and then the mixture of 
tissue and buffer was transfered into a dounce tissue grinder. By moving the 
tight pestle up and down 10-15 times, the tissue was homogenisated. Then, 
the homogenat was transferred into a 1.5 ml eppendorf tube and pulse soni-
ficated for 5 seconds at 10 % intensity. Afterwards, an incubation at 4 °C (on 
ice) for 15 minutes followed. Then the lysate was centrifuged at 4 °C and 
10000 g for 15 min. The supernatant was collected and stored at -80 °C until 
further processing.  
 
6.3.2 Gel Preparation 
 
After mixing the ingredients needed for the adequate percentage of the run-
ning gel (see solutions western blot) the solution was quickly poured into the 
gel casting form, while space for the stacking gel was left. The top of the run-
ning gel layer was loaded with water saturated isopropanol to remove bub-
bles. After the gel fully polymerized, isopropanol was washed out with aqua 
dest. and the freshly prepared stacking gel solution was added on top. Then 
a comb was placed in the stacking gel. After its polymerization the complete 
gel was transferred into the electrophoresis chamber, which was filled with 1 
x Elpho buffer, and the comb was removed.  
 
 
6 Methods 162
 
6.3.3 Sample Preparation  
 
The amount of protein was measured using the BCA assay, a colorimetric 
assay, according to manufacturer’s protocol. It is based on the so called Bi-
uret reaction, where, under alkaline conditions, substances containing two or 
more peptide bonds form a purple complex with copper salts in the reagent. 
More specifically, it involves the reduction of Cu2+ (copper) to Cu+ by peptide 
bonds of proteins. The BC Assay (bicinchoninic acid) chelates Cu+ ions with 
very high specificity to form a water soluble purple coloured complex. 
The reagent B from the BC Assay kit was diluted 1:50 in reagent A, which 
results in a green solution. 10 µl lysate were mixed to 1 ml of the solution for 
30 min at 37°C. As the protein standard, samples with different bovine serum 
albumin (BSA) amounts were also mixed with the solution. Afterwards, the 
absorption of the BSA standards, measured with a spectrometer, generated 
a standard curve, which was used to measure the concentration of the pro-
tein lysate samples. According to the protein amount, the probes were ad-
justed to an amount of 30 μg with aqua dest. After addition of the 4 x loading 
buffer, samples were boiled for 5 minutes at 95 °C, without shaking. Then the 
samples were transferred to 4 °C on ice for another 5 minutes before they 
were loaded in the gel. Then a voltage of 80 V was applied, until the samples 
traveled through the stacking gel. When the samples entered the running gel, 
the voltage was increased up to 120 V. In order for the proteins to migrate 
through the gel they are first negatively charged by exposure to the detergent 
sodium dodecyl sulfate (SDS). The amount of bound SDS is relative to the 
size of the protein, and the proteins have a similar charge to mass ratio. 
Therefore, they migrate according to their size and can be separated within 
the gel. Smaller proteins migrate faster than bigger ones. As the concentra-
tion of acrylamide determines the resolution of the gel, 12 % acrylamid were 
used for the running gel, to obtain a good resolution of lower molecular 
weight proteins. 
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6.3.4 Transfer  
 
In order to make the proteins accessible to antibody detection, they are 
moved from the gel onto a membrane. An electric current is applied to the gel 
and the proteins migrate out of the gel onto the membrane. PVDF-
membranes (Millipore) were incubated prior to the blotting for 10 min in 
methanol and then another 10 min in transfer buffer. For the "'semi-dry"' blot-
ting method, membranes and filter papers (Whatman-3MMChromatography 
papers) were cut to the exact size of the gel. Also, the filter papers were kept 
in transfer buffer prior to the transfer. Now the following order was used to 
prepare for the transfer: 
1. Anode 
2. Filter paper 
3. PVDF membrane 
4. Gel 
5. Filter paper 
6. Kathode 
 
The transfer was conducted for 40 min with constant voltage of 15V. 
6.3.5 Signal Detection 
 
Proteins of interest were visualized using immunostaining. Therefore, the 
membranes were blocked for 1 hour with 5 % milk powder in TBS. Then they 
were probed with the respective antibody over night at 4 °C. The antibodies 
used include: anti-CNPase (mouse, 1:1000, Sigma); anti-NF70 (mouse, 
1:1000, Chemicon); For protein loading control, membranes were reprobed 
with mouse anti-Gapdh (Glyceraldehyde 3-phosphate dehydrogenase) anti-
body (mouse, 1:7500, abcam). The detection was performed with the Licor 
scanning system. The secondary antibodies were coupled to near infrared 
fluorescent dyes. Membranes were incubated with these secondary antibod-
ies (1:15000 in TBST) for 2 hours at room temperature. Western blots were 
replicated at least 2 times for quantification. For quantification the Odyssey 
V3.0 software was employed to calculate the pixels of each band by sub-
straction of the background signal. A minimum of 2 blots were performed for 
1 tissue sample and 1 tissue sample equals 1 animal. Quantification was per-
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formed for all obtained data points using the one sample t –test seperately for 
each column, where the hypothetical value was set at 100. 
6.4 Test for Integrity of the Blood Brain Barrier 
 
First the mice were anesthesized and then a stab wound was performed in 
one hemisphere, which served as a positive control. Afterwards, a floures-
cent dextran with a molecular size of 3000 Da (5mg/ml dissolved in saline) 
was injected into the tail vein. 15 minutes after the injection, animals were 
sacrificed by cervical dislocation. After the careful dissection of the brain, it 
was frozen on a metal plate which was located on dry ice. The brains were 
then stored at -20 °C until they were cut at a cryostat at a thickness of 16 µm. 
The slides containing sections of interest were then defrosted at room tem-
perature, rinsed with 1 x PBS and fixed for 20 min with 4 % PFA. After an 
additional intensive washing step in 1 x PBS, the sections were dried and 
finally coversliped with AquaPolymount. The blood brain barrier integrity was 
analyzed using a microscope.  
6.5 Immuno/cyto-histochemistry 
6.5.1  Perfusion 
 
Animals were deeply anethesised using ketamin/xylazine. Transcardial per-
fusion was first performed with 1 x PBS for approximately 3 minutes, followed 
by 4 % PFA for 25 minutes. After careful preparation of the brains, these 
were post-fixed in 4 % PFA for another 5 minutes and cryoprotected by incu-
bation in 30 % succrose solution until the brains saturated (usually 12 hours 
at 4 °C). Brains were kept in this solution until free floating sections were 
made (maximal 5 days of storage).  For vibratome sectioning the cryopotec-
tion-step was omitted. Rather the brains were kept in PBS until embedding in 
4 % agarose solution until further processing.  
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6.5.2  Brain Sectioning 
 
For free floating sections, brains were cut at the cryostat at a thickness of 30 
μm. Vibratome sections on the contrary were cut at the vibratome at a thick-
ness of 50 μm. Free floating as well as vibratome sections were stored at -20 
°C in a 1.5 ml tube filled with 1 ml storing solution until immunohistochemis-
try.  
6.5.3 Immunohistochemistry 
 
Primary antibodies (for details see table 7- 1) were incubated with specimen 
overnight at 4 °C blocking solution. Afterwards, brain sections were washed 3 
times with 1 x PBS. Incubation with the secondary antibody directed against 
the host of the primary antibody, was performed in blocking solution contain-
ing DAPI (1:1000) for 1 hour at room temperature. After careful rinsing in 1 x 
PBS, sections were placed by the use of brushes on glass slides and dried 
and embedded with Aqua Polymount. Stained sections were then analyzed 
either at the light or confocal microscope.  
For BrdU and Olig2 staining a pretreatment to better access proteins or DNA 
in the cell nucleus was necessary. Before staining, the sections were trans-
ferred into 1 x sodium citrate buffer and kept shaking at 96 °C for 20 minutes. 
Afterwards, sections were rinsed carefully 3 times for 10 minutes in 1 x PBS 
until incubation with the primary antibody. Double-labelling was performed by 
staining first with the antibody not requiring pre-treatment. After a short fixa-
tion of the first staining 5-10 minutes in 4 % PFA, pre-treatment for BrdU or 
Olig2 was started. Other antibodies required an amplification using as a first 
secondary a biotinylated antibody and then an amplification with strepta-
vidin488 or streptavidin594. Another method to amplify the signal from the 
biotynilated secondary antibody was achieved by using the Thyramid kit 
(Perkin Elmar Life Science). Some antibodies had a better and more specific 
signal when the subtype specific secondary was used. All special treatments 
are indicated in the primary antibody list. 
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Table 6- 1. List of Primary Antibodies (unless otherwise indicated for immu-
nohistochemistry): 
Recognized 
Antigene 
Host Dilution Special 
Treatment 
Company  
(Order number) 
473HD Rat IgG 1:100 No Triton Kindly provided by 
Andreas Faissner 
6E10 Mouse IgG1 1:200  Millipore (MAB1560) 
Amyloid beta 
(1-14) 
Rabbit IgG 1:200  Acris 
 (BP2185) 
BrdU 
 
 
βIIItubulin 
Rat IgG2a 
 
 
Mouse 
IgG2b 
1:200 
 
 
1:200 
Boiling; evtl. 
biotinylated  
   Secondary 
subtype specific 
secondary 
Biozol  
(OPT0030) 
 
Sigma (T8600) 
Activated 
Caspase 3 
Rabbit IgG 1:100 Thyramid Kit Promega 
(G7481) 
Cux1 Rabbit IgG 1:100  Sigma (C5922) 
GFAP Mouse IgG1 1:1000  Sigma (G3898) 
GFAP Rabbit IgG 1:1000  DAKO (Z0334) 
GFP Chick IgG 1:500  Abcam (139070) 
GSTpi Mouse IgG1 1:500 subtype specific 
secondary 
BD Bioscience 
(610718) 
Iba1 Rabbit IgG 1:500  WAKO (01919741) 
MAG Mouse IgG 1:100  Millipore (ST1684) 
Nestin 
 
 
Mouse IgG1 
 
 
1:100 
 
 
subtype specific 
secondary 
 
Millipore  
(MAB377) 
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NeuN Mouse IgG1 1:100 subtype specific 
secondary 
Millipore  
(AB5922) 
NF70 Mouse IgG1 1:100 immunostaining Millipore (MAB1615) 
NG2 Rabbit 1:200  Chemicon (AB5320) 
Olig2 Rabbit 1:500 boiling Chemicon (AB9610) 
S100b Mouse IgG 
IgG1 
1:500  Sigma (S2532) 
S100b Rabbit 1:100  Sigma (S2644) 
TNC 
 
Rabbit 1:100 No Trition Kindly provided by 
Andreas Faissner  
For Westernblot Signal Detection 
CNPase Mouse IgG1 1:1000 western blot Sigma (C5922) 
Gapdh Mouse IgG 1:7500 western blot Abcam (ab8245) 
NF70 Mouse 
IgG1 
1:1000 western blot Millipore 
(MAB1615) 
 
 
 
Table 6- 2. List of Secondary Antibodies: 
Antibody Host Label Dilution Company 
 
Anti-chick 
 
Donkey FITC 1:200 Dianova (106166003)  
Goat Alexa488 1:500 Invitrogen (A11039)  
Anti-rat 
 
Donkey 
 
Alexa488 1:500 Invitrogen (A21208) 
Alexa594 1:500 Invitrogen (A21209) 
Goat Cy3 1:500 Dianova (112165167) 
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Rabbit biotinylated 1:200 Vector (BA-4001) 
Anti-rabbit Donkey Alexa488 1:500 Invitrogen (A21206) 
Alexa594 1:500 Invitrogen (21207) 
Cy3 1:500 Dianova (711165152) 
Goat Cy3 1:500 Dianova (111165144) 
biotinylated 1:200 Vector (BA-1000) 
 
Anti-mouse  
IgG1 
 
Goat 
 
Alexa488 
 
1:500 
 
Invitrogen (A21121) 
Alexa594 1:500 Invitrogen (21125) 
biotinylated 1:200 Biozol (1070-08) 
Anti-mouse 
IgG2b 
Goat TRITC 1:200 Biozol (1090-03 
Anti-mouse IgG Goat Alexa488 1:500 Invitrogen (A11029) 
Cy3 1:500 Dianova (115165166) 
Cy5 1:500 Dianova (115176072) 
Donkey Alexa594 1:500 Invitrogen (A-21203) 
 
Streptavidin 
 Goat Alexa647 1:500 Invitrogen (S21374) 
  Alexa555 1:500 Invitrogen (S21381) 
For Western Blot Signal Detection  
Anti-mouse Goat IRDye 500 1:15000 Li-Cor 926-68020 
Anti-rabbit  Goat IRDye 800 1:15000 Li-Cor 926-32211 
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6.5.4 Analysis of Immunostainings 
 
Stainings were analyzed at the Zeiss LSM700 confocal microscope with opti-
cal sections of maximum 0.5-2 μm intervals. Pictures were taken with a z-
stack between 6-8 μm. Afterwards, pictures were saved as tiffs. The area of 
interest was measured and cells were quantified using Image J. In sections 
quantified at the light microscope, cell numbers or overlays were counted 
flipping fast between channels, to verify them. Statistical analysis was per-
formed with the Graph Pad Prism program. Quantification of immunolabelled 
cells was determined in sections from more than 3 animals and tested for 
normal distribution using then either the unpaired Student’s t-test or Mann-
Whitney test (* p< 0.05; ** p< 0.01; *** p < 0.001). Significant changes are 
indicated in the diagram bars.  
6.6 Immunostaining of Human Brain Tissue 
6.6.1 Brain Tissue 
The analysis of human brain tissue samples were conducted in collaboration 
with Dr. Kristin Baer from the Institute of Neuroscience and Molecular Psy-
chiatry, Swansea University. The human brain tissue for this study was ob-
tained from the Neurological Foundation of New Zealand Human Brain Bank 
(Department of Anatomy with Radiology, University of Auckland). The Uni-
versity of Auckland Human Participants Ethics Committee approved the pro-
tocols used in this study, and all tissue was obtained with full consent of the 
families. Brain tissue was obtained from 8 neurologically normal cases, with 
no history of neurological disease and no evidence of neuropathology and 
from 8 Alzheimer’s Disease cases. The average age was 73 years with an 
age range of 35-85 years. The cases had a post-mortem interval between 2 
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and 36 hrs after death (mean post-mortem interval 14.75 hrs) and included 8 
female and 8 males.  
Table 6- 3. Human Brain Tissue Samples:  
Case Age 
(years) 
Sex Postmortem 
Delay 
(hours) 
Diagnosis 
H123 78 f 7.5 Control - Rupt. Aortic aneurysm 
H126 35 f 10 Control - Suicide - hanging 
H136 75 m 13 Control - Rupt. Aorta, abdom. aneurysm 
H137 77 m 12 Control - Coronary artherosclerosis 
H150 78 m 11 Control - Rupt. Myocardial infarction 
H191 77 m 20 Control  
H192 65 f 24 Control  
H193 71 m 23 Control  
AZ32 75 f 3 Alzheimer’s Dementia (mild) 
AZ34 74 f 18 Alzheimer’s Dementia  
(moderate-definite) 
AZ52 68 f 36 Alzheimer’s Dementia (severe) 
AZ53 85 f 2 Alzheimer’s Dementia (probable) –  
Bronchial pneumonia 
AZ57 82 m 14.5 Alzheimer’s Dementia (possible) –  
Bronchial pneumonia 
AZ58 75 m 20 Alzheimer’s Dementia (severe) 
AZ59 83 m 15 Alzheimer’s Dementia (mild) 
Cardiopulm collapse 
AZ72 70 f 7 Alzheimer’s Dementia 
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6.6.2 Immunohistochemical procedures 
The following preparation was conducted as previously described576 in the 
Department of Anatomy with Radiology, University of Auckland. The human 
brains were fixed by perfusion through the vertebral and internal carotid arter-
ies, first with phosphate-buffered saline (PBS) with 1% sodium nitrite, fol-
lowed by 15% formalin in 0.1M phosphate buffer, pH 7.4.  After perfusion, 
blocks from the  cerebral cortex were carefully dissected and kept in the 
same fixative for 24 hours. The tissue blocks were cryoprotected in 20% su-
crose in 0.1 M phosphate buffer with 0.1% Sodium azide (Sigma) for 2-3 
days, and then in 30% sucrose in 0.1 M phosphate buffer with 0.1% Sodium 
azide for a further 2-3 days. The blocks were sectioned on a freezing micro-
tome at 50 µm and the sections stored in PBS with 0.1% sodium azide (PBS-
azide) until use.  
6.6.3 Single Immunoperoxidase Labelling  
The following procedure was conducted in the Institute of Neuroscience and 
Molecular Psychiatry, Swansea University. Free-floating brain sections were 
transferred into 6-well tissue culture plates and washed in PBS containing 
0.2% Triton-X (PBS-triton) and pretreated for antigen retrieval. Therefore, the 
sections were incubated overnight in 0.1 M sodium citrate buffer, pH 4.5, 
transferred into 10 ml of fresh sodium citrate buffer solution, microwaved in a 
650 W microwave oven for 30 seconds and allowed to cool before washing 
(3 x 15 minutes) in PBS-triton. The sections were then incubated for 20 min-
utes in 50 % methanol and 1 % H2O2. After washing (3 x 15 minutes) in PBS-
triton, the sections were incubated in the primary antibody (polyclonal rabbit 
anti-Olig2 antibody; 1:500; Santa Cruz (sc-48817))  for 2-3 days on a shaker 
at 4°C. Then the primary antibody was washed off (3 x 15 minutes, PBS-
triton) and the sections incubated overnight in species-specific biotinylated 
secondary antibodies (diluted 1:500; sheep anti-rabbit; Chemicon, USA). Af-
terwards the secondary antibody was washed off (3 x 15 minutes, PBS-triton) 
and the sections were incubated for 4 hours at room temperature in ABC so-
lution diluted at 1:250 (Vectastain). The sections were reacted in 0.05 % 3,3-
diaminobenzidine tetrahydrochloride (DAB; Sigma) and 0.01% H2O2 in 0.1 M 
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phosphate buffer, pH 7.4, for 15-30 minutes to produce a brown reaction 
product. A nickel-intensified procedure was also used in which 0.4 % nickel 
ammonium sulphate was added to the DAB solution to produce a blue-black 
reaction product577. The sections were washed in PBS, mounted from gela-
tine solution onto glass slides, rinsed in distilled water, dehydrated, and cov-
erslipped with DPX (BDH, Poole, UK). Control sections were routinely proc-
essed to determine nonspecific staining using the same immunohistochemi-
cal procedures detailed above except that the primary antibody was omitted 
from the procedure.  
 
6.6.4 Analysis 
Single immunoperoxidase labeled sections were examined by light micros-
copy using a Zeiss Axioscope. Digital images were captured and contrast 
optimised using ImageJ software (NIH) and quantitative observations were 
recorded. Statistical analysis was carried out using Excel and Minitab soft-
ware.  
Three independent rounds of staining were carried out, each time using one 
brain section from 3-5 healthy control brains and from 3-5 AD brains. Per 
brain section, using the 4x magnification, a minimum of 3 digital pictures was 
captured from the white matter and from the grey matter. The digital pictures 
were coded and the quantification (count of Olig2 immunoreactivity positive 
nuclei) was carried out using ImageJ software (NIH). The sections were ana-
lyzed with the Mann-Whitney test (* p< 0.05; ** p< 0.01; *** p < 0.001). Sig-
nificant changes are indicated in the diagram bars. 
6.7 Gallyas Silver Impregnation  
 
First, the brain sections were mounted on superfrost microscopic glass 
slides. After drying, the sections were left for 5 minutes in aqua dest. Then an 
incubation of 30 minutes in pyridine (200 ml) mixed with acetic acid anhydrid 
(100 ml) followed. After washing for 10 minutes in aqua dest., including 
changing the water 2 times, the tissue specimen was incubated at 30 °C for 
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45-50 minutes in pre-warmed incubation solution (see material). The incuba-
tion solution was rinsed off for 3 x 5 minutes with acetic acid (0.5 %). For the 
physical development first 70 ml solution B and then 30 ml solution C were 
added slowly upon stirring to 100 ml solution A. Physical development took 
place in this solution for 3-15 minutes. Afterwards, the slides were washed 3 
x 5 minutes with acetic acid (1 %). After a short wash in aqua dest., slides 
were then incubated for 5 minutes in sodium thiolsulfate (2 %). Finally, a 
washing step for 3 x 5 minutes in aqua dest. was conducted. After passing 
the slides through an increasing ethanol chain (70 %, 80 %, 90 %, 95 %, 100 
% each solution 10 minutes) slides were incubated in xylol for 10 minutes 
and then coversliped with DPX mounting medium. The method for the gallyas 
silver impregnation is based on the principle that myelin can bind colloidal 
silver particles in a 0.1% ammonical silver nitrate solution of pH 7.5. The pro-
duction of metallic silver by other tissue elements is suppressed by the sec-
tions pre-treated with 2:1 mixture of pyridine an d acetic anhydride for 30 
minutes. The collodial silver particles bound in the myelin are enlarged to 
microscopic dimensions by a special physical developer381,382.  
6.8 Neurosphere Assay 
6.8.1 Dissection 
 
Mice were shortly euthanized by asphyxiation in CO2 and then killed by cer-
vical dislocation. The brain was removed and transferred into a petridish con-
taining HBSS with 10 mM Hepes. As a postive control, the lateral wall of the 
lateral ventricle was isolated and kept in a 1.5 ml tube filled with 500 µl Solu-
tion 1 on ice until further processing. For detection of the stem cell capacity of 
reactive tissue a defined volume of the lesioned and non-lesioned areas of 
the acute injured cerebral cortex (Stab wound, MCAO) or the corresponding 
anatomical areas of APPPS1 and Ck/p25 mice were punched out using a 
“stanze” after removal of meninges. The remaining white matter was then 
carefully removed using forceps. The collected tissue was stored in a 1.5 ml 
tube containing 500 µl solution 1 on ice until further processing.  
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6.8.2 Preparation 
 
After the dissection, the dissociation medium was freshly prepared and filter 
sterilized. The dissected tissue pieces were gently pipetted up and down with 
a blue pipette. Then, 500 μl of dissociation medium was added to the tube 
containing the dissected tissue as well as 500 μl of solution 1. The tubes 
were incubated for 20 minutes at 37 °C. Afterwards, the enzyme activity was 
stopped by adding 1 volume ice cold solution 3, meanwhile pipetting up and 
down again with a blue pipette tip. The pellet was re-suspended in 1 ml pre-
warmed neurosphere medium. A centrifugation step of 5 minutes at 1500 
rpm followed. The pellet was again re-suspended in 1 ml neurosphere me-
dium. The suspension was carefully pipetted through a 70 μm filter on top of 
8 ml ice-cold solution 2 in a 15 ml tube. Another centrifugation step at 2000 
rpm for 20 minutes was performed. The pellet was re-suspended in 1 ml pre-
warmed neurosphere medium. Cells were plated at a density of 3000 cells 
per 600 μl per well in a 24-well-plate. EGF as well as FGF was added in a 
concentration of 20 ng/ml. The number of neurospheres were counted after 2 
weeks in culture using the microscope Axiovert 40CFL (Zeiss). 
6.8.3 Passaging of Neurospheres 
 
Neurospheres were collected in a 15 ml falcon tube and Trypsin-EDTA wa-
sadded to a final concentration of 0.01 % (diluted 1:5). Then the tube was 
incubated for 3 minutes at 37 °C. After addition of an equal amount of solu-
tion 3 to stop the reaction a single cell suspension was generated from the 
neurospheres pipetting up and down. Centrifugation at 700-800 rpm for 5 min 
was used to pellet the cells. Then, the cells were re-suspended in pre-
warmed neurosphere medium and plated at clonal density of 3000 cells per 
600 μl (5 cells per 1 μl) medium per well in a 24-well-plate. The number of 
neuropheres was quantified after 7 days.  
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6.8.4 Differentiation of Neurospheres 
 
First neurospheres were picked in a very small volume with a yellow pipette 
and carefully plated on poly-D-lysine (PDL) coated coverslips in a 24-well-
plate in differentiation medium (without growth factors). Then the plate was 
kept for approximately 3 hours in the incubator at 37 °C. After the neuro-
spheres have settled down, 1 ml fresh neurosphere medium, without growth 
factors was added. The next day the medium was changed and the differen-
tiation medium was added. After 7-10 days the medium was removed and 
the neurospheres were fixed for 5 minutes with 4 % PFA.  
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